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now and then finding a smoother pebble or a prettier shell than ordinary, 
whilst the great ocean of truth lay all undiscovered before me”. 
Isaac Newton 
  
 P a g e  4 | 136 
 
Abstract 
 
During my postgraduate training in Radiology at the University of Genoa, 
Italy, I developed research projects on the application of molecular magnetic 
resonance imaging for tumour targeting. Molecular imaging (MI) aims to 
provide “pictures of what is happening inside the body at molecular and 
cellular level”. Magnetic resonance imaging (MRI) has been applied to many 
aspects of MI. Although it offers better temporal and spatial resolution than 
other methodologies, it is less sensitive for molecular or cellular activities, 
and therefore there is a need to develop more efficient contrast agents. The 
publications included in this PhD thesis demonstrate the successful 
application of two classes of MRI contrast agents: ultrasmall 
superparamagnetic iron oxide nanoparticles (USPIO) and manganese 
(Mn2+). Novel USPIO-antibody-conjugated probes for investigating 
lymphoma tumours were applied, and the potential of labelling natural killer 
cells by SPIO was demonstrated, offering a great opportunity for in vivo 
investigation of these lymphocytes that play an essential role in cell-based 
immune defence. The development of a birdcage prototype coil for a clinical 
3T MR scanner with a commercial scientific collaboration was carried out. 
Research projects for investigating tumour calcium metabolism and risk of 
bone metastases were developed preclinically (by using Mn2+ in human 
preclinical cancer animal models) and clinically (by using in vivo proton 
magnetic resonance spectroscopy to investigate human breast cancer). An in 
vivo Manganese-enhanced-MRI (MEMRI) technique to visualise brown 
adipose tissue, its physiopathology, and its role in breast or prostate cancer 
progression, has been included as well. The last research projects carried out 
as the conclusion of this PhD were focused on: 1) the development of a novel 
USPIO-MR imaging approach to monitor chronic lymphocytic leukaemia 
(CLL), induced by interfering with both miR-15 and miR-16 expression; and 
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2) evaluating response to a potential treatment with the use of miRNA 
mimics or inhibitors. 
  
 P a g e  6 | 136 
 
Table of Contents 
 
Abstract ......................................................................................................... 4 
List of Figures ............................................................................................. 11 
Acknowledgements ..................................................................................... 14 
Abbreviations Used in this Thesis .............................................................. 19 
List of Papers: Impact factor and Role ....................................................... 23 
Objective of this Thesis and Hypothesis ..................................................... 27 
Chapter 1: Critical Analysis ........................................................................ 28 
1. Background and Introduction .............................................................. 28 
1.1. Tumour targeting and cell labelling with MR ............................... 28 
1.1.1. Tumour targeting by USPIO-antibody conjugates ................. 28 
1.1.2. Cell labelling by iron oxide nanoparticles .............................. 45 
1.2. Investigation of tumour imaging by using MEMRI ..................... 47 
1.3. Exploring a new role of MEMRI for visualising brown adipose 
tissue ..................................................................................................... 57 
1.4. Application of in vivo proton MR spectroscopy in breast cancer 
expressing different levels of calcium sensing receptors ..................... 62 
1.5. A non-invasive approach to investigate chronic lymphocytic 
leukaemia by using iron oxide nanoparticles ....................................... 69 
Chapter 2: Original peer reviewed papers .................................................. 83 
2.1. Tumour targeting and cell labelling with MR ............................... 83 
2.1.1. Tumour targeting by USPIO-conjugates ................................ 83 
2.1.1.2. Title of paper .................................................................... 83 
2.1.1.3. Objective of the study ...................................................... 83 
 P a g e  7 | 136 
 
2.1.1.4. What this study added to the literature ............................. 83 
2.1.1.5. What changed as a result of the papers? .......................... 84 
2.1.1.6. In retrospect, what should have been done differently in 
this study? ...................................................................................... 84 
2.1.1.7. Future work as a result of this publication ....................... 85 
2.1.1.8. Confirmation of authorship .............................................. 85 
2.1.1.9. External link to the papers on the journal website ........... 85 
2.1.2. Cell labelling by iron oxide nanoparticles .............................. 87 
2.1.2.1. Title of paper .................................................................... 87 
2.1.2.2. Objective of the study ...................................................... 87 
2.1.2.3. What this study added to the literature ............................. 87 
2.1.2.4. What changed as a result of the paper? ............................ 88 
2.1.2.5. In retrospect, what should have been done differently in 
this study? ...................................................................................... 88 
2.1.2.6. Future work as a result of this publication ....................... 89 
2.1.2.7. Confirmation of authorship .............................................. 89 
2.1.2.7. External link to the paper on the journal website ............. 89 
2.2. Investigation of tumour imaging by using MEMRI ..................... 91 
2.2.1. Title of paper ....................................................................... 91 
2.2.2. Objective of the study ......................................................... 91 
2.2.3. What this study added to the literature ................................ 91 
2.2.4. What changed as a result of the paper? ............................... 91 
2.2.5. In retrospect, what should have been done differently in this 
study? ............................................................................................. 92 
 P a g e  8 | 136 
 
2.2.6. Future work as a result of this publication .......................... 92 
2.2.7. Confirmation of authorship ................................................. 92 
2.2.8. External link to the paper on the journal website ................ 92 
2.2.1. Title of paper ....................................................................... 94 
2.2.2. Objective of the study ......................................................... 94 
2.2.3. What this study added to the literature ................................ 94 
2.2.4. What changed as a result of the paper? ............................... 94 
2.2.5. In retrospect, what should have been done differently in this 
study? ............................................................................................. 94 
2.2.6. Future work as a result of this publication .......................... 95 
2.2.7. Confirmation of authorship ................................................. 95 
2.2.8. External link to the paper on the journal website ................ 95 
2.3 Exploring a new role of MEMRI to visualize Brown adipose tissue
 .............................................................................................................. 97 
2.3.1. Title of the abstract .............................................................. 97 
2.3.2. Objective of the study ......................................................... 97 
2.3.3. What this study added to the literature ................................ 97 
2.3.4. In retrospect, what should have been done differently in this 
study? ............................................................................................. 97 
2.3.5. Confirmation of authorship ................................................. 97 
2.3.6. External link to the paper on the journal website ................ 98 
2.4. Application of in vivo proton MR spectroscopy in breast cancer 
expressing different level of Calcium sensing receptors ................... 100 
2.4.1. Title of papers .................................................................... 100 
 P a g e  9 | 136 
 
2.4.2. Objective of the study ....................................................... 100 
2.4.3. What this study added to the literature .............................. 100 
2.4.4. What changed as a result of the paper? ............................. 101 
2.4.5. In retrospect, what should have been done differently in this 
study? ........................................................................................... 101 
2.4.6. Future work as a result of this publication ........................ 101 
2.4.7. Confirmation of authorship ............................................... 102 
2.4.7. External link to the paper on the journal website .............. 102 
2.5. A non-invasive approach to investigate chronic lymphocytic 
Leukaemia by using iron oxide nanoparticles.................................... 104 
2.5.1. Title of papers .................................................................... 104 
2.5.2. Objectives of the studies ................................................... 104 
2.5.3. What these studies added to the literature ......................... 105 
2.5.4. What changed as a result of the papers? ........................... 105 
2.5.5. In retrospect, what should have been done differently in 
these studies? ............................................................................... 105 
2.5.6. Future work as a result of these publications .................... 105 
2.5.7. Confirmation of authorship ............................................... 106 
2.5.8. External link to the paper on the journal website .............. 106 
Discussion and Conclusion ....................................................................... 108 
Where are we now? Where are we going? ............................................ 108 
References ................................................................................................. 117 
 
  
 P a g e  10 | 136 
 
  
 P a g e  11 | 136 
 
List of Figures 
 
Figure 1. Surface expression of CD20 antigen by D430B and Raji 
lymphoma cell lines by immunofluorescence and cytofluorimetric analysis.
 ..................................................................................................................... 36 
Figure 2. Detection of anti-CD20-USPIO conjugates bound to the cell 
surface by cytofluorimetric analysis.. ........................................................ 36 
Figure 3. T2-weighted three-dimensional fast field echo images of D430B 
CD20 high tumour analysed before and after USPIO-anti-CD20 antibody 
administration. ............................................................................................ 37 
Figure 4. T2-weighted three-dimensional fast field echo images of Raji 
CD20 low tumour analysed before and after USPIO-anti-CD20 antibody 
administration. ............................................................................................ 38 
Figure 5. Representative MR Images of the control group injected with 
ferumoxides. ............................................................................................... 38 
Figure 6. Immunofluorescence analysis of CD70 surface expression. ... 40 
Figure 7. Coronal MR images of pseudo-metastatic lymphoma xenografts.
 ..................................................................................................................... 42 
Figure 8. Experimental prototype birdcage coil for use with a clinical 3T 
MR scanner ................................................................................................ 48 
Figure 9. Manganese enhanced MR imaging (MEMRI) of the orthotopic 
human breast cancer xenografts. .............................................................. 52 
Figure 10. Immunohistochemical analysis of CaSR in human breast 
cancer MDA-MB-231 cells xenograft (a–c). ............................................. 53 
Figure 11. A, B Coronal MR images of the orthotopic human breast cancer 
xenograft in a verapamil-treated control. ................................................. 54 
Figure 12. Amount of internalized Mn2+ in B16F10 cells incubated with 
MnCl2 and Mn-DO2A for 1 and 7 h. ......................................................... 56 
 P a g e  12 | 136 
 
Figure 13. In vivo Non-invasive Detection of Brown adipose Tissue (BAT) 
through Manganese Enhanced Magnetic Resonance Imaging (MEMRI) 
in healthy controls. ..................................................................................... 59 
Figure 14. In vivo Non-invasive Detection of Brown adipose Tissue (BAT) 
through Manganese Enhanced Magnetic Resonance Imaging (MEMRI) 
in metastatic prostate and breast cancer animal models. ......................... 60 
Figure 15. In vivo Non-invasive Detection of Brown adipose Tissue (BAT) 
through Manganese Enhanced Magnetic Resonance Imaging (MEMRI) 
in orthotopic prostate and breast cancer animal models. ......................... 61 
Figure 16. Immunohistochemical analysis of CaSR expression in human 
breast cancers specimens (score 0-5) ........................................................ 65 
Figure 17. Proton MR Spectroscopy choline peak and calcium sensing 
receptor (CaSR) correlation. ...................................................................... 66 
Figure 18. Proton MR Spectroscopy choline peak and calcium sensing 
receptor (CaSR) correlation.   .................................................................... 67 
Figure 19. Representative slices of the sequence protocol used to measure 
the signal intensity (SI) in tissues of interest. ........................................... 72 
Figure 20. Magnetic resonance image signal determination and 
histological analysis in control (NSG-CTR) compared to engrafted (NSG-
CLL) mice. .................................................................................................. 73 
Figure 21. Comparison of magnetic resonance image signal intensity 
change in the spleen of control mice (NSG-CTR), mice engrafted (NSG-
CLL) at 2 and 4 weeks, and non-engrafted (NSG-ne) mice. .................... 74 
Figure 22. Representative experiment of treatment with rituximab. ....... 76 
Figure 23. Representative Immunohistochemistry and flow cytometry 
analysis of mouse spleens from a rituximab experiment. ........................ 77 
Figure 24. CLL cell engraftment in NSG mice following in vitro 
transfection with miRNA mimics or inhibitors.. ....................................... 80 
 P a g e  13 | 136 
 
  
   
 P a g e  14 | 136 
 
 
Acknowledgements 
 
The bulk of the published work on which this thesis is based is my own. My 
contribution to each of the publications is stated per each paper discussed.  
  
There are however notable contributions to the body of work from a number 
of friends and colleagues that I would like to acknowledge here. 
 
When I started to develop my research projects, I was a radiology trainee at 
the University of Genoa, and the field of “Molecular Imaging”, at that time, 
was not well-known in the Italian scientific community. I have been asked 
several times by colleagues and friends, “how I could develop certain 
research ideas” and actually, I still have not a single answer. Looking back, 
I do believe that having started my graduation at University of Pisa in 
Biology (before my degree in Medicine), certainly contributed to my interest 
in the molecular and biology study of cancer. At the same time, having a 
family member, like my mum, affected by breast cancer, had a considerable 
contribution too. The knowledge of being doctor but “feeling useless” to 
someone you really love because of the lack of knowledge in detecting 
disease at very early stage, certainly, pushed my “imagination and will” in 
thinking “how as radiologist I could cover this gap”.  
 
During my postgraduate training in radiology, I spent most of my “free time” 
in the laboratory of many colleagues and scientists. For this reason, I would 
like to thank all the colleagues from the Centre of Advanced Biotechnology 
(CBA- Centro di Biotecnologie Avanzate), at the National Italian Cancer 
Research Institute (IST-Istituto Nazionale per la Ricerca sul Cancro). 
Especially, Dr Marina Fabbi and Dr Silvano Ferrini at the Immunology Unit. 
 P a g e  15 | 136 
 
Marina and Silvano, provided me the great chance of learning several lab 
techniques in the field of Immunology. It has been one of my most exciting 
experiences learning basic science methods for supporting my molecular 
imaging study. Thanks to their extensive research knowledge I could also 
learn how to develop a full research project grant application and write a 
scientific paper for peer reviewed journals. Most of the pioneer work done 
by using iron oxide nanoparticles is the result of the collaboration with 
Marina and Silvano and I will always be thankful to their immense patience 
and availability at any time of the day and night, for performing all our 
experiments on MRI. 
 
A special thanks to Mrs Anna Maria Cappelli and Mrs Laura Canton, the two 
MR radiographers, at IST. They both have been great in teaching me how to 
use a clinical MR scanner and how to apply all the clinical MR protocols to 
my preclinical studies. Their patience, support and friendship will always be 
part of my life.  
 
I would like also to thank Dr Michele Cilli and Dr Laura Emionite, at the 
Animal Facility at CBA, IST, Genoa. They both have been great in teaching 
me all the techniques to develop cancer animal models and they have been 
constantly available in supporting “my risky research ideas”. 
 
I am thankful to Dr Fabrizio Levrero, the MR physicist at IST, for 
supervising most of my technical MR measurements, especially in the work 
of USPIO-antibody-conjugates, which needed extensive MR studies for 
relaxivity measurements.  
 
 P a g e  16 | 136 
 
I have a special thanks to Dr Carlo Emanuele Neumaier, which was the head 
of the Radiology Department, at IST.  Carlo has been not only my Radiology 
supervisor but also my research supervisor and a very good friend. We 
developed together the bulk of the work that is included in this thesis. Thanks 
to his support I could apply for several research project grant applications, 
first as Radiology trainee and later as consultant radiologist. One of these 
projects, allowed me to develop a scientific collaboration with General 
Electric (GE, Milwaukee, USA). Developing a new prototype MR coil 
together with Flick Engineering (Netherlands) and GE, has been an exciting 
experience. I certainly improved my MR physics and MR engineering 
knowledge, and I had the opportunity to experience how research is 
developed in a commercial environment too. For this reason, I would like 
here to mention Piero Ghedin and Sabina Prato from GE, for their substantial 
scientific support and collaboration. 
 
I have been very lucky to collaborate with Prof Silvio Aime and Dr Eliana 
Gianolo, at the Molecular Imaging Center, at University of Turin. Silvio is 
one of the well-known pioneer scientists in the field of Molecular Imaging 
who has received during the World Molecular Imaging Conference 2013 the 
Gold Medal Award (“From Relaxation Enhancers to Frequency-Encoding 
Agents: How MRI Competes in the Molecular Imaging Arena”). He is a 
great Professor and, thanks to our collaboration, I not only improved the 
experiments on the application of manganese as MR tumour contrast agent, 
but I also found a fantastic team of scientists with whom I am still 
collaborating. 
 
The last work developed on chronic lymphocytic leukaemia was done thanks 
to the collaboration with Prof Manlio Ferrarini and Dr Giovanna Cutrona. It 
 P a g e  17 | 136 
 
has been something very interesting and “out of my comfort zone as 
radiologist” developing a preclinical imaging method in the study of this 
disease treated with a very novel treatment such as miRNA mimics and 
miRNA inhibitors. 
 
I would like to thank my PhD thesis supervisors, Dr Andoni Toms and Dr 
Donnie Cameron, for their great support and supervision. They are not only 
great colleagues and good friends, but thanks to their input and suggestions 
I had the opportunity to reflect a lot on the research developed all over these 
years, making myself more eager to improve in the Molecular Imaging field 
as Radiologist. A special thank also to Prof Alastair Forbes, for his advices 
and support during the writing of this thesis. 
 
I thank all of my co-authors that I cannot list here, one by one, but without 
their collaboration and support I could not achieve any of the results that we 
obtained and, also all my radiology colleagues at the Norwich Nowrfolk 
University Hospital (NNUH), Norwich, for supporting and constantly 
motivating me, over these months. 
 
I would like to dedicate a special thanks to Prof Chrit Moonen, at the 
University of Utrecht, for proof reading my PhD thesis. Chrit was the first 
scientist that I met during an International conference (ISMRM, Galveston, 
2007) and he has been all over these twelve years, not only a very good 
scientific mentor, but also my best friend. I will never be thankful enough 
for his great support and friendship. 
 
 P a g e  18 | 136 
 
I take here also the opportunity to thank spider Greg for biting me during my 
University time and, transmitting his DNA: I am sure it gave me “the special 
power to become an insatiable researcher and doctor, too”. 
 
Last but not least, I would like to express from the depth of my heart how 
grateful I am to my family, which provided, and still provides me, with their 
constant support and love every day of my life. 
            
               Norwich, 2019 
 P a g e  19 | 136 
 
Abbreviations Used in this Thesis 
 
Ab - antibody 
ATP - adenosine triphosphate 
BRCA1 - breast cancer type 1 susceptibility protein 
BREASE - single-voxel breast spectroscopy sequence 
BAT - brown Adipose Tissue  
CA - contrast agent 
CAs - contrast agents 
Ca2+ - calcium ions 
CaSR - calcium sensing receptor 
CaSRs - calcium sensing receptors 
CDP - cytidine diphosphate 
CDP - ethanolamine 
CH-L - close homolog of L1 like protein 
ChoK - choline kinase 
CLL - chronic lymphocytic leukaemia 
CT - computed tomography 
DAG - diacylglycerol 
DCE-MRI - dynamic contrast enhanced-magnetic resonance imaging 
del(13)(q14) - deletion at 13q14.3  
D430B and Raji - lymphoma cell lines 
EANM - The European Association of Nuclear Medicine and Molecular 
Imaging and Society of Nuclear Medicine and Molecular Imaging joint  
EBV - Epstein Barr virus 
ESMI - European Molecular Imaging Society 
FC - flow cytometry 
18FDG-PET/CT - 2-deoxy-2-fluorine-18-fluoro-D-glucose-positron 
emission tomography/computed tomography 
 P a g e  20 | 136 
 
18F-FACBC - anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid  
FISH - fluorescence in situ hybridization 
GEP-NETs - gastroentero-pancreatic neuroendocrine tumors 
68Ga-PSMA - 68Gallium-prostate specific membrane antigen 
1H-MRS - 1hydrogen proton magnetic resonance spectroscopy  
IHC - immunohistochemistry 
IL-2 - interleukin 2 
111In-PSMA - 111In-prostate specific membrane antigen 
IST - National Italian Cancer Research Institute (Istituto Nazionale per la 
Ricerca sul Cancro) 
177Lu DOTA-TATE - 177Lutetium DOTATATE, DOTA-octreotate, 
oxodotreotide, DOTA-(Tyr3)-octreotate, and DOTA-0-Tyr3-Octreotate 
mAb - monoclonal antibody 
mAbs - monoclonal antibodies 
MEMRI - manganese enhanced magnetic resonance Imaging 
Mg2+ - magnesium ions 
MI - molecular imaging  
MICAD - Molecular Imaging and Contrast Agent Database 
MICoE - Molecular Imaging Center of Excellence 
MIP - maximum intensity projection 
miRNAs - microRNAs  
Mn2+ - manganese ions 
MnCl2 – manganese chloride 
MR - magnetic resonance  
MRI - magnetic resonance imaging 
NETTER-1 - phase 3 Neuroendocrine Tumors Therapy trial 
NETPET - NeuroEndocrine Tumor Positron Emission Tomography 
grading system for NETs 
 P a g e  21 | 136 
 
NIH - National Institutes of Health 
NHLs - non-Hodgkin lymphomas 
NSG-CTR - NOD SCID gamma mouse control 
NSG-CLL - NOD SCID gamma mouse chronic lymphocytic leukaemia 
NSG-ne - non-engrafted mice 
NK cells - natural killer cells 
SD - standard deviation 
SNR - signal-to-noise ratio 
PBMC - peripheral blood mononuclear cell 
PCho - phosphocholine 
PET/CT - Positron emission tomography/Computed Tomography 
PET/MR - Positron emission tomography/Magnetic Resonance 
PROMISE - PROstate cancer Molecular Imaging Standardization 
Evaluation  
PtdCho - phosphatidylcholine 
PtdEtn - phosphatidylethanolamine 
PTH - parathyroid hormone 
PTHrP - parathyroid hormone related protein 
PSMA - prostate specific membrane antigen 
R1 - longitudinal relaxivity 
R2 - transverse relaxivity 
ROI - region of interest 
RS - Richter syndrome 
SE - signal enhancement  
SI - signal intensity 
SPECT/CT - Single-photon emission computed tomography/Computed 
Tomography 
SPIO - superparamagnetic iron oxide nanoparticles 
 P a g e  22 | 136 
 
tCho - total choline-containing compounds 
TNF – tumour necrosis factor 
TRP – transient receptor potential channel 
UCP1 - uncoupling protein one 
USPIO – ultrasmall superparamagnetic iron oxide nanoparticles 
USPIO-anti-CD20 - ultrasmall superparamagnetic iron oxide nanoparticles 
antibody  
3’-,UTR - 3’-un-translated region 
VIBRANT - volume imaging for breast Assessment 
VOI – volume of interest 
WAT - white adipose tissue 
WMIC - World Molecular Imaging Conference 
γc - receptor gamma chain gene 
 
  
 P a g e  23 | 136 
 
List of Papers: Impact factor and Role 
 
List of publications on which the thesis is based, including impact factor of 
the journal and my role to each of these studies. 
 
• Baio G, Fabbi M, de Totero D, Ferrini S, Cilli M, Derchi LE, Neumaier CE. 
Magnetic resonance imaging at 1.5 T with immunospecific contrast agent in 
vitro and in vivo in a xenotransplant model. MAGMA. 2006 Dec; 19(6):313-
20. Epub 2006 Dec 12. 
Impact Factor: 1.832       Cited by 23 
Role: Principal investigator, conception and design, development of 
methodology, acquisition of data, analysis and interpretation of data, writing, 
review, and/or revision of the manuscript, study supervision. 
 
• Neumaier CE, Baio G, Ferrini S, Corte G, Daga A. MR and iron magnetic 
nanoparticles. Imaging opportunities in preclinical and translational 
research. Review. Tumori 2008 Mar-Apr; 94(2):226-33. 
Impact Factor: 1.304       Cited by 59 
Role: Principal investigator, conception and design, development of 
methodology, acquisition of data, analysis and interpretation of data, writing, 
review, and/or revision of the manuscript, study supervision. 
 
• Baio G, Fabbi M, Salvi S, de Totero D, Truini M, Ferrini S, Neumaier CE. 
Two-step in vivo tumour targeting by biotin-conjugated antibodies and 
superparamagnetic nanoparticles assessed by magnetic resonance imaging 
at 1.5T. Mol Imaging and Biol. 2010 Jun; 12(3):305-15. 
Impact Factor: 3.608       Cited by 25 
 P a g e  24 | 136 
 
Role: Principal investigator, conception and design, development of 
methodology, acquisition of data, analysis and interpretation of data, writing, 
review, and/or revision of the manuscript, study supervision. 
 
• Baio G, Fabbi M, Emionite L, Cilli M, Salvi S, Ghedin P, Prato S, Carbotti 
G, Tagliafico A, Truini M, Neumaier CE. In vivo imaging of human breast 
cancer mouse model with high level expression of calcium sensing receptor 
at 3T. Eur Radiol. 2012 Mar; 22(3):551-8. 
Impact Factor: 4.027         Cited by 16 
Role: Principal investigator, conception and design, development of 
methodology, acquisition of data, analysis and interpretation of data, writing, 
review, and/or revision of the manuscript, study supervision. 
 
• Baio G, Valdora F, Pace D, Salvi S, Villosio N, Truini M, Calabrese M and 
Neumaier CE. The key role of correlation between MR spectroscopy choline 
peak and calcium sensing receptor for breast cancer: Diagnosis by a 3T MR 
scanner. Journal of Clinical Oncology. ASCO 2013 Vol 31, No 15_suppl 
(May 20 Supplement). 
Impact Factor: 26.303 
Role: Principal investigator, conception and design, development of 
methodology, acquisition of data, analysis and interpretation of data, writing, 
review, and/or revision of the manuscript, study supervision. 
 
• Baio G, Rescinito G, Rosa F, Pace D, Boccardo S, Basso L, Salvi S, 
Calabrese M, Truini M, Neumaier CE. Correlation between Choline Peak at 
MR Spectroscopy and Calcium-Sensing Receptor Expression Level in 
 P a g e  25 | 136 
 
Breast Cancer: A Preliminary Clinical Study. Mol Imaging Biol. 2015 Aug; 
17(4):548-56. 
Impact Factor: 3.608           Cited by 6 
Role: Principal investigator, conception and design, development of 
methodology, acquisition of data, analysis and interpretation of data, writing, 
review, and/or revision of the manuscript, study supervision. 
 
• Gianolio E, Arena F, Di Gregorio E, Pagliarin R, Delbianco M, Baio G, 
Aime S. MEMRI and Tumours: A method for the evaluation of the 
contribution of Mn(II) ions in the extra- cellular compartment. NMR in 
Biomedicine. 2015 Sep; 28(9):1104-10. 
Impact Factor: 3.031           Cited by 7 
Role: Co-investigator, conception and design, development of methodology, 
acquisition of data, analysis and interpretation of data, writing, review, 
and/or revision of the manuscript, study supervision. 
 
• Valdora F, Cutrona G, Matis S, Morabito F, Massucco C, Emionite L, 
Boccardo S, Basso L, Recchia AG, Salvi S, Rosa F, Gentile M, Ravina M, 
Pace D, Castronovo A, Cilli M, Truini M, Calabrese M, Neri A, Neumaier 
CE, Fais F, Baio G, Ferrarini M. A non-invasive approach to monitor 
chronic lymphocytic leukaemia engraftment in a xenograft mouse model 
using ultra-small superparamagnetic iron oxide-magnetic resonance 
imaging (USPIO-MRI). Clin Immunol. 2016 Nov; 172:52-60. 
Impact Factor: 3.557           Cited by 5 
Role: Principal Investigator, conception and design, development of 
methodology, acquisition of data, analysis and interpretation of data, writing, 
review, and/or revision of the manuscript, study supervision. 
 P a g e  26 | 136 
 
 
• Cutrona G, Matis S, Colombo M, Massucco C, Baio G, Valdora F, Emionite 
L, Fabris S, Recchia AG, Gentile M, Neumaier CE, Reverberi D, Massara 
R, Boccardo S, Basso L, Salvi S, Rosa F, Cilli M, Zupo S, Truini M, Tassone 
P, Calabrese M, Negrini M, Neri A, Morabito F, Fais F, Ferrarini M. Effects 
of miRNA-15 and miRNA-16 expression replacement in chronic 
lymphocytic leukaemia: implication for therapy. Leukaemia. 2017 Feb 3 
2017 Sep; 31(9):1894-1904. 
Impact Factor: 10.023         Cited by 17 
Role: Conception and design of the imaging methodology, development of 
imaging methodology, acquisition of data, analysis and interpretation of 
data, writing, review, and/or revision of the manuscript, imaging study 
supervision. 
 
Conference Abstract 
• Rosa F, Basso L, Pace D, Secondini L, Boccardo S, Neumaier CE, Baio G. 
In vivo Non-invasive Detection of Brown Adipose Tissue through 
Manganese Enhanced Magnetic Resonance Imaging (MEMRI). WMIC 
2015. P688. 
Role: Principal investigator, conception and design, development of 
methodology, acquisition of data, analysis and interpretation of data, writing, 
review, and/or revision of the manuscript, study supervision. 
  
 P a g e  27 | 136 
 
Objective of this Thesis and Hypothesis 
 
Objective: to highlight some of the peer reviewed publications that I and my 
collaborators at the National Italian Cancer Research Institute (IST-Istituto 
Nazionale per la Ricerca sul Cancro) have written in the field of Molecular 
Imaging by using Magnetic Resonance Imaging, over the period 2006-2017.  
 
Hypothesis: the research that we developed was part of a pioneering work 
started in 2005. We were the only two Italian groups working in the field of 
Molecular Imaging who were using Magnetic Resonance Imaging and new 
molecular imaging probes. The hypothesis of this PhD thesis is that the 
results of this work improved the knowledge in Molecular Imaging and the 
awareness of its potential, impacting positively on the scientific community. 
The scientific impact and novelty is highlighted and discussed for each 
publication in this thesis.
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Chapter 1: Critical Analysis 
 
1. Background and Introduction 
 
This chapter provides an overview of the scientific background of the 
research that is part of this thesis. All the topics included in this thesis belong 
to a specific field of imaging called Molecular Imaging. Molecules and 
molecular processes have been made visible by nuclear medicine for decades 
and even the concept of molecular imaging is not new, it is only in 2000 that 
it became a “hot topic” in Radiology. During this period there has been a 
significant increase in the number of publications together with the release 
of several specialised journals and the foundation of several “Molecular 
Imaging Institutes” with the involvement of more radiologists [1]. This thesis 
is focused on the application of Magnetic Resonance Imaging (MRI) as a 
tool of Molecular Imaging (MI) to investigate “tumour targeting” (see 
below). Figures belonging to each paper have been included in the text, as 
published, in support of the critical analysis, without elaboration. 
1.1. Tumour targeting and cell labelling with MR 
 
1.1.1. Tumour targeting by USPIO-antibody conjugates 
 
The concept of “tumour targeting” was first introduced in the imaging 
world in the 1950s when research led by Pressman et al. demonstrated for 
the first time that a radiolabelled antibody directed against a tissue antigen 
was able to perform selective tumour-targeted imaging [2,3]. Successively, 
between 1978 and 1987, Goldenberg et al. set an important imaging 
milestone in tumour targeting by demonstrating that a radiolabelled antibody 
directed against the tissue antigen was not only able to selectively target the 
antigen but could also be used for therapy, introducing for the first time the 
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concept of “theragnostic agents” [4-7]. In 1987, the investigation carried out 
on the strong affinity of the two molecules biotin and avidin (streptavidin) 
by Hnatowich at al. (biotin and avidin exhibit the highest known affinity in 
nature between a ligand and a protein; Ka 1015M-1) [7] enabled a form of 
imaging called “pretargeting”. 
Pretargeting imaging was first conceived as a procedure to improve imaging 
by reducing background activity, thereby enhancing tumour/no tumour 
ratios. Thus, it is not surprising that in preclinical testing, pretargeting has 
provided an exceptional ability to detect small lesions in xenograft models. 
All tumour targeting studies were performed by the application of 
radiolabelled tracers detected by a gamma scintillation camera at various 
intervals after administration of the radioactive antibody. The application of 
MRI and a receptor-directed imaging probes was demonstrated later on, 
between 1990 and 1992 by et al. [8,9]. In these studies, a new contrast agent 
for magnetic resonance imaging, directed to a specific receptor on 
hepatocytes, was used for detecting liver cancer in rats.  
 
To better understand the role of MRI in tumour targeting we need to 
consider the main physical properties of this technique. MRI is an imaging 
method able to produce high-resolution three-dimensional maps delineating 
morphological features of the tissue [10]. Differential contrast in soft tissues 
depends on, variously, endogenous differences in water content, relaxation 
times of water protons, and diffusion characteristics of the water in the tissue 
of interest. The specificity of MRI can be further increased using exogenous 
contrast agents (CAs) such as gadolinium chelates, iron oxide nanoparticles 
or manganese. The signal enhancement produced by MRI CAs (i.e., the 
efficiency of the CAs) depends on their longitudinal (r1) and transverse (r2) 
relaxivity (expressed in mmol-1s-1), which is defined as the increase of the 
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nuclear relaxation rate (the reciprocal of the relaxation time) of water protons 
produced by 1 mmol per litre of CA [11]. The paramagnetic CAs (most of 
them complexes of gadolinium but also manganese compounds) produce the 
so-called paramagnetic effect, which results in T1 shortening (and R1 
enhancement) [11]. Organs taking up such agents will become hyperintense 
on T1-weighted MR images; these CAs are thus called positive contrast 
media. The CAs known as negative agents are generally composed of iron 
oxide nanoparticles (such as magnetite, Fe3O4, maghemite, gammaFe2O3, or 
other ferrites). These CAs influence signal intensity mainly by shortening 
T2* and T2, making the contrast-enhanced tissue appear hypointense on T2 
and T2*-weighted MR images, the so-called superparamagnetic effect 
[12,13].  
 
The study carried out by Reimer et al. using iron oxide nanoparticles 
conjugated to an antibody for detecting liver cancer [8,9], introduced two 
novel assays in the application of MRI for tumour targeting: the relaxation 
time measurements of incubated human cell membrane solutions and the 
iron staining of biopsy samples. This study successfully indicated that in 
vitro imaging receptor assays were useful in predicting the affinity of a new 
receptor-directed MR imaging contrast agents in human tissue prior to 
clinical trials, opening new avenues in this field. 
 
Development of targeted MR CA directed to specific molecular 
entities dramatically expanded the range of MR applications by combining 
the non-invasiveness and high spatial resolution of MRI with specific 
localisation of molecular targets. However, due to the intrinsically low 
sensitivity of MRI compared with nuclear imaging, high local concentrations 
of the CA at the target site are required to generate detectable MR contrast. 
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To meet these requirements, the MR-targeted CA should recognise targeted 
cells with high affinity and specificity. It should also have high relaxivity, 
which for a wide variety of CAs depends on the number of contrast-
generating groups per single molecule of the agent. In order to improve CAs’ 
affinity and specificity, important studies have been carried out by Artemov 
et al. to investigate the Her-2/neu receptor on breast cancer cells [14]. Breast 
cancer cells were imaged by MRI in the presence of a monoclonal antibody 
conjugated to iron oxide nanoparticles. This application of antibodies 
conjugated to iron oxide nanoparticles to target breast cancer cells was seen 
to be of great value for basic science studies in the laboratory, and showed 
tremendous potential for the clinic, offering new opportunities for 
diagnosing disease and guiding therapy, for example by providing 
information on the usefulness of the drug herceptin. The application of 
imaging technologies available for molecular imaging in the laboratory 
allowed the characterisation of a growing number of animal tumour models 
addressing important questions about tumorigenesis, and in development of 
new disease treatments. This study also served to decrease the number of 
animals to be sacrificed compared to when these techniques were not 
available [15,16]. 
 
In 2005, at the National Italian Cancer Research Institute (IST-Istituto 
Nazionale per la Ricerca sul Cancro), we were investigating the application 
of novel iron-oxide nanoparticle-antibody conjugates to target lymphoma 
tumours by a clinical MR human scanner [17]. 
 
Superparamagnetic iron oxide (SPIO) nanoparticles consist of iron oxides, 
magnetite (Fe3O4), maghemite (Fe2O3) or other ferrites, which are insoluble 
in water. SPIO nanoparticles are strong enhancers of proton relaxation, with 
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superior T2 (transverse relaxation) shortening effects, that can be used at a 
much lower concentration than paramagnetic agents. An important 
advantage of iron oxide nanoparticles is that they exhibit magnetic properties 
in the presence of an applied magnetic field, and they can form stable 
colloidal suspensions which can be crucial in biomedical fields, especially 
in vivo. Indeed, they can be directed to a desired site in the body, making 
them useful for controlled targeting in clinical and in pre-clinical studies 
[18]. 
 
The successful application of SPIOs is strongly dependent on the structural 
characteristics, such as the size, distribution, shape, and the ability to detect 
macromolecules. This opens up the possibility to engineer the surface of 
these particles, creating a polymeric or inorganic molecular shell 
surrounding the iron oxide cores, followed by the functionalisation with 
specific biomolecules on the outer shell layer.  
 
Magnetic field gradients induced by superparamagnetic particles contribute 
to the dephasing of protons that move by diffusion in the vicinity of particles, 
resulting in significant T2/T2* relaxation. SPIOs are mostly used because of 
their negative enhancement effect on T2 and T2* weighted sequences. The 
predominant effect on the T2 relaxation time does not prevent the use of the 
properties of these agents on the T1 relaxation time when appropriate 
imaging sequences are chosen. The mean size of SPIOs ranges from 
approximately 60 to 250 nm, making them subject to phagocytosis by 
monocyte–macrophage system (i.e. Kupffer cells). Sequestered SPIO 
particles are metabolically biodegradable and bioavailable. They therefore 
exhibit a rapid turnover into the body iron stores and incorporate into 
erythrocyte haemoglobin. Depending on the iron oxide nanoparticle 
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composition and size, which influence their biodistribution, several pre-
clinical applications (i.e., tumour targeting, cell labelling, immune cell 
trafficking) and clinical applications (i.e., detection of liver metastases, 
metastatic lymph nodes, inflammatory and/or degenerative diseases) are 
possible. SPIOs are also investigated as blood pool agents, in particular, 
ultrasmall superparamagnetic iron oxide particles (USPIO), which range 
from 10-40 nm in size, are used for their relaxivity properties, and applied 
for: angiography, tumour permeability and tumour blood volume using T1 
weighted sequences; and steady-state cerebral blood volume and vessel size 
index measurements using T2* weighted sequences [18].  
 
In order to provide different signal intensity from targeted and non-
targeted tissue, SPIOs or USPIOs can be conjugated with different kinds of 
ligands (i.e. monoclonal antibodies, peptide, and oligonucleotides) [18]. The 
association of MRI with specific superparamagnetic tumour contrast agents 
offers increased accuracy and specificity of imaging [18]. In particular, 
monoclonal antibodies (mAbs) were an important emerging tool in cancer 
therapy at the time of this work, and the study of specific surface markers on 
tumour cells determined the feasibility of developing the monoclonal 
antibodies for using as targeted therapeutic agents. The main therapeutic 
effect of mAbs is due to the antigen-binding regions, which provide 
specificity to the tumour-killing effects. Therapeutic mAbs can also act by 
blocking the binding of growth factors, directly signalling arrest and 
apoptosis, or inducing elimination of mAb-decorated target cells via 
activation of host defence mechanisms [19]. The paucity of tumour specific 
antigens has led to the development of mAbs directed against receptors that 
are overexpressed in cancers compared with normal tissues (for example, 
trastuzumab for breast cancer). Alternatively, antibodies have been used to 
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target cell surface molecules characteristic of the lineage from which the 
malignant cells derive (for example, mAbs against CD20 (rituximab), CD52 
(alemtuzumab), and CD33 (gemtuzumab ozogamicin)). 
 
We focused our MI research on anaplastic large B-cell lymphoma, 
since our research group was very experienced in the investigation of this 
type of tumour and had previously established a CD30+ Epstein Barr virus 
(EBV)-infected B cell line that showed a B clonal rearrangement and strong 
CD30 antigen expression [20]. 
 
Anaplastic large B-cell lymphoma is the most common of the non-Hodgkin 
lymphomas (NHLs). The normal counterparts of these lymphomas are 
thought to be proliferating B cells (centroblasts or immunoblasts). As such, 
it is not surprising that, aside from pan-B markers such as CD19, CD20, and 
CD22, many NHLs express markers commonly associated with B-
lymphocyte activation. Some of these activation markers could be viable 
alternative targets for antibody-based therapeutics. One such activation 
marker, CD70, is a member of the tumour necrosis factor (TNF) family 
whose expression is tightly regulated and only transiently induced on 
antigen-stimulated B and T cells. Of interest, CD70 is expressed by a variety 
of transformed cells of both hematopoietic and epithelial cell origin. 
 
Our research team previously demonstrated the role of LD6 mAb (CD70 
mAb) in recognising a novel non-lineage-specific activation antigen that 
was involved in the induction of the functional programme of long-
term cultured T or natural killer cells [21,22]. Seventy one percent of diffuse 
large B-cell lymphomas, 33% of follicular lymphomas, 50% of B-cell 
lymphocytic leukaemia, 25% of Burkitt and mantle cell lymphomas, and 
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100% of Waldenström macroglobulinemia, as well as most Hodgkin disease 
Reed-Sternberg cells, express CD70 [23]. 
 
Following the identification of the tumour antigens that we aimed to target 
(CD20 and CD70), we then performed two imaging studies [17, 24] to image 
lymphoma tumour antigen expression by using mAbs conjugated to iron-
oxide nanoparticles. 
 
We applied two types of targeting approach: direct tumour targeting (where 
the primary antibody is directly conjugated to a specific tumour label) [17] 
and indirect tumour targeting (where the primary antibody is directly 
conjugated to a secondary non-specific tumour label) [24]. 
 
We applied a tumour mAb, USPIO-anti-CD20, specifically directed to CD20 
lymphoma antigens for the direct tumour targeting experiment. Surface 
expression of CD20 antigen by D430B or Raji lymphoma cell lines and of 
anti-CD20-USPIO conjugates bound to the cell surface was performed by 
immunofluorescence and cytofluorimetric analysis (Figure 1, 2). 
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Figure 1.  Surface expression of CD20 antigen by D430B and Raji lymphoma cell lines 
by immunofluorescence and cytofluorimetric analysis. D430B cells display higher levels 
of Mfi (mean fluorescence intensity) than Raji cells. CTR= Control [17]. 
 
 
Figure 2. Detection of anti-CD20-USPIO conjugates bound to the cell surface by 
cytofluorimetric analysis. Immunofluorescence profile of D430B control cells (CTR, 
dottedline) and of D430B USPIO-anti-CD20 cells stained with a phycoerythrin-labelled 
anti-mouse immunoglobulin antibody. With the increase of cell-bound USPIO-anti-
CD20, higher fluorescence signal is detectable (continuous line). X axis: fluorescence 
intensity in log scale, Y axis: cell number [17]. 
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MRI at 1.5T allowed the detection of USPIO-antibody conjugates 
specifically bound to human tumour cells both in vitro and in vivo (Figure 
3, 4) and, the MRI SI correlated with the concentration of USPIO-antibody 
used and with the antigen density at the cell surface. A control group injected 
with ferumoxides demonstrated that the decrease in SI was related to USPIO-
antibody targeting (Figure 5). 
 
 
Figure 3. T2-weighted three-dimensional fast field echo images of D430B CD20 high 
tumour analysed before and after USPIO-anti-CD20 antibody administration. On T2-
weighted three-dimensional fast field echo images after USPIO-anti-CD20 antibody 
administration the CD20high D430B tumour showed an inhomogeneous decrease in 
signal intensity (arrows). T2-weighted three-dimensional fast field echo sequences=T2-
3D-FFE (50/12/with flip angle7◦). T1-weighted three-dimensional fast field echo 
sequences=T1-3D-FFE (17/4.6/with flip angle13◦). USPIO ultrasmall 
superparamagnetic particle iron oxide, SI signal intensity [17]. 
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Figure 4. T2-weighted three-dimensional fast field echo images of Raji CD20 low 
tumour analysed before and after USPIO-anti-CD20 antibody administration. On T2-
weighted three-dimensional fast field echo images, the Raji CD20 low tumour analysed 
after USPIO-anti-CD20 antibody administration showed an inhomogeneous decrease in 
signal intensity (arrows). T2-weighted three-dimensional fast field echo sequences=T2-
3D-FFE (50/12/with flip angle 7◦); T1-weighted three-dimensional fast field echo 
sequences=T1-3DFFE (17/4.6/with flip angle13◦). USPIO ultrasmall superparamagnetic 
particle iron oxide, SI signal intensity [17]. 
 
 
Figure 5. Representative MR Images of the control group injected with ferumoxides. 
No changes of SI on T2-weighted three-dimensional fast field echo images before and 
after ferumoxides administration (arrows) were observed. T2-weighted three-
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dimensional fast field echo sequences=T2-3D-FFE (50/12/with flip angle7◦). SI signal 
intensity [17]. 
 
Many antibodies directed to tumour antigens, potentially useful especially in 
experimental settings, are not available as USPIO conjugates. We therefore 
sought to evaluate whether an indirect targeting technique, which employs 
unlabelled mAbs followed by a common USPIO-conjugated secondary 
reagent, could provide an equally suitable contrast agent. The feasibility of 
targeting superparamagnetic particles to tumours by means of a two-step 
system based on the administration of tumour-specific biotin-conjugated 
antibodies followed by USPIO-anti-biotin, was assessed. We chose to target 
the human CD70 antigen, expressed by lymphoma cells and only transiently 
by normal activated lymphocytes, identified by the murine mAb LD6. Since 
LD6 does not react with murine cells, it seemed suitable for the monitoring 
of human lymphoma xenografts in mice. An isotype-matched murine mAb 
that does not react with human lymphoma cells, CH-L, was used as negative 
control. The two purified antibodies were both biotin-conjugated in-house 
and labelling was assessed by Western blot with streptavidin-HRPO and 
found to be equal (Figure 6). As common secondary reagent, commercially 
available USPIO particles conjugated with monoclonal anti-biotin were 
chosen since their physical characteristics matched those of the USPIO-anti-
CD20 contrast agent successfully used in our previous experiment of the 
direct tumour targeting. 
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Figure 6. Immunofluorescence analysis of CD70 surface expression. (A) Surface 
expression of CD70 antigen by D430B lymphoma, A2774, ovarian carcinoma and Jurkat 
leukaemia cells as assessed by indirect immunofluorescence and cytofluorimetric 
analysis (upper panels) or confocal microscopy (lower panels). Immunofluorescence 
profiles of cells stained with biotin-conjugated anti-CD70 LD6 mAb (continuous line), or 
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with biotin-conjugated CH-L mAb as isotype matched negative control (dotted line), 
followed by FITC-Streptavidin. (B) Purity of LD6 and CH-L mAbs (1µg/lane) resolved 
by SDS-PAGE analysis under non-reducing conditions, as assessed by Coomassie blue 
staining of 8% polyacrylamide gels (upper panels). As standard 3 and 1 µg of a 
commercially available IgG2b mAb were run in parallel lanes. (C) Immunofluorescence 
profile of D430B cells challenged with biotin-conjugated monoclonal antiCD70 (LD6) 
plus (continuous line) and minus (gray profile) USPIO-anti-biotin, followed by FITC-
anti-mouse serum. (D) MRI analysis at 1.5 T of antibody+USPIO-treated cell pellets in 
test tubes. Only D430B cells treated with biotinylated LD6+USPIO-anti-biotin showed a 
clearly hypointense signal on T2-weighted threedimensional fast-field echo images [24]. 
 
LD6 and CH-L antibody display a similar degree of biotinylation as detected 
by western blot analysis of equimolar amounts of the two antibodies and 
staining with HRPO-streptavidin and revealed by chemoluminescence. 
Antibodies were resolved on 8% acrylamide gel under non-reducing 
conditions. 
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Figure 7. Coronal MR images of pseudo-metastatic lymphoma xenografts. MRI images 
demonstrated the presence of tumour masses in the retroperitoneal space, in particular 
in the right kidney (arrow) with hydronephrosis (hyperintense signal area). On b-FFE 
weighted images, before (A) and 24 hours after (B) the administration of biotin-
conjugated LD6 antibody plus USPIO-anti-biotin, tumours (arrows) and liver (*) showed 
an evident and homogeneous decrease in SI. On T2-weighted three-dimensional fast field 
echo images, before (C) and 24 hours after (D) the administration of biotin-conjugated 
LD6 antibody plus USPIO-anti-biotin, tumours (arrows) did not show decrease in SI 
whereas the liver showed a significant decrease in SI (*) [24]. 
 
The novelty of these studies was in the application of USPIO-mAbs 
microbeads produced by a Biotech company (Miltenyi Biotec, Bergisch 
Gladbach, Germany) for in vitro cell separation as an MR contrast agent and 
the preclinical application of these microbeads using a clinical MR scanner. 
All previous studies applied high or ultra-high field MR scanners, up to 7T, 
which were dedicated for small animal models [25,26]. In our study, MR 
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imaging was performed on a clinical scanner at 1.5T, providing a good 
signal-to-noise ratio (SNR) for both tumour/no tumour. The use of a clinical 
MR scanner for preclinical studies in 2005 was novel, supporting the proof 
of concept that preclinical experiments could be carried out by using clinical 
tools, and thus the results obtained were more easily translatable into a 
clinical setting. The application of a molecular imaging platform such as 
USPIO-mAbs conjugates (specifically anti-CD20 mAb, rituximab or anti-
CD70), once bound to the tumour antigen could also be applied as 
therapeutic tool, supporting once again the concept of imaging 
“theragnostic”. 
 
The application of the USPIO-mAbs microbeads as MR probes was the first 
application in this type of experiment, as they had never been applied in an 
imaging study as contrast agents. With our experiments, MR imaging 
features of these microbeads were established for the first time. We 
measured the iron content of the USPIO-antibody core by inductively 
coupled plasma optical emission spectrometry with a Varian Vista Pro 
spectrometer (Varian Inc., Palo Alto, CA, USA) and calculated the specific 
MR Relaxivity features of the microbeads. The discovery of the MR 
microbeads’ features allowed us to apply this tool as an MR probe for in 
vitro and in vivo imaging studies. 
 
Following our experiments, the Molecular Imaging and Contrast Agent 
Database (MICAD; https://www.ncbi.nlm.nih.gov/books/NBK5330/), a key 
component of the “Molecular Libraries and Imaging” programme of the 
National Institutes of Health (NIH) Common Fund (formerly NIH 
Roadmap), in Bethesda, Maryland, cited and officially included our 
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experiments as the first demonstration of the development of a new MI probe 
for MR imaging [27]. 
 
During this period, in 2005, in Europe, many scientific groups were 
developing research on MI and for this reason the European Molecular 
Imaging Society (ESMI- http://www.e-smi.eu/index.php?id=1987) was 
established; it became an independent structure in 2010. In the USA, the 
members of the Molecular Imaging Centre of Excellence (MICoE) agreed 
with respect to the important role of MI in Radiology and agreed world-wide 
with the official definition for “Molecular Imaging” and “molecular probes” 
[28]. All the studies that aimed to visualise, characterise, and measure 
biological processes at the molecular and cellular levels in humans and other 
living systems, were then officially termed “Molecular Imaging” and the 
endogenous or exogenous probes applied as imaging tools were defined as 
“Molecular Imaging probes”.  
 
The improvement of these laboratory-based studies improved the potential 
of translating the basic science principles into the clinical environment. For 
this reason, we can consider MI as the interface between our growing 
understanding of the molecular basis of the disease and the translation of this 
knowledge to new treatments in the clinic and for a better selection of 
patients for specific therapies. With the opportunity of investigating the 
morphology plus function/metabolism, MI aims to increase both the 
specificity and sensitivity of tumour detection. The information coming out 
of genome sequencing can be used to develop imaging methods that are 
targeted at specific molecular features of the diseased tissue. In this view, 
imaging becomes a tool with tremendous potential for the early detection of 
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tumours, characterisation of the disease process, and understanding of the 
underlying biochemistry and evaluation of subsequent treatment. 
 
1.1.2. Cell labelling by iron oxide nanoparticles 
 
Following the MR tumour targeting investigation, we also explored 
the opportunity to target immune cells, such as Natural Killer (NK) cells: a 
subpopulation of lymphocytes that play an essential role in the cell-based 
immune defence against viruses and malignant cells. Various investigators 
have evaluated the antitumoural activity of NK cells, including mechanisms 
of immunosurveillance, escape strategies of the malignant cells, and risk of 
adverse reactions [29,30,31]. Previous cell labelling studies were performed 
with radioactive or fluorescent markers [30,31]. Labelling techniques with 
radioactive markers provide high sensitivity but limited spatial resolution 
and the risk of radiotoxic cell damage. Labelling techniques with fluorescent 
markers provide high sensitivity but are currently restricted to experimental 
applications at limited depth. Labelling with MR contrast agents have the 
advantage of being less toxic than radioactive markers and provide an 
anatomical resolution at the near microscopic level in vivo. However, MR 
cell tracking techniques are restricted by limited sensitivity, which require 
highly efficient labelling techniques in order to load up the investigated cells 
with high amounts of contrast agent particles. Such optimised labelling 
methods have been developed before for various haematopoietic cell 
populations, including lymphocytes, monocytes, and haematopoietic 
progenitor cells [30,31]. For non-phagocytic cell types, such labelling 
techniques required transfection, i.e., internalisation of contrast agents into 
the cells with the help of liposomes, proteins, or viral vectors. Genetically 
engineered lymphocytes already undergo a transfection process in order to 
shuttle new genetic information into the cells. A subsequent secondary 
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transfection, e.g., for purposes of contrast agent internalisation, has a known 
lower efficiency than the primary transfection. Therefore, cell labelling 
protocols for genetically engineered cells need to be tailored and optimised 
to these cells.  
 
In our study, we aimed to demonstrate a non-invasive method to label NK 
lymphocytes. We applied a commercially available ferumoxides suspension 
(Endorem, Guerbet, Paris), combined either with protamine sulphate or with 
polylysine as transfection agents. For the assessment of labelling efficiency 
and to study the signal intensity we performed our experiments on a clinical 
MR scanner at 1.5 T and four groups were compared, respectively: 
unlabelled NK cells; NK-ferumoxides alone; NK-ferumoxides plus 
protamine (Pro); NK-ferumoxides plus polylysine (PLL). Significant 
decrease in SI on T2 MRI was achieved in human ferumoxides-PLL-NK-
labeled cells (60%) compared with human ferumoxide-Pro-NK-labeled cells 
(30%) at concentrations that did not have deleterious effects on cellular 
viability or function. The detected contrast change lasted for at least 24 
hours. 
Our results raised the possibility that iron-oxide-nanoparticle-labelled 
lymphocytes could be used to track these cells in tumours and other tissues 
using high spatial resolution MRI. The optimisation of molecular-targeted 
contrast agents, MRI technology and the generation of new USPIO or SPIO 
antibodies, or other USPIO or SPIO ligands, may provide useful 
immunospecific-contrast agents for the diagnosis of tumours and for 
targeting cells for cell therapy. In this way, it promises to provide new 
methods for the early detection of cancer and support for personalised cancer 
therapy. 
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Our studies on the preclinical application of iron oxide nanoparticles, 
allowed us the opportunity to provide our contribution to a Molecular 
Imaging textbook, edited by Xiaoyuan Chen, with two chapters [18]. 
 
1.2. Investigation of tumour imaging by using MEMRI 
 
The concept of using a clinical MR scanner for preclinical studies in 
order to easily translate results into a clinical setting, brought us to the 
development of a new prototype birdcage coil for animal models in 
conjunction with a clinical 3T MR scanner (Figure 8). This was the result of 
a scientific collaboration between me, General Electric Healthcare (GE, 
Milwaukee, USA), and Flick Engineering (The Netherlands). 
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Figure 8. Experimental prototype birdcage coil for use with a clinical 3T MR scanner 
(Baio G & GE Healthcare & Flick Engineering-Department of Radiology, IRCCS AOU 
San Martino - IST - Genoa/IT). 
 
Some of the research produced using the new prototype birdcage coil is not 
part of this thesis; however, since this was an important part of my research 
career, I here cite a few works in which the new prototype birdcage coil was 
applied in small rodents for the first time [32,33]. The subsequent research 
project that we developed, using the new prototype birdcage coil for tumour 
targeting, aimed to investigate calcium metabolism in breast cancer animal 
models [34]. 
 
Changes in calcium metabolism can be a feature of cancer [35-39] and 
to better understand altered calcium metabolism in vivo, a non-invasive 
method such as imaging is of great value. To investigate calcium metabolism 
in tumours we used manganese as an MR contrast agent, because of the 
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interesting combined physical and biological properties of this contrast 
agent. 
 
Manganese-enhanced-MRI (MEMRI) is a very old technique, and 
several imaging studies have been performed in order to target calcium ion 
metabolism. Manganese is a T1 contrast agent, which permits to combine 
anatomical with functional imaging in multiple systems. Furthermore, since 
it is an analogue of calcium ions, it can enter cells via the same transport 
systems as Ca2+ and can bind to several intracellular structures because of its 
high affinity for Ca2+ and Mg2+ binding sites on proteins and nucleic acids 
[40,41]. Several research studies applied manganese as an MR contrast agent 
to investigate the brain [42,43], heart [44,45], olfactory [46], visual [47,48] 
and somatosensory pathways of rats and mice [49-51]. Early investigation in 
the application of manganese to visualise breast cancer tumours was 
performed using a paramagnetic metalloporphyrin that chelates Mn2+ as an 
MR contrast agent in murine models [52,53]. 
In our experiments, we applied manganese to target breast cancer 
tumours with high level expression of Calcium Sensing Receptors (CaSRs) 
[34]. In the past decade the role of Ca2+ as the extracellular first messenger 
in causing or preventing cancer has been under active investigation [54] 
following the cloning of plasma membrane CaSR from the parathyroid gland 
[55]. CaSRs are seven-transmembrane G-protein-coupled receptors capable 
of sensing changes in extracellular calcium concentration, which inhibits 
secretion of parathyroid hormone (PTH) following binding with its 
physiological ligand Ca2+[56]. CaSRs are expressed at different levels in 
normal human breast duct cells, in the duct cells of fibrocystic breast tissue, 
and in ductal carcinomas of the breast [57]. In addition, calcium ions play 
key roles not only in normal breast physiology but also in various 
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pathological conditions. In vitro studies have shown that increased Ca2+ 
levels induce terminal differentiation of normal human breast epithelial cells 
in culture [58]. Breast cancer has a marked tendency to spread to bone [59]. 
The observation that numerous cells within the bone marrow express CaSRs 
under normal circumstances [60], leads to the hypothesis that the presence 
of CaSRs on metastatic cells may contribute to their propensity to reside in 
bone, where locally high levels of Ca2+ are present during the resorption 
processes. The local Ca2+ level at resorption sites has been reported to rise as 
high as 40 mM [61]. Indeed, high Ca2+ levels (5, 7.5 and 10 mM) stimulate 
the secretion of parathyroid hormone related protein (PTHrP) in some breast 
cancer cell lines in vitro, presumably via a CaSR-mediated mechanism [62]. 
Excess PTHrP could contribute to the massive osteolysis caused by breast 
cancer bone metastases by promoting a feed-forward mechanism in which 
release of Ca2+ from the bone stimulates further PTHrP production and more 
bone resorption [63-65]. Interruption of this cycle by blockade of CaSR 
activity [66] could potentially offer substantial therapeutic benefit in this 
situation. Therefore, given the importance of Ca2+ in both the physiology and 
pathophysiology of the breast and bone, the CaSR could play different roles 
in these processes. 
Moreover, the interest in CaSR has been refreshed by the finding that, in a 
selected group of patients with advanced breast cancer, CaSR expression 
assessed by immunohistochemistry is high, predominantly in tissue 
specimens from patients who developed bone metastases [67]. 
 
In our imaging study we addressed the possibility of using free MnCl2 
as a contrast agent in MRI of in vivo human breast cancer. This hypothesis 
was supported by previous observations showing that activation of CaSR by 
divalent cations such as Ca2+ and Mn2+ [68,69] triggers ion influx through 
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non-selective cation channels [38,70,71]. Therefore, we speculated that Mn2+ 
may accumulate in CaSR-positive breast cancer cells and allow their 
imaging. In addition, human breast cancer cell lines MDA-MB-231 and 
MCF-7, which give rise to tumours if transplanted in immunocompromised 
mice, express CaSR at different levels and secrete PTHrP upon stimulation 
[57,62,71,72]. 
 
Tumours formed by human breast cancer cells orthotopically implanted in 
the mammary fat pad of NOD/SCID mice maintain high CaSR expression 
and intravenous injection of MnCl2 permits tumour imaging by a 3T MR 
scanner (Figure 9, 10).  
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Figure 9. Manganese enhanced MR imaging (MEMRI) of the orthotopic human breast 
cancer xenografts. a–f MRI of the same mouse at two different time points. The tumour 
dimension was 5 mm at the first determination and 10 mm the week after. On T1-weighted 
gradient echo images tumours showed a hyperintense area at their periphery (ring of 
manganese enhancement) 10 min after Mn2+ administration (b–e) and full contrast 
enhancement 40 min, with persistence of a brighter peripheral area (c–f) [34]. 
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Figure 10. Immunohistochemical analysis of CaSR in human breast cancer MDA-MB-
231 cells xenograft (a–c). CaSR is detected in tumour cells (score 4–5) and displays more 
intense staining at the tumour periphery, as detailed in b and c. Original magnification 
200× [34]. 
 
The involvement of CaSR in MnCl2 contrast enhancement was suggested by 
the study of its distribution in the tumour tissue and by blockade of MEMRI 
through the Ca2+-antagonist drug verapamil (Figure 11).  
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Figure 11. A, B Coronal MR images of the orthotopic human breast cancer xenograft 
in a verapamil-treated control. MR images show no signal intensity increase after 40 
minutes of Mn2+ administration (b) in the mouse treated with verapamil [34]. 
 
A potential drawback to the use of Mn2+ as a contrast agent is its cellular 
toxicity, which limits the dose administered. It has been described that a dose 
of 30 mg/kg MnCl2·4H2O did not interfere with the animals’ well-being [73]. 
Nevertheless, MR relaxation rates are proportional to the effective 
concentration of Mn2+ in tissue, thus significant amounts of Mn2+ are 
required to produce robust and detectable contrast. In our study, a single 
maximum dose of 8.5 mg/kg MnCl2 was administered per mouse, well below 
the toxicity threshold described, and still permitted good SI in the MR 
images. 
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The goal of this study was to give proof of principle that Mn2+ could 
accumulate in breast cancer, possibly as result of CaSR expression in vivo. 
However, further studies to validate the role of manganese as tumour 
contrast agent were needed. Thus, we set up a method to evaluate the 
contribution of Mn2+ ions in the intra- and extracellular tumour 
compartments [74]. For imaging tumour detection and staging, it is relevant 
to assess whether the observed signal enhancement (SE) originates from the 
intracellular or the extracellular compartment. To tackle this task, we 
silenced the relaxation enhancement arising from Mn2+ in the extracellular 
space by using a sequestering agent which kept all the Mn2+ ions in the 
extracellular compartment in a highly stable chelate. The chelate was 
characterised by a low relaxivity (“MRI silent”). The comparison of the 
signal intensities of the region of interest (ROI) before and after the 
“sequestering” step allowed the identification of the relative contributions 
from intra- and extracellular tumour compartments in in vitro MEMRI 
experiment (Figure 12). 
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Figure 12. Amount of internalized Mn2+ in B16F10 cells incubated with MnCl2 and 
Mn-DO2A for 1 and 7 h. (statistical analysis:  P < 0.01; P < 0.001) [74]. 
 
The interesting findings of this experiment underlined the different 
internalisation of Mn2+ ions also in in vivo experiments, between healthy and 
tumour tissues, since we found that in healthy tissue Mn2+ is mainly localised 
in the extracellular compartment while in the tumour tissues it is internalised 
in the intracellular compartment. The chemical composition of the 
extracellular microenvironment in healthy tissue may be very different from 
that present in tumours. Serum albumin could represent a reason why Mn2+ 
is temporarily sequestered. The main impact of this study was in providing 
a new insight in the investigation of Mn2+ as MR contrast agent to target 
tumours and thus strengthen the MEMRI approach for early detection and 
characterisation of tumours’ calcium metabolism. 
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1.3. Exploring a new role of MEMRI for visualising brown adipose 
tissue. 
 
The recent increased attention on the role of active BAT in adult 
humans, and its relationship with different pathological conditions, has 
opened new avenues, particularly in obesity research and treatment, diabetes, 
hypertension, and cancer cachexia. The study of BAT is interesting because, 
although the amount of this tissue is very small, it can have a pivotal role in 
the biology of energy balance. This tissue is found mainly in the neck, chest, 
around major blood vessels, muscles or white adipose tissue. High 
mitochondrial and capillary content, as well as the presence of uncoupling 
protein one (UCP1), are the main characteristics. Activation of UCP1 
enables free-flow of protons across the mitochondrial membrane, resulting 
in rapid dissipation of chemical energy as heat. The primary energy source 
for this process comes from esterified fatty acids that are released from lipids 
at the same time as UCP1 is activated, usually through activation of the 
sympathetic nervous system.  
Obesity and cancer cachexia are two conditions that result from an imbalance 
between energy intake and energy expenditure where the activation of BAT 
seems to play an important role. How cancer induces thermogenesis in 
brown fat cells and how this might relate to the wasting of fat and skeletal 
muscle is still unknown. 
 
Clinical investigations on BAT’s role and its activation in cancer are 
currently limited by the lack of non-invasive tools for measuring the mass 
and function of this tissue in humans. Currently, 18FDG-PET/CT (2-deoxy-
2-fluorine-18-fluoro-D-glucose positron emission tomography/ computed 
Tomography) is considered the “gold-standard” method to identify BAT in 
humans [75], although BAT glucose metabolism does not accurately reflect 
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BAT thermogenic activity [76]. It is important to note that accurate 
quantification of total BAT volume of metabolic activity by the addition of 
numerous small regions of interest, typically less than 1 cm3 each, is very 
challenging with PET [76,77]. 
 
During the MEMRI experiments, we incidentally observed 
manganese uptake by Brown Adipose Tissue (BAT). We thus performed a 
new set of experiments to further investigate brown adipose tissue in both 
healthy controls and breast or prostate cancer animal models (orthotopic and 
pseudo-metastatic cancer animal models) using MEMRI [78]. We applied 
manganese as a contrast agent because of its accumulation in cells via 
calcium channels. Calcium ion influx has been linked with brown adipose 
tissue activation through adenosine triphosphate (ATP) [79,80] and we 
hypothesised that Mn2+, as a calcium surrogate, may accumulate in BAT 
through mitochondria and transient receptor potential channels (TRP), thus 
allowing its imaging. 
 
MEMRI was able to visualise the activation and localisation of BAT vs white 
adipose tissue (WAT) in healthy controls (Figure 13) and in cancer animal 
models (Figure 14, 15).  
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Figure 13. In vivo Non-invasive Detection of Brown adipose Tissue (BAT) through 
Manganese Enhanced Magnetic Resonance Imaging (MEMRI) in healthy controls. 
Signal intensity of liver, axillary, inguinal and scapular BAT, was calculated before and 
20 minutes and 20 hours after MnCl2 administration. ∆SI% values are indicated in the 
table per each organ [78]. 
 
In cancer animal models BAT manganese uptake was independent from cold 
exposure or chemical drug activation. Especially, cancer animal models with 
advanced disease (pseudo-metastatic breast or prostate cancer animal 
models; Fig. 14) demonstrated a significant increase in BAT manganese 
uptake compared to localised tumour animal models (orthotopic breast or 
prostate cancer animal models; Fig. 15) (P<0.05). 
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Figure 14. In vivo Non-invasive Detection of Brown adipose Tissue (BAT) through 
Manganese Enhanced Magnetic Resonance Imaging (MEMRI) in metastatic prostate 
and breast cancer animal models. Signal intensity of liver and scapular BAT was 
calculated before and one hour after MnCl2 administration. ∆SI% values are indicated 
in the table per each organ [78].  
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Figure 15. In vivo Non-invasive Detection of Brown adipose Tissue (BAT) through 
Manganese Enhanced Magnetic Resonance Imaging (MEMRI) in orthotopic prostate 
and breast cancer animal models. Signal intensity of liver and scapular BAT was 
calculated before and one hour after MnCl2 administration. ∆SI% values are indicated 
in the table per each organ [78]. 
 
The increased activity of BAT in the metastatic animal model (advanced 
disease) compared with the orthotopic model (localised disease) may suggest 
important implications of BAT in tumour progression and, thus, cancer 
cachexia. More studies in the molecular characterisation of the two different 
BATs are necessary to better understand the molecular process behind 
cancer progression and BAT activation. 
 
Our findings opened important opportunities in the application of manganese 
as an MRI contrast agent to better understand BAT physiology and 
physiopathology in vivo and its role in cancer progression. The results of this 
research are not completely published yet, but they have been included in 
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this thesis because they were presented and awarded with a prize during the 
World Molecular Imaging Congress in 2015. This study was also selected as 
high impact research by Professor John C. Gore during his Highlighted 
Plenary Lecture (session 7- WMIC) [78]. 
 
1.4. Application of in vivo proton MR spectroscopy in breast cancer 
expressing different levels of calcium sensing receptors. 
 
The main limitation of studies using Manganese as an MR contrast 
agent is that Manganese is not commercially available for application in the 
clinical setting, and thus can only be investigated in preclinical Molecular 
Imaging studies. To overcome this limitation and to further explore the role 
of CaSR in breast cancer tumours, we developed a prospective clinical MR 
investigation using in vivo proton magnetic resonance spectroscopy (1H-
MRS) in breast cancer patients [81]. 
Cancer cells have a multitude of redundant pathways and networks, and one 
of the hallmarks of cancer is the “cholinic phenotype” [82]. Activated cancer 
choline metabolism is characterised by increased phosphocholine (PCho) 
and total choline-containing compounds (tCho), which was discovered 
mostly via magnetic resonance spectroscopy (MRS) studies of tumours in 
the 1980s [83,84]. Initially, the increased PCho levels in cancer cells were 
considered as a significant indication of high rate of cancer cell proliferation 
[85]. Subsequent studies demonstrated that PCho and tCho levels in non-
malignant breast or prostate epithelial cells identified malignant 
transformation, rather than just cell proliferation, as the cause of abnormal 
choline metabolism in cancers [86]. The search for biomarkers to detect 
cancer and to monitor non-invasively the response to treatment has led to 
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several clinical studies evaluating the non-invasive detection of tCho for 
these objectives.  
Similar to studies in cancer cells [87], human tumour xenograft models [87], 
excised tumour tissue [88,89] and clinical studies have confirmed the 
activation of choline metabolism in human tumours in vivo [87,90]. 
Phosphocholine is both a precursor and a breakdown product of 
phosphatidylcholine (PtdCho), which, together with other phospholipids 
such as phosphatidylethanolamine (PtdEtn) and neutral lipids, forms the 
characteristic bilayer structure of cellular membranes and regulates 
membrane integrity [91]. The synthesis of PtdCho and PtdEtn, which are the 
most abundant phospholipids in the cell membrane, was first described by 
Kennedy and Weiss in 1956 [92] and this de novo biosynthesis of PtdCho 
and PtdEtn is termed the Kennedy pathway. The high-energy intermediates 
cytidine diphosphate (CDP)-choline and CDP-ethanolamine are required to 
synthesise PtdCho and PtdEtn. These two mirror pathways, one that uses 
choline and the other that uses ethanolamine, are called the CDP-choline and 
CDP-ethanolamine pathways, respectively. The biosynthesis and hydrolysis 
of PtdCho mediates mitogenic signal transduction events in cells, and 
products of choline phospholipid metabolism, such as PCho [93], 
diacylglycerol (DAG) [94,95], and arachidonic acid metabolites [94], may 
function as second messengers that are essential for this mitogenic activity. 
Growth factor stimulation [95], cytokines [96], oncogenes [86] or 
requirements for eicosanoid production [94] also regulate choline 
phospholipid metabolism. Underlying these phenotypic alterations in 
choline metabolism is a network of transporter systems and enzymes 
involved in choline phospholipid metabolism that are deregulated in cancer 
cells. The increased PCho and tCho levels that have been detected in human 
cancers are caused by interplay between multiple enzymes, which are at the 
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core of choline metabolism and which constitute the biosynthetic and 
catabolic pathways of PtdCho.  
 
The understanding of the molecular mechanisms that regulate the 
production of PCho compound is very limited. In vitro studies on breast 
cancer cells demonstrated the important role of the CaSR in the pathway of 
choline kinase (ChoK) activity and PCho. Calcium ions induce a significant 
increase in extracellular PCho production in breast cancer cells primarily 
related to CaSR-induced ChoK activation and not from degradation of 
choline phospholipids [97]. Since a high level of CaSR expression induces a 
high concentration of calcium ions that activate ChoK in breast cancer cells, 
resulting in increased PCho production, we hypothesised that 1H-MRS may 
detect elevated choline peak levels in breast cancer patients related to CaSR 
activity and expression levels demonstrated with immunohistochemistry 
analysis.  
We prospectively correlated clinical results of breast MR 
spectroscopy obtained with a 3T MR scanner and CaSR-positive and 
negative breast specimens at immunohistochemistry analysis [81]. CaSR=-
expression-level quantification at immunohistochemistry analysis was also 
developed (Figure 16). 
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Figure 16. Immunohistochemical analysis of CaSR expression in human breast cancers 
specimens (score 0-5) [81]. 
 
The aim of this preliminary study was to evaluate a potential role of the CaSR 
in choline metabolism in breast lesion detected by 1H-MRS. A total of 68% 
of the malignant lesions showed a positive choline peak (Figure 17), while 
32% were negative (Figure 18). The combination of of tCho measurement 
with DCE-MRI increases the specificity of malignancy up to 88% (100% 
after the inclusion of a single-slice T2* perfusion measurement) [98]; indeed, 
tCho is significantly higher in mass-type cancers compared to non-mass-type 
cancers [99]. In our study, 32% of breast cancers showed a negative tCho 
and in 91% of these lesions CaSR expression was low (score 1–2) (Figure 
18). These results were supporting the correlation between the expression of 
this receptor in breast lesions and how this expression may influence the 
choline production within the tumour subsequently detected with 1H-MRS. 
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Figure 17. Proton MR Spectroscopy choline peak and calcium sensing receptor (CaSR) 
correlation. A 58-year-old woman with an invasive lobular carcinoma. a) Axial 
VIBRANT (Volume Imaging for BReast AssessmeNT) contrast-enhanced magnetic 
resonance (MR) image (repetition time/echo time [TR/TE] 5.3/2.4ms; 1.2mm slice 
thickness) shows an enhancing irregularly multifocal and multicentric lesion in the right 
breast. b) Malignant type kinetics intensity curve with rapid enhancement in the initial 
phase followed by a plateau in the late phase. c) MIP reconstruction image of the lesion 
in the right breast. d-e) Single-voxel MR spectroscopy (BREASE sequence): VOI 
localisation on the axial VIBRANT contrast-enhanced magnetic resonance MR image 
and the resonance peak of total composite choline compounds (tCho) that was evident at 
3.2 ppm. f) Immunohistochemical analysis of CaSR expression in human breast cancer 
specimen (score 5) [81]. 
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Figure 18. Proton MR Spectroscopy choline peak and calcium sensing receptor (CaSR) 
correlation.  A 62-year-old woman with an invasive lobular carcinoma. a) Axial 
VIBRANT (Volume Imaging for BReast AssessmeNT) contrast-enhanced magnetic 
resonance (MR) image (repetition time/echo time [TR/TE] 5.3/2.4ms; 1.2mm slice 
thickness) shows an enhancing nodule in the left breast. b) Malignant type kinetics 
intensity curve with rapid enhancement in the initial phase followed by washout. c) MIP 
reconstruction image of the lesion in the left breast. d-e) Single voxel MR spectroscopy 
(BREASE sequence): VOI localisation on the axial VIBRANT contrast enhanced 
magnetic resonance MR image and the resonance peak of total composite choline 
compounds (tCho) that was not evident at 3.2 ppm. f) Immunohistochemical analysis of 
CaSR expression in human breast cancer specimen (score 1) [81]. 
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Benign lesions on DCE-MRI, diagnosed as papillary hyperplasia/apocrine 
metaplasia at the histology examination (“borderline benign lesions”), 
showed a consistent choline peak and CaSR with a high score (score 3). 
Although the sample size is insufficient in this group for clear conclusions, 
this result is consistent with the idea that this receptor is expressed and 
probably differently regulated in both benign and malignant conditions 
[100], thus influencing the 1H-MRS results. 
 
The physiological mechanism behind the CaSR-choline pathway confirms 
the importance of the role of this receptor in breast cancers. DCE-MRI plus 
1H-MRS could play an important role in the study of breast cancer and CaSR, 
allowing a “molecular imaging diagnosis” of this select group of patients 
with a high risk to develop bone metastases. Many clinical studies have 
already applied 1H-MRS to monitor the response of locally advanced breast 
cancer, showing that the change in tCho concentration can serve as an 
indicator for predicting clinical response to therapy [101,102]. It would be 
challenging to investigate more how the receptor expression changes under 
chemotherapy and how this relates to the choline peak changes. Recent 
investigation of BRCA1 and CaSR showed how these two factors together 
suppress the expression of survinine and promote sensitivity to paclitaxel in 
human breast cancer cell [103]: this is another example of how CaSR could 
influence not only therapy response, but also the imaging results when using 
a technique such as 1H-MRS (CaSR-choline production).  
 
The future in biomarker research for the evaluation of treatment response 
will be the correlation of gene expression and MR imaging. Gene arrays and 
immunohistochemistry analysis of CaSR-Cho pathways could help to better 
Chapter 1   Critical Analysis 
 
P a g e  69 | 136 
 
understand which gene expression is related to specific changes in the 
aggressiveness of the disease, as assessed by MRI.  
 
The ongoing research and the development of new functional MR techniques 
applied in routine clinical care indicates that the prospects for substantial 
improvements in monitoring therapeutic response, as well as for early 
detection of breast cancer, are promising [104]. A key factor to success will 
depend on the reproducibility of the qualitative and quantitative 
measurements performed by imaging techniques such as MRI-1H-MRS. 
 
1.5. A non-invasive approach to investigate chronic lymphocytic 
leukaemia by using iron oxide nanoparticles. 
 
Chronic lymphocytic leukaemia (CLL) is the most common form of 
adult leukaemia in Western countries. CLL is characterized by the clonal 
expansion of mature CD5+/CD23+ lymphocytes that can infiltrate multiple 
organs including lymph nodes, the bone marrow, spleen, and liver. CLL is 
heterogeneous in terms of therapy-free interval, response to treatment, and 
overall survival, ranging from rapid disease progression requiring early and 
frequent treatment, to survival for decades with minimal or no treatment. 
Computed tomography (CT) is used as the first-line modality for imaging of 
lymphoid malignancies [105]. The role of CT has not been clearly defined 
in CLL patients, although CT for routine disease monitoring of CLL has been 
largely discouraged [106-108. CT scans are recommended for baseline and 
final assessment in clinical trials, but CT is not the method of choice for 
clinical staging [109,110]. On the other hand, FDG/PET, although not 
recommended on a routine basis, has proven useful in detecting the 
transformation of CLL into Richter Syndrome (RS) and for selecting the 
optimal site for performing a diagnostic biopsy [111-114]. Magnetic 
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resonance imaging (MRI) has been applied to investigate the involvement of 
the nervous system by CLL [115] or, for example, to diagnose bone marrow 
infiltration by CLL cells [116,117]. The interest for MRI relates to the 
intrinsic physical properties of this technique, which provides high 
sensitivity without the need for exposure to ionising radiation. 
 
Several mouse models for the study of CLL development have been 
established. These encompass transgenic models in which key genes have 
been altered or xenograft models that use immunodeficient mice that are 
engrafted with human leukemic cells. In all instances, development of the 
CLL clone can be followed by monitoring peripheral blood for the presence 
of leukemic cells, but the evaluation of lymphoid tissues (i.e. the spleen in 
immunodeficient mice, as lymph nodes are mostly atrophic), where the 
leukemic cells have to seed to begin their proliferative phase, requires 
sacrificing the animals. Thus, sensitive and safe imaging techniques to 
monitor disease development may be useful in preclinical models and, more 
importantly based on the above considerations, may also find application in 
routine clinical practice. The sensitivity of MRI in in vivo preclinical studies 
can be improved by using a specific molecular imaging agent. With the help 
of efficient imaging agents, it is possible to detect early-stage disease 
precisely and to monitor the response to drug therapy. The efficacy of iron 
oxide nanoparticles used as specific contrast agents in MRI for liver, spleen, 
and lymph nodes has been demonstrated in experimental and clinical studies. 
Several studies have shown that these particles can significantly improve the 
detection and characterisation of focal lesions within these organs [119-121]. 
 
In our study [122], we aimed to establish a non-invasive specific MRI 
method to better visualise and quantify the presence of CLL disease by 
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USPIO within the spleen in a pre-clinical setting (Figure 19, 20). In 
particular, we used a mouse xenogeneic transplantation model, NOD/Shi-
scid,γcnull (NSG) mice, a NOD/SCID-derived strain that lacks the IL-2 
family common cytokine receptor gamma chain gene (γc) [123,124]. A 
secondary goal of this study was to monitor CLL disease evolution using 
imaging strategies to reduce the overall number of mice needed to evaluate 
CLL cell engraftment over several time points, limiting their sacrifice and 
suffering during experimental protocols. We first observed that changes in 
spleen organisation could be identified four weeks after CLL cell inoculation 
using a 3T clinical scanner and USPIO nanoparticles (Figure 21). Histology 
of the spleens confirmed the presence of CD20+ nodular structures 
surrounded by CD3+ cells (Figure 21). In addition, Perls' Prussian blue 
staining demonstrated that iron particles were excluded from the nodular 
areas occupied by lymphoid cells, providing a rational explanation for the 
MRI signals observed (Figure 21). The combination of extracellular with 
intracellular iron oxide nanoparticle compartmentalisation within the CLL 
spleen affected iron oxide proton relaxivity, which sometimes resulted in an 
increase rather than the expected SI decrease. This high T2-USPIO effect 
has also been reported by Simon G.H. et al. [125]. Measuring circulating T 
and B cells can be employed to assess CLL engraftment in NSG mice by 
using flow cytometry (FC) analysis; however, this method may be 
misleading, as leukemic cells can be difficult to track due to their extremely 
low number in peripheral blood. In addition, when tracked, the leukemic 
cells may represent cells merely surviving after the injection. In contrast the 
application of USPIO enhanced MRI spleen analysis was able to assess the 
engraftment of CLL cells two weeks after their injection, as could also be 
confirmed by immunohistochemistry (IHC) evaluation.  
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Figure 19. Representative slices of the sequence protocol used to measure the signal 
intensity (SI) in tissues of interest. The regions of interest (ROIs, white circles) were 
drawn in the tissues of interest, spleen and in the region outside the anatomy of the mice 
(background noise) in order to measure the signal intensity (SI), as mean ± standard 
deviation (SD) and to calculate the signal-to-noise ratio (SNR) [122]. 
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Figure 20. Magnetic resonance image signal determination and histological analysis in 
control (NSG-CTR) compared to engrafted (NSG-CLL) mice. The figure shows 
representative in vivo USPIO magnetic resonance images (MRI) obtained after 24 h of 
USPIO administration in NSG-CTR (A) and NSG-CLL mouse (D). The position of the 
spleen is indicated by the red outline. Matched histology sections (magnification, 100×) 
show the absence (B) or the presence (E) of CD20 (red) and Ki67 (brown) positive cells; 
Perls' Prussian blue ferric iron staining (C and F) allows the detection of USPIO 
nanoparticles [122]. 
 
A reliable assessment of CLL engraftment two weeks after leukemic clone 
inoculation is most advantageous given that this animal model does not allow 
long term persistence/expansion of the inoculated leukemic cells beyond 
six–to-eight weeks. Thereafter, mice can develop a graft-versus-host disease 
that may also cause the reduction and even disappearance of the leukemic 
cells [124]. In addition, leukemic cells can mature into plasmablasts/plasma 
cells [126]. The above limitations might confound the experimental data, 
particularly when drug treatments are evaluated, because this time-frame 
may not be sufficient to provide information on the long-term effect of drugs. 
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We also reported the possibility of identifying a cut-off value for ΔSNR% 
able to discriminate NSG-CLL from NSG-CTR or NSG-ne mice. 
 
 
Figure 21. Comparison of magnetic resonance image signal intensity change in the 
spleen of control mice (NSG-CTR), mice engrafted (NSG-CLL) at 2 and 4 weeks, and 
non-engrafted (NSG-ne) mice. (A) The scatter dot plot represents percentage signal-to-
noise ratio change (ΔSNR%) of the MRI acquisition analysis comparing NSG-CLL mice 
at 2 weeks (red dots) and 4 weeks (blue dots) from peripheral blood mononuclear cell 
(PBMC) CLL injection, NSG-CTR mice (black dots) and NSG-ne (grey dots, evaluated at 
4 weeks from PBMC CLL injection). Values of ΔSNR% are expressed as mean ± sd. NSG-
CTR mice: −42.16 ± 5.6; NSG-CLL at 2 weeks: +16.32 ± 3.95; NSG-CLL at 4 weeks: 
+30.49 ± 4.0; NSG-CLL-ne mice: −37.21 ± 5.5. Statistical comparisons were carried out 
using the Mann-Whitney U test. A P-value < 0.0001 is indicated by *** and P = 0.017 
by *. (B) Comparison of MRI signals detected in the same mice 2 weeks (red dots) or 4 
weeks (blue dots) from PBMC CLL injection (P = 0.02, Wilcoxon-matched pair test) 
[122]. 
 
A similar cut-off value was used to identify the different disease extension 
at two and four weeks after inoculum in NSG-CLL mice. The identification 
of a relatively precise cut-off allows investigators to accurately define when 
a single mouse can be considered engrafted or not and make decisions 
regarding the subsequent experimental procedures. This analysis however 
requires standardisation of the instrument(s) used for the image acquisition.  
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USPIO-enhanced MRI was also able to detect CLL disease regression after 
rituximab treatment of engrafted mice. MRI images, acquired before and 
following treatment, detected definite changes with an inversion of the 
ΔSNR% value (Figure 22). 
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Figure 22. Representative experiment of treatment with rituximab. The figure shows a 
representative in vivo USPIO magnetic resonance image (MRI) obtained 24 h after 
USPIO administration in a NSG-CLL mouse treated with saline solution (A) and a NSG-
CLL mouse treated with rituximab (B). The position of the spleen is indicated by the red 
outline. MRI images show acquisition at therapy start (T.S.) and at therapy completion 
(T.C.). The scatter dot plots (C) and (D) display data for each mouse and percentage 
signal-to-noise ratio change (ΔSNR %) mean values are calculated for each treatment-
mice group (n= 3) and the control NSG-CTR group [122]. 
 
Immunohistochemistry (IHC) showed a radical change in the architecture of 
the spleen of treated animals compared to controls. Following treatment, 
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lymphoid infiltrates were mainly represented by unorganised T lymphocytes 
with the loss of the typical CD20+ nodular areas. Tissue Perls' Prussian blue 
stain confirmed the diverse disposition of USPIO nanoparticles. Thus, this 
technique clearly distinguished between the different types of lymphoid 
infiltrates based on their organisation (Figure 23). 
 
 
Figure 23. Representative Immunohistochemistry and flow cytometry analysis of mouse 
spleens from a rituximab experiment. The figure shows the histological analysis carried 
out for the presence of CLL cells (CD20, red), proliferating cells (Ki67, brown), T cells 
(CD3, red) and USPIO nanoparticles (Perls' Prussian blue) in the NSG-CLL mice treated 
with saline solution (A) and in NSG-CLL mice treated with rituximab (B). Magnification 
40× (left panels) and 200× (right panels). In panels C and D, the scatter-plots show the 
presence of CLL cells and autologous T-cells, respectively, evaluated by flow cytometry 
(CD45+/CD19+/CD5+ or CD45+/CD19−/CD5+), indicating a significant decrease of 
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the percentage of CLL cells in the group of mice treated with rituximab (n = 4) compared 
to the control group treated with saline solution (n = 5). Statistical comparisons were 
carried out using a Wilcoxon test [122]. 
Another point that should be underlined is that the use of this technique limits 
the number of animals to be tested and sacrificed. This is important for 
several reasons: first, it requires fewer leukemic cells for injection, thus 
sparing other cells for additional experimental procedures. Although many 
CLL cells can generally be recovered from CLL patients, a typical 
experiment may require more than half a billion cells, a quantity often 
obtained from selected patients only. Second, this approach facilitates 
clearance of animal experimentation protocols by ethics committees. 
Currently, animal testing regulations pay increasing attention to the 
procedures and the experimental settings applied, encouraging the use of 
methods that limit animal sacrifice and, ultimately, the suffering of animals. 
A related point is the control of experimental variability, as only animals 
with evidence of disease are used to complete the experimental procedures 
with no additional trauma. 
 
The results of this research were published in a special issue of Clinical 
Immunology to commemorate Dr Henry G. Kunkel, father of both clinical 
and basic immunology [127]. 
 
The established USPIO-MRI imaging approach to investigating CLL has 
been applied successively in new set of experiments [128]. In 
lymphoproliferative disorders, chromosomal abnormalities, including 
deletions, translocations or duplications, have traditionally led to the 
identification of genes that frequently have a pivotal role in disease 
pathogenesis [129]. Specifically, the deletion at 13q14.3 [del(13)(q14)] is 
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observed in approximately 50% of CLL cases, either in a mono- or biallelic 
form, and is also present in the early disease stages [130,131], including 
monoclonal B cell lymphocytosis [132,133], suggesting a likely 
pathogenetic role. The search for the gene(s) involved in the deletion was 
complex and unfruitful for a long time until the identification of the DLEU2 
gene: a DNA segment that carries the locus of two microRNAs (miRNAs), 
called miR-15a and miR-16-1 (miR-15 and miR-16, respectively), located in 
the fourth intronic region [135-139]. miRNAs are single stranded, non-
coding RNA, which are evolutionarily conserved and capable of regulating 
the expression of several genes concomitantly [140]. The regulation of gene 
expression occurs mainly through the specific binding of miRNAs to the 3’-
un-translated region (3’-,UTR) of the messenger RNA of the target gene via 
a RNA-induced silencing complex (RISC) [141], although additional 
mechanisms have been described [142].  
 
In this study [129], we investigated the possibility of interfering with both 
miR-15 and miR-16 expression by CLL cells, both in in vivo and in vitro 
experiments. Collectively, the data indicate that control of target genes by 
miR-15 and miR-16 is still functional in full-blown leukaemia, since the 
transfection of miR-15 or miR-16 mimics in CLL cells, with del(13)(q14), 
results in diminished survival in vitro and impaired growth in NSG mice. In 
contrast, inhibition of miR-15 or miR-16 expression by specific inhibitors in 
CLL cells lacking del(13)(q14) favours cell survival in vitro and cell 
engraftment and expansion in NSG mice. This experimental approach also 
provides a model for investigating the potential treatment of CLL with the 
use of miRNA mimics or inhibitors. The effects of in vitro transfection with 
miRNA-15 or miRNA-16 mimics/inhibitors on the growth of CLL cells in 
NSG mice and the inhibition of CLL cell expansion in NGS mice by 
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treatment with miR-15 and miR-16 mimics have been monitored using MRI 
and iron oxide nanoparticles (Figure 24). 
 
 
Figure 24. CLL cell engraftment in NSG mice following in vitro transfection with 
miRNA mimics or inhibitors. Representative tests on mice engrafted with CLL cells pre-
treated in vitro with miRNA mimics (CLL CD0310), miRNA inhibitors (CLL PM0608), 
or miRNA-CTR. (a-b) the figure shows the MRI images 24h after USPIO administration. 
The position of the spleen is indicated by the dotted red outline. ΔSNR% values also are 
indicated. The spleens with superior iron uptake and consequent lower ΔSNR% values, 
appear darker and less nodular. Conversely, spleens with lower iron uptake and higher 
ΔSNR% values are not so dark and show a nodular structure possibly related to the 
presence of follicles. (c-d) α-CD20 Ab staining (red) of paraffin tissue embedded spleen 
samples following injection of CLL cells pre-treated with the indicated miRNA (d). The 
CD20+ follicle-like structures are highlighted by red squares in (c) (magnification 40x). 
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The 400x magnification of a representative follicle for each panel is shown. IHC index is 
indicated in each panel. (e-f) Flow-cytometry analysis of cells from of the same spleens 
used for the IHC analyses shown in (c) and (d). (e) Pooled flow-cytometry data obtained 
from 4 CLL cases with biallelic del(13)(q14) pre-treated with miRNA mimics in vitro 
before injection into mice (n=8 mice for each treatment group). The cells, harvested from 
mice at the end of tests, were stained and counted. Statistical comparisons were carried 
out using Wilcoxon-matched pair test. A P value=0.0078 is indicated by **. (f) Pooled 
flow-cytometry data on cells from 2 CLL cases with normal FISH pre-treated in vitro 
with miRNA inhibitors prior to injection into mice (n=5 mice for miR-CTR, n=4 for miR-
15 and n=5 for miR-16 inhibitors). * and ** indicate P=0.016 and P=0.007 P-values 
respectively (Mann-Whitney U test). In (e-f) values are expressed as mean ± s.d [129]. 
 
This study provides a proof of principle supporting the potential use of 
miRNA mimics to block CLL clonal expansion. Notably, additional miRNA 
other than miR-15 or miR-16 may become suitable therapeutic targets, since 
several studies have demonstrated anomalous expression of various miRNAs 
in CLL cells compared to normal cells [135,136,143]. Moreover, when 
certain miRNAs are excessively expressed, specific miRNA inhibitors can 
be employed. In connection with this, it is of note that Ibrutinib, which is 
effective in reducing CLL clonal expansion, causes significant down-
regulation of some miRNAs [144]. Several anomalies in miRNA expression 
have prognostic/predictive value for disease course and outcome, indicating 
a potential mechanistic role in the disease pathogenesis/progression 
[143,145]. Thus, the miRNA approach, especially if multiple miRNA 
mimics and inhibitors can be targeted, either alone or in combination with 
other drugs, may represent an additional tool for therapy of a disease that so 
far has escaped attempts towards a radical cure.
   
 
P a g e  82 | 136 
 
 
 
Chapter 2       Original peer reviewed papers 
  
 
P a g e  83 | 136 
 
Chapter 2: Original peer reviewed papers 
 
 
2.1. Tumour targeting and cell labelling with MR 
 
2.1.1. Tumour targeting by USPIO-conjugates 
 
2.1.1.2. Title of paper 
 
• Baio G, Fabbi M, de Totero D, Ferrini S, Cilli M, Derchi LE, Neumaier 
CE. Magnetic resonance imaging at 1.5 T with immunospecific contrast 
agent in vitro and in vivo in a xenotransplant model. MAGMA 2006 Dec; 
19:313-20. 
• Baio G, Fabbi M, Salvi S, de Totero D, Truini M, Ferrini S, Neumaier 
CE. Two-step in vivo tumour targeting by biotin-conjugated antibodies 
and superparamagnetic nanoparticles assessed by magnetic resonance 
imaging at 1.5T. Mol Imaging and Biol, 2010 Jun; 12(3):305-15. 
2.1.1.3. Objective of the study 
 
To demonstrate that MRI at 1.5T allows the detection of USPIO-antibody 
conjugates specifically bound to human tumour cells in vitro and in vivo, and 
that the MRI signal intensity (SI) correlates with the concentration of 
USPIO-antibody used and with the antigen density at the cell surface. 
2.1.1.4. What this study added to the literature 
 
The magnetic nanoparticles used in these experiments are a well-known tool 
for immunomagnetic cell separation. In our experiments, these microbeads 
were tested and characterised as MR contrast agents for tumour targeting. 
The Molecular Imaging and Contrast Agent Database (MICAD), a key 
component of the “Molecular Libraries and Imaging” program of the 
National Institutes of Health (NIH) Common Fund (formerly NIH 
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Roadmap), in Bethesda, Maryland, cited and officially included our 
experiments as the first demonstration for the development of new Molecular 
Imaging probes for MR imaging [27]. 
2.1.1.5. What changed as a result of the papers? 
 
The mAbs-USPIO-based MR molecular imaging probe is still not used in 
the clinical setting. However, our experiments had a commercial impact, 
since in 2010, the Biotech Company that was producing these microbeads 
(Miltenyi Biotec, Germany, https://www.miltenyibiotec.com/GB-en/) 
together with Nano-PET Pharma (Germany, http://www.nanopet-
pharma.com/company/about-us/) developed a new Preclinical section 
(Viscover™ Imaging Agents; https://www.miltenyibiotec.com/GB-
en/products/macs-imaging-and-microscopy/viscover-imaging.html) and a 
new marketing section for the production of preclinical MR contrast agents. 
2.1.1.6. In retrospect, what should have been done differently in this study? 
 
Looking back at this work, we had relatively few mice tested, and even 
though we had sufficient numbers to show statistical significance in terms of 
MR signal intensity, a larger number would have made the argument 
stronger. However, the application of an imaging tool such as MR, especially 
a clinical human MR scanner, to basic science research, was something very 
novel and most of the scientific studies published over this period in the 
scientific community used a small number of animals too. For this reason, 
our results are still considered consistent. As a control group, we applied 
unconjugated iron oxide nanoparticles; however, the possibility to compare 
an alternative MR CA, such a MAb conjugated-gadolium compound could 
have possibly decreased the non-specific uptake of Kupffer cells that we 
instead observed with iron oxide nanoparticles. Another possibility could 
have been to, first, block the tumour antigen expressed by cells and then 
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administer the USPIO-mAb conjugates, in order to demonstrate that the 
decrease in SI observed was due to the specificity of this compound in 
lymphoma tumour targeting. 
2.1.1.7. Future work as a result of this publication 
 
Following the preclinical application of mAbs-USPIO beads for MR tumour 
targeting we developed new research with the application of USPIO 
nanoparticles to label cells for in vivo MR tumour immunotherapy. 
2.1.1.8. Confirmation of authorship 
 
This is shown at the end of Chapter 2. 
2.1.1.9. External link to the papers on the journal website 
 
https://www.ncbi.nlm.nih.gov/pubmed/17160691 
https://www.ncbi.nlm.nih.gov/pubmed/19806404 
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Abstract Object: Demonstrating the
feasibility of magnetic resonance
imaging (MRI) at 1.5 T of ultrasmall
particle iron oxide
(USPIO)-antibody bound to tumor
cells in vitro and in a murine
xenotransplant model.
Methods: Human D430B cells or
Raji Burkitt lymphoma cells were
incubated in vitro with different
amounts of commercially available
USPIO-anti-CD20 antibodies and
cell pellets were stratified in a test
tube. For in vivo studies, D430B
cells and Raji lymphoma cells were
inoculated subcutaneously in
immunodeficient mice. MRI at 1.5 T
was performed with T1-weighted
three-dimensional fast field echo
sequences (17/4.6/13◦) and
T2-weighted three-dimensional
fast-field echo sequences (50/12/7◦).
For in vivo studies MRI was
performed before and 24 h after
USPIO-anti-CD20 administration.
Results: USPIO-anti-CD20-treated
D430B cells, showed a
dose-dependent decrease in signal
intensity (SI) on T2*-weighted
images and SI enhancement on
T1-weighted images in vitro. Raji
cells showed lower SI changes, in
accordance to the fivefold lower
expression of CD20 on Raji with
respect to D430B cells. In vivo 24 h
after USPIO-anti-CD20
administration, both tumors showed
an inhomogeneous decrease of SI on
T2*-weighted images and SI
enhancement on T1-weighted
images.
Conclusions: MRI at 1.5 T is able to
detect USPIO-antibody conjugates
targeting a tumor-associated antigen
in vitro and in vivo.
Keywords Iron oxide particle ·
Cell-specific MRI · In vivo small
animal MRI · Targeted contrast
material · Lymphoma
Introduction
In the last few years molecular imaging has emerged as
a new way to perform diagnostic imaging. Advances
in molecular and cell biology, and genetics have pro-
vided a new set of tumor-associated targets suitable for
the development of imaging technologies in oncology.
In particular, magnetic resonance imaging (MRI) with
specific probes is an important area under development.
Many promising probes are being, or will be, applied to
the diagnosis of cancer and may also facilitate cancer
therapies. Furthermore a growing number of antibod-
ies specifically directed to tumor-associated antigens are
available for clinical use [1]. MRI is a non-invasive and
reproducible technique with high spatial and contrast res-
olution.Ultrasmall superparamagnetic particle ironoxide
(USPIO)may represent a suitable tool for labellingmolec-
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ular probes targeting specific tumor-associated markers
for in vitro and in vivo detection by MRI. An important
property of USPIO is the strong T2 relaxivity that pro-
duces a decrease in signal intensity (SI) on T2-weighted
images [2,3] and also a high T1 relaxivity with an increase
of SI on T1-weighted images [4,5]. The association of
MRI with specific superparamagnetic tumor contrast
agents is able to increase the accuracy and the specific-
ity of imaging [1].
Previous studies were often performed with MRI sys-
tems with high field strength up to 7T [6,7].
In the present study we demonstrate thatMRI at 1.5 T
allows the detection of USPIO-antibody conjugates spe-
cifically bound to human tumor cells in vitro, and that
the MRI SI correlates with the concentration of USPIO-
antibody used and with the antigen density at the cell
surface.
We also studied the possible use of these conjugated
monoclonal antibodies as contrast agents for in vivo label-
ling of human tumor cells. CD20+ B cell lymphomas [8,
9] were used as suitable models for targeting by commer-
cially available USPIO-anti-CD20 conjugates.
Methods
Contrast agent
Superparamagnetic antibodies
We used commercially available USPIO bound to an anti-CD20
monoclonal antibody (IgG1-murine) and stabilized with sodium
citrate (Miltenyi Biotech, Germany). The overall mean particle
diameter is approximately 50 nm: assuming a diameter of 30 nm
for the magnetic bead there are typically 10–200 antibody mol-
ecules/particle. Particles are composed of a biodegradable, non-
toxic ferromagnetic matrix (dextran) [10].
The r1 and r2 relaxivities were 30 and 60L s−1 mmol−1,
respectively [measured at 37◦C in vitro at 1.5 T (Philips Gyro-
scan NT-Intera)].
Ferumoxides
For in vivo studies in a murine model, we used commer-
cially available ferumoxides non targeted by CD20-antibody
as reference product for our control group (Endorem, Labora-
toire Guerbet, Aulnay-sous-Bois, France). This contrast is made
of colloid-based superparamagnetic iron oxide (SPIO) particles
with a diameter of 120–180 nm.
The r1 and r2 relaxivities are 40 and 160L s−1 mmol−1 [11,
12].
Ferumoxides particles consist of magnetic cores, which are
covered with a dextran T-10 layer [11,13]. Ferumoxides, instead
of Ferumoxtran (Sinerem, Laboratoire Guerbet), is approved in
Italy as a MR contrast agent specific for the reticulum-endothe-
lial system.
USPIO-antibody binding to cells in vitro
Five million human D430B cells (anaplastic large cell lymphoma
B cell line) [8] and Raji Burkitt lymphoma cells (ICLC, Inter-
lab Cell Line Collection) were incubated with different amounts
(0.001, 0.005, 0.01 and0.03μmolFe/L) of anti-CD20monoclonal
antibody USPIO conjugates, for 15min both on ice and at 37◦C
(in order to operate in the same condition as in vivo). Unbound
beads were then removed by centrifugation and cells were sub-
sequently included in a matrigel sponge (BD Biosciences, Italy).
The D430B cell pellets and Raji cell pellets were then stratified in
two test-tubes with 2.5% agarose. Lymphoma cell pellets without
USPIO-anti-CD20 were also prepared. As a control, another test
tube containing different amounts of USPIO-anti-CD20 (0.005,
0.01 and 0.03μmolFe/L) included inmatrigel sponges wasmade.
Immunofluorescence analysis
Expression of surface antigens by D430B and Raji cell lines
was analyzed by immunofluorescence using commercially avail-
able fluorescein isothiocyanate (FITC)-conjugated antibodies to
CD20 antigen (Caltag, CA, USA) or isotype-matched control
antibodies. The presence of USPIO-antibody bound to the cells
was verified by stainingwith a phycoerythrin-labelled anti-mouse
immunoglobulin antibody (Southern Biotec Inc., USA). All sam-
ples were analyzed by cytofluorimetric analysis on a FACScan
(BD Biosciences, Italy).
Animal model
Experiments were performed on ten mice, were approved by the
Institutional Review Committee of the National Cancer Insti-
tute (IST), and were performed in accordance to the National
Regulation on Animal Research Resources. Six-week old female
NOD-SCIDmice were obtained from a colony bred under sterile
conditions in the animal facility of the house. Mice were injected
s.c. with 2×107 cells of the humanD430B cell line or with 2×106
cells of the Raji Burkitt lymphoma cell line. Two to three weeks
following cell inoculation, mice developed palpable masses of
0.5–1 cm2 with a superficial ulceration characteristic of the sub-
cutaneous growth of these lymphomas. The superparamagnet-
ic antibodies were injected through the tail vein at a dose of
8μmolFe/Kg per mouse 24 h before MRI. We performed the
same experiments in the control group injecting ferumoxides in
the tail vein at the dose of 17μmolFe/Kg per mouse 24 h before
MRI.
Magnetic resonance imaging
MRI was performed with a clinical 1.5 T MR system (Philips
Gyroscan NT-Intera).
For in vitro studiesTest-tubes were placed in a surface coil and
were analyzed byMR using a coronal plane on their longitudinal
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axis. The temperature during the experiment was 28◦C and the
mean acquisition time was 30min per experiment.
For in vivo studies The animals were anaesthetized by intra-
peritoneal injection of a mixture of xylazine and ketamine and
were placed on a surface coil in prone position, on a support filled
with water at 37◦C to preserve their body temperature. Images
were obtained on coronal and axial planes perpendicular to the
vertebral column of the animal. MRI was performed before and
24 h after USPIO-anti-CD20 monoclonal antibody administra-
tion. The temperature during the experimentwas 28◦C.Themean
acquisition time was 30min for each experiment.
For in vitro and in vivo studies, we performed the follow-
ing sequences T1-weighted three-dimensional fast-field echo
sequences (repetition time in ms/echo time in ms/flip angle/
/number of acquisitions/17/4.6/13◦/10) and T2-weighted three-
dimensional fast-field echo sequences (repetition time in ms/echo
time in ms/flip angle/number of acquisitions/ 50/12/7◦/2) were
performed with a field of view of 100× 100mm, a matrix of
256× 256 pixels and a slice thickness of 2mm. In addition,
T1-weighted TSE sequences (450/20/90◦/2), T2-weighted TSE
sequences (3111/130/90◦/2),were performedwith afield of viewof
100×100mm, a matrix of 256×256 pixels and a slice thickness
of 2mm. PDW-weighted TSE sequences (1500/9.8/90◦/2) were
performed only for in vivo experiments, with a field of view of
100×100mm, a matrix of 256×256 pixels and a slice thickness
of 2mm.
Data analysis
Qualitative visual analysis and quantitative SI measurements
were performed. Qualitative analyses, for both experiments, were
performed by two radiologists (C.E.N.; G.B.) on a commercially
available workstation (DICOMed Review, EbitAET, 3Mpixel,
Barco Monitor). Both observers were blinded. They selected the
imaging sequences and parameters providing optimal SI and
contrast in relationship with the superparamagnetic properties
of USPIO for each pellet and in vivo before and after USPIO
administration.
For in vitro studies SI was measured in the middle section of
the pellets for each test-tube by one investigator using defined
region of interest (ROI) on T1- and T2*-weighted images. The
size of the ROI was as small as possible (0.22mm2). We mea-
sured SI of each matrigel pellet containing only USPIO-anti-
CD20 at different doses, andof the pellets containing non labelled
lymphoma cells; the same analysis was performed on the pel-
lets containing D430B cells with different doses of USPIO-anti-
CD20 (0.001, 0.005, 0.01 and 0.03μmolFe/L), and for the pellets
containing Raji cells with USPIO-anti-CD20 at different doses
(0.001, 0.005, 0.01 and 0.03μmolFe/L).
For in vivo studies PDW-weighted TSE sequences were used
to get an anatomical image of the mouse and for tumor detec-
tion. The SI of the lesion was measured in the middle section of
the tumor by one investigator using a defined region of interest
(ROI) on T1- and T2*-weighted images. The size of the region
of interest depended on the diameter of the tumor, with a mini-
mumof 4.43mm 2.We performed this analysis also in the control
group.
For in vitro and in vivo studies the SI data were divided by
the background noise to yield the signal-to-noise ratio (SNR).
SNR= SI/noise [14].
The difference in SI (ΔSI) was calculated, for D430B cells-
USPIO-anti-CD20 and Raji cells-USPIO-anti-CD20, as follows:
ΔSI= (SInon labelled cells −SIcells−USPIO−antiCD20)/noise.
The difference in SI (ΔSI) for the in vivo studies was calculated
comparing SI before and after USPIO-anti-CD20 administra-
tion, as follows:
ΔSI= (SIbefore−microbeads −SIafter−microbeads)/noise.
Results
Detection of USPIO-antibody conjugates binding to
human lymphoma cells in vitro by MRI at 1.5 T
Immunofluorescence analysis showed that the D430B cell
line expressed the CD20 molecule at levels approximately
fivefold higher than the Raji lymphoma cell line: 126 ver-
sus 29 in terms of mean fluorescence intensity by immu-
nofluorescence and cytofluorimetric analysis (Fig. 1a).
We then analyzed cell pellets containing D430B cells
and Raji cells, which were allowed to react with different
amounts of USPIO-anti-CD20 conjugates (0.001, 0.005,
0.01 and 0.03μmolFe/L).
Immunofluorescence analysis, using a phycoerith-
rin-labelled anti-mouse immunoglobulin, showed that
USPIO-antibody conjugates bind to the cell surface, as
indicated by a dose-dependent shift in the mean fluo-
rescence intensity values with respect to controls in the
absence of USPIO (Fig. 1b).
D430B cells-USPIO-anti-CD20 showed an important
decrease in SI on T2*-weighted images and SI enhance-
ment on T1-weighted images, which is more evident
in the pellet treated with 0.03μmolFe/L of USPIO-
anti-CD20. Raji cells-USPIO-anti-CD20 showed a slight
hypointensity on T2-weighted images and an inho-
mogeneous hyperintensity on T1-weighted images. On
T1- and T2*-weighted images there were no differences
in SI between the pellet with only cells and the pellet
with 0.001μmolFe/L of beads; only an inhomogeneous
decrease in SI in the pellets with 0.005 and 0.01μmolFe/L
of beads was observed (Fig. 2).
The analysis of matrigel pellets containing USPIO-
anti-CD20 conjugates (0.005, 0.01, 0.03μmolFe/L) used
as control was performed to detect the SI of only
USPIO-antiCD20. Pellets showed a decrease in SI on
T2-weighted three-dimensional fast field echo images
(T2*), whereas SI enhancement was observed on
T1-weighted three-dimensional fast field echo images
(Fig. 3). The observed changes in SI are in accor-
dance with the typical properties of ultrasmall super-
paramagnetic particle iron oxide: strong T2 relaxivity
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Fig. 1 a Surface expression of CD20 antigen by D430B and Raji lymphoma cell lines by immunofluorescence and cytofluorimetric analysis.
D430B cells display higher levels of Mfi than Raji cells. Mfi mean fluorescence intensity. b Detection of anti-CD20-USPIO conjugates
bound to the cell surface by cytofluorimetric analysis. Immunofluorescence profile of D430B control cells (CTR, dotted line) and of D430B-
USPIO-anti-CD20 cells stained with a phycoerythrin-labelled anti-mouse immunoglobulin antibody. With the increase of cell-bound
USPIO-anti-CD20, higher fluorescence signal is detectable (continuous line). X axis: fluorescence intensity in log scale, Y axis: cell number.
Mfi mean fluorescence intensity
Fig. 2 Representative MR images of cell pellets in test-tubes. Each pellet contains 5× 106 D430B lymphoma cells (a) and 5× 106 Raji
lymphoma cells (b), with of USPIO-anti-CD20 respectively. a D430B cells-USPIO-anti-CD20 showed an important decrease in SI on
T2-weighted three-dimensional fast field echo images that was more evident in the pellet treated with 0.03μmolFe/L of USPIO-anti-CD20,
while Raji cells-USPIO-anti-CD20 showed a slight hypointensity in the same sequences. b D430B cells-USPIO-anti-CD20 showed a SI
enhancement on T1-weighted three-dimensional fast field echo images and Raji cells-USPIO-anti-CD20 an inhomogeneous hyperintensity
on T1-weighted three-dimensional fast field echo images. T2-weighted three-dimensional fast field echo sequences =T2-3D-FFE (50/12
with flip angle 7◦); T1-weighted three-dimensional fast field echo sequences =T1-3D-FFE (17/4.6 with flip angle 13◦). USPIO ultrasmall
superparamagnetic particle iron oxide, SI signal intensity
on T2-weighted images and high T1 relaxivity on
T1-weighted images.
At the quantitative analysis, the values of decrease
in ΔSI on T2*-weighted images of the D430B-pellet
with 0.03μmolFe/L of USPIO-anti-CD20were threefold
higher than the values of the pellet with 0.01μmolFe/L,
and sixfold higher than the values of the pellet with
0.005μmolFe/L. The same results were observed for
the ΔSI on T1-weighted images (Table 1). When Raji
lymphoma cells were used as target cells, the propor-
tional differences of ΔSI, observed at different USPIO
doses, were less evident than those found for D430B, in
accordance with the differential expression of the CD20
antigen by the two cell lines (Table 2).
Table 1 ΔSI values of D430B cells with different doses of USPIO-
anti-CD20 on T1- and T2-weighted 3D-FFE images calculated on
the pellets
ΔSI
T1-3D-FFE T2-3D-FFE
D430B-USPIO-anti-CD20 3μL −36.6 ∼73
D430B-USPIO-anti-CD20 1μL −12.4 ∼24
D430B-USPIO-anti-CD20 0.5μL −6.2 ∼12
ΔSI = (SID430B non labelled − SID340B−USPIO−antiCD20)/noise,
T1-3D-FFE = T1 three-dimensional fast field echo sequences,
T2-3D-FFE = T2 three-dimensional fast field echo sequences
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Fig. 3 Representative MR images of USPIO-anti-CD20 conjugated without cells in a test-tube. Each pellet contains 0.005, 0.01 and
0.03μmolFe/L of USPIO-anti-CD20 without cells. One pellet contains only 5× 106 lymphoma cells. On T2-weighted three-dimensional
fast field echo images note a the decrease in SI of USPIO at different dose. On T1-weighted three-dimensional fast field echo images
b note the increase of SI of USPIO-anti-CD20 at different dose. T2-weighted three-dimensional fast field echo sequences =T2-3D-FFE
(50/12/with flip angle 7◦); T1-weighted three-dimensional fast field echo sequences =T1-3D-FFE (17/4.6 with flip angle 13◦). USPIO
ultrasmall superparamagnetic particle iron oxide, SI signal intensity
Table 2 ΔSI values of Raji cells with different doses of USPIO-anti-
CD20 on T1- and T2-weighted 3D-FFE images calculated on the
pellets
ΔSI
T1-3D-FFE T2-3D-FFE
Raji-USPIO-anti-CD20 3μL −25 ∼43
Raji-USPIO-anti-CD20 1μL −9 ∼17.7
Raji-USPIO-anti-CD20 0.5μL −6 ∼12
ΔSI = (SIRaji-non-labelled − SIRaji-USPIO-anti-CD20)/noise, T1-
3D-FFE = T1 three-dimensional fast field echo sequences, T2-
3D-FFE = T2 three-dimensional fast field echo sequences
Therefore, themagnitude ofΔSI observed was related
both to the CD20 expression level and to the dose of US-
PIO-CD20 used.
In vivo MRI of human lymphoma xenografts
using USPIO-anti-CD20 contrast agent
PDW-weightedTSE-sequences gave an anatomical image
of the mouse and were used for tumor detection. Subse-
quently, we acquired T1- and T2*-weighted images from
D430BandRaji xenotransplanted lymphomas before and
24 h after USPIO-anti-CD20 i.v. injection.
The D430B tumor showed an inhomogeneous
decrease in SI on T2*-weighted images and a slight SI
enhancement on T1-weighted images (Fig. 4).
Under the same experimental conditions, the Raji
tumor showed slight inhomogeneous hypointensity and
hyperintensity, respectively, on T2*- and T1-weighted
images, at the visual analysis (Fig. 5).
For quantitative analysis we positioned the ROI
on the tumor of each mouse before (mean± SD;
1,665± 190) and after (mean± SD; 1,000± 200) beads
administration. Mean values and standard deviations
have been calculated in all ten mice: the SNR
(signal-to-noise ratio) of D430B tumor after US-
PIO-anti-CD20 administration showed an important
decrease on T2*-weighted sequences (mean SNRbefore ±
SD/meanSNRafter ± SD;82± 9/57± 11). For the Raji
tumor, the decrease of SNR on T2*-weighted sequences
after the USPIO-antibody administration was less impor-
tant (mean SNRbefore ± SD/mean SNRafter,±SD;47 ±
10/40±13).
The different values ofΔSI inD430B tumor (35%± 7)
and in Raji tumor (15%± 8) were consistent with the
different expression of CD20 obtained at immunoflu-
orecence analysis, with a major accumulation of the
USPIO-anti-CD20 antibody 24 h after administration at
the CD20high D430B tumor site and a minor accumula-
tion at the CD20low Raji tumor site (detected on both
tumors by a decrease in SI on T2*-weighted images).
In the control group injected with ferumoxides at
the visual analysis there were not appreciable differ-
ences in the SI (Fig. 6). These results were confirmed
at the quantitative analysis setting ROIs on tumors
before (mean± SD:1,392± 86) and after (mean± SD:
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Fig. 4 On T2-weighted three-dimensional fast field echo images after USPIO-anti-CD20 antibody administration the CD20high D430B
tumor showed an inhomogeneous decrease in signal intensity (arrows). On T1-weighted three-dimensional fast field echo images obtained
after USPIO-anti-CD20 antibody administration, the CD20high D430B tumor showed an inhomogeneous SI enhancement (arrows). T2-
weighted three-dimensional fast field echo sequences =T2-3D-FFE (50/12/with flip angle7◦). T1-weighted three-dimensional fast field echo
sequences =T1-3D-FFE (17/4.6/with flip angle13◦). USPIO ultrasmall superparamagnetic particle iron oxide, SI signal intensity
1,322± 80) ferumoxides administration. A ΔSI not sta-
tistically significant (5%± 6) was observed.
Discussion
A wide set of commercially available USPIO-antibody
conjugates used for cells separation techniques are avail-
able and some of them are also developed as clinical grade
reagents [1].
Our in vitro study was designed to assess the feasibil-
ity of the use of MR equipment at 1.5 T to detect US-
PIO-antibodies bound to tumor cells at doses potentially
suitable for small animal models in a pre-clinical setting.
In this study we demonstrate that commercially avail-
able USPIO-antibody conjugates specific for a B cell lym-
phoma-associated antigen binding to the human D430B
cells or to the Raji Burkitt lymphoma cell line can be
visualized on MRI at 1.5 T.
We also demonstrate by in vitro assays that there is a
dose-response relationship between the different amounts
of USPIO-anti-CD20 bound to the cells and the ΔSI
(Table 1) on T2*-weighted images. This effect is more
evident on cells expressing high levels of the target anti-
gen (D430B) with respect to cells with lower expression
(Raji), indicating that the magnitude of ΔSI observed
depends both on the dose of the immunospecific contrast
agent and on the target antigen expression levels of the
cells.
On the basis of our in vitro assays, we estimated that
the minimal dose providing a detectable signal byMRI in
vitro (0.005–0.01μmolFe/L) is largely compatible with
the amount of USPIO injectable into living mice with-
out toxic effects (8μmolFe/kg) as reported by previous
studies [6,7], and that accumulation of less than 5% of
the injected dose at the tumor site in vivo in the mouse
would provide a detectable signal. All MR signal findings
observed correlate with the known T2* and T1 relaxation
properties of USPIO.
Indeed, in vivo experiments indicated that the intrave-
nous administration of a single dose ofUSPIO-anti-CD20
antibody conjugates, 18–24 h before performing MRI at
1.5 T is sufficient to induce detectable changes of SI, in a
reproducible fashion (35%± 7).
The control group was injected with ferumoxides,
in the in vivo studies, to investigate the possible role
of the non-specific distribution of USPIO in the tumor.
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Fig. 5 On T2-weighted three-dimensional fast field echo images, the Raji CD20low tumor analysed after USPIO-anti-CD20 antibody
administration showed an inhomogeneous decrease in signal intensity (arrows). On T1-weighted three-dimensional fast field echo images
obtained after USPIO-anti-CD20 antibody administration the tumor showed a slight SI enhancement (arrows). T2-weighted three-dimen-
sional fast field echo sequences =T2-3D-FFE (50/12/with flip angle7◦); T1-weighted three-dimensional fast field echo sequences =T1-3D-
FFE (17/4.6/with flip angle13◦). USPIO ultrasmall superparamagnetic particle iron oxide, SI signal intensity
Fig. 6 Representative MR images of the control group injected with ferumoxides. No changes of SI on T2-weighted three-dimensional
fast field echo images before and after ferumoxides administration (arrows) were observed. T2-weighted three-dimensional fast field echo
sequences =T2-3D-FFE (50/12/with flip angle7◦). SI signal intensity
The results obtained in this control group suggested that
non-specific localization is low in this type of tumor,
indicating that the higher ΔSI of the USPIO-anti-CD20
conjugate is related to the specific ability of the conju-
gated antibodies to target the tumor-associated antigen
in vivo.
The bigger size of the ferumoxides that we have used
in the control group (120–180 nm) compared to the size of
USPIO-anti-CD20 (50 nm), probably represents a poten-
tial limitation of our study. Actually, unconjugated US-
PIO from Miltenyi are not commercially available. In
addition, another type of USPIO (Sinerem, Guerbet,
Paris, France) whose size (30–50 nm) is more compara-
ble to the particles we used (50 nm), is still not commer-
cially available in Italy. For these reasons we have used
Endorem as a reference product for our control group.
Our results are consistent with those obtained in pre-
vious studies using similarUSPIO contrast agents to visu-
alize inflammatory cell infiltrating the brain in a murine
model of autoimmune encephalomyelitis [6]. However,
these previous studies used a 3.5–7T MRI equipment,
while in the present investigation the high antigen expres-
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sion by a homogeneous population of tumor cells allowed
the detection of cell-bound USPIO by a 1.5T standard
equipment. The ΔSI observed in specific ROIs indicates
that this strategy is certainly suitable for highly expressed
antigens.
The potential limitation of the present study may
relate to the relatively low iron concentration in the com-
mercially available USPIO-antibody conjugate in com-
parison to the clinically available non-targeted MRI
contrast agents, which are non-specifically internalized
by the reticulum-endothelial cells. Thus the develop-
ment of similar USPIO-targeted antibodies with high
iron-oxide content may allow to enhance the sensitiv-
ity of detection, in order to permit the MRI of tumors
with small diameters or with lower target antigen den-
sity. Another possible application of antibody targeted
MRI technology is related to in vivo tracking of cells
that had been labelled by MRI contrast agents in vitro
after manipulations and then transferred into a recip-
ient host. Previous studies showed that in vitro cell
labelling by MRI contrast agents can be performed by
either non-targeted nano-particles which enter the cell in
a non-specific fashionor by specificUSPIO-antibody con-
jugates that specifically bind to a cell surface antigen and
can be then eventually internalized [15,16].
We believe that optimizing molecular targeted con-
trast agents, MRI technology and the generation of new
USPIO-antibodies or other USPIO-ligands, specifically
able to bind to tumor-associated markers, may provide
useful immunospecific contrast agents for the diagnosis
of tumors and for targeting therapies of cancer.
Conclusion
MRI at 1.5 T provides a simple method of molecular
imaging using commercially available antibodies specific
for human targets, opening the possibility for cell tracking
in vitro and in vivo. The development of new tumor spe-
cific contrast agents may further improve this technology.
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Abstract
Purpose: The purpose of this study was to assess two-step in vivo tumor targeting by specific
biotin-conjugated antibodies and ultrasmall superparamagnetic iron oxide (USPIO)-anti-biotin
nanoparticles as contrast agents for magnetic resonance imaging (MRI) at 1.5 T.
Procedures: D430B human lymphoma cells, expressing the CD70 surface antigen, were
injected either s.c. or i.v. to induce pseudo-metastases in NOD/SCID mice. Thirty micrograms of
biotin-conjugated monoclonal anti-CD70 was injected i.v., followed 4 h later by 8 µmol Fe/Kg
USPIO-anti-biotin. After 24 h, MRI was performed on T2* and b-FFE sequences. Signal intensity
(SI) was calculated before and after USPIO-anti-biotin administration.
Results: Subcutaneous xenografts showed a dishomogeneous 30% decrease in SI on T2* with
anti-CD70+USPIO-anti-biotin treatment. Pseudo-metastatic xenografts showed a slight reduc-
tion in SI on T2*, but a 60% decrease in SI on b-FFE-weighted sequences. Prussian blue
staining confirmed the presence of iron nanoparticles in the excised tumors.
Conclusion: MRI at 1.5 T can detect tumors by a two-step in vivo biotin-based protocol, which
may allow the targeting of any cell surface antigen.
Key words: Magnetic resonance imaging, Iron oxide particles, In vivo small animal MRI,
Targeted contrast agent, Antibody
Introduction
The selection of monoclonal antibodies (mAbs) directedto surface antigens expressed by tumor cells has
increasingly enabled the development of new reagents for
diagnostic purposes or for targeted therapies. Therapeutic
mAbs can act in a variety of ways, such as by blocking
growth factors, by signaling arrest and apoptosis, or by
eliminating mAb-decorated target cells through the activa-
tion of host effector mechanisms. The antigen-binding
regions of these antibodies provide specificity to the
tumor-killing effects, whereas the Fc portion of the mAbs is
involved in complement activation and antibody-dependent
cellular cytotoxicity mediated by specific Fc receptors on NK
cells [1]. In hematological malignancies, mAbs directed
Correspondence to: Carlo Emanuele Neumaier; e-mail: carlo.neumaier@
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Significance Biotin-labeled tumor-specific antibodies followed by a
common USPIO-conjugated secondary reagent represent a suitable contrast
agent for the diagnosis and monitoring of tumors by MR using balanced
fast-field echo sequences.
against lineage-specific markers are used to target neoplastic
cell populations which express such markers similarly to the
normal cellular lineage from which they derive. In the case of
B cell lymphomas or leukemias, mAbs directed against
CD20 (rituximab) are currently used in combination with
chemotherapy. Nonetheless, because CD20 is expressed by
all mature B cells, monoclonal anti-CD20 therapy also affects
the normal B cell population. The normal counterpart of non-
Hodgkin’s lymphomas (NHLs) is represented in most
instances by proliferating B cells (centroblasts or immuno-
blasts). Therefore, NHLs frequently express B lymphocyte
activation markers in addition to B cell lineage markers such
as CD19, CD20, and CD22. Some activation markers may
represent good alternative targets for antibody-based ther-
apeutics for NHLs since targeting of such activation antigens
would spare the normal resting B cell population. CD70, a
member of the TNF family of ligands, is an activation marker
that is transiently expressed on antigen-stimulated B and T
cells. Furthermore, CD70 is expressed by thymic stromal
cells and by mature dendritic cells, but not by other normal
tissues. During the immune response, CD70 interacts with its
specific receptor CD27, a member of the TNF receptor
family. The CD27/CD70 interaction regulates the expansion
and differentiation of effector and memory T cell popula-
tions, B cell expansion, germinal center formation, and
plasma cell differentiation. CD70 is found on 70% of diffuse
large B cell lymphomas, 33% of follicular lymphomas, 50%
of B cell lymphocytic leukemias, 25% of Burkitt’s and
mantle cell lymphomas, and 100% of Waldenström macro-
globulinemia, as well as the majority of Reed–Sternberg
cells. CD70 has also been detected on nasopharyngeal
carcinoma, thymic carcinoma, astrocytoma, glioblastoma,
and renal cell carcinoma [2].
Beyond their use as therapeutic agents, mAbs can also be
used as specific probes for the molecular imaging of tumors
[3]. In particular, magnetic resonance imaging (MRI) can be
effectively applied to molecular imaging approaches in view
of its reproducibility and of its high spatial and contrast
resolution. Ultrasmall superparamagnetic iron oxide
(USPIO) nanoparticles may represent suitable tools for
labeling molecular probes which target specific tumor-
associated markers for in vitro and in vivo detection by
MRI. Important properties of USPIO are the strong T2
relaxivity that produces a decrease in signal intensity (SI) on
T2-weighted images [4, 5] and high T1 relaxivity that causes
an increase in SI on T1-weighted images [6, 7]. The
association of MRI with specific superparamagnetic tumor
contrast agents is able to increase the accuracy and the
specificity of imaging [8]. Molecular imaging is often
performed with MR scanners which operate at field strengths
up to 7 T [9–12].
In the present study, we demonstrate that MRI at 1.5 T
allows the detection of USPIO-antibody conjugates specif-
ically bound to human tumor cells by means of a two-step
procedure. The possible use of specific biotin-labeled anti-
bodies combined with the USPIO-anti-biotin as contrast
agents for in vivo labeling of human tumor cells is explored
in a xenotransplantation model.
Material and Methods
Cells and Antibodies
Human D430B anaplastic large B cell lymphoma [13], A2774
ovarian carcinoma (from J. Bénard, Institut Gustave Roussy, Paris,
France), and Jurkat T cell leukemia cell lines (American Type
Culture Collection) were cultured in RPMI 1640 (Cambrex,
Verviers, Belgium), supplemented with L-glutamine, 10% heat-
inactivated fetal calf serum (FCS; BioWhittaker Cambrex), and
antibiotics at 37°C in a 5% CO2 incubator. Monoclonal anti-human
CD70, murine IgG2a clone LD6 [14, 15], was purified from serum-
free culture medium by affinity chromatography on Sepharose-
Protein A (GE Healthcare®, Little Chalfont, UK) and subsequently
conjugated with EZ-Link Sulfo-NHS-LC-biotin (Pierce®, Rock-
ford, IL, USA) according to the manufacturer’s instructions. As
isotype-matched negative control, murine mAb CH-L, directed
against the CD158b antigen [16], which is not expressed by D430B
cells, was similarly prepared. The concentration of the purified
mAbs was determined by measuring the optical density at 280 nM
and by the Lowry protein assay [17]. Purity of the antibodies was
checked by resolving them by sodium dodecyl sulfate–polyacryla-
mide gel electrophoresis (SDS-PAGE) under non-reducing con-
ditions on an 8% acrylamide gel followed by Coomassie blue
staining [17]. The degree of mAb biotinylation was assessed with
the Biotin Quantitation Kit (Pierce®).
Contrast Agent
Commercially available (Miltenyi Biotech, Bergisch Gladbach,
Germany) USPIO nanoparticles coated with a monoclonal anti-
biotin (murine IgG1), stabilized with sodium citrate, and approved
for clinical use in humans as magnetic cell separators were used.
Particles were composed of a biodegradable, non-toxic ferromag-
netic matrix (dextran-based), and their overall mean diameter was
approximately 50 nm. Assuming a diameter of 30 nm for the
magnetic core, there were typically 10–200 antibody molecules per
particle [18]. The iron content of the USPIO-anti-biotin core was
measured by inductively coupled plasma optical emission spec-
trometry with a Varian Vista Pro spectrometer (Varian Inc., Palo
Alto, CA, USA) and found to be 20 mM/L. The r1 and r2
relaxivities were 30 and 60 L s−1mmol−1, respectively, as assessed
at 1.5 T (Philips Gyroscan NT-Intera, Philips, Best, The Nether-
lands) by measuring particles in vitro at 37°C [19].
Immunofluorescence Analysis
Surface expression of the CD70 antigen by the cell lines was
analyzed by immunofluorescence and flow cytometry. Immuno-
fluorescence was performed by incubating 105 viable cells with
2 µg/mL biotin-conjugated monoclonal anti-CD70 (clone LD6) or
isotype control (clone CH-L) for 30 min on ice. The cells were then
washed twice with phosphate-buffered saline (PBS) 2% FCS and
incubated with fluorescein isothiocyanate (FITC)-conjugated strep-
tavidin (Caltag Laboratories, Burlingame, CA, USA) as secondary
reagent. After washes, cells were analyzed on a FACScan (Becton
Dickinson, Mountain View, CA, USA).
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In addition, the localization of CD70 antigen was studied by
immunofluorescence and confocal microscopy analysis. Cell
suspensions were stained with 2 µg/mL LD6 or CH-L followed
by Alexa488-conjugated (Fab)2 goat anti-mouse Ig as secon-
dary reagent. Cells were then fixed (1% paraformaldehyde in
PBS), permeabilized (0.2% Triton-X-100 in PBS), and cell
nuclei were counterstained with propidium iodide. Mowiol-
mounted slides were analyzed by confocal fluorescence micro-
scopy using an Olympus (Olympus Optical, Tokyo, Japan)
laser scanning microscope FV500 equipped with an Olympus
IX81 inverted microscope.
To detect the binding of USPIO-anti-biotin to the biotin-
conjugated antibodies, D430B cells were incubated with biotin-
LD6 and biotin-CH-L as above. After washes, cells were
challenged with 10 µL of the USPIO-anti-biotin suspension for
20 min on ice. D430B cells were then washed again, and the
presence of USPIO-anti-biotin bound to the cells carrying biotin-
conjugated monoclonal anti-CD70 was verified by staining with
FITC-labeled anti-mouse immunoglobulin goat serum (Caltag)
followed by flow cytometry analysis.
USPIO-antibody Binding to Cells In Vitro
Two million human D430B, A2774, or Jurkat cells were incubated
with biotin-conjugated LD6 or CH-L mAb or with PBS for 30 min
on ice, washed, and further incubated with 10 µL of the USPIO-
anti-biotin suspension for 15 min on ice. Unbound beads were then
removed by centrifugation and cells were subsequently included in
a matrigel sponge. The cell pellets were then stratified in test tubes
with 2.5% agarose as described [19] and analyzed by MRI.
Animal Experiments
In vivo experiments were approved by the Institutional Review
Board of the National Cancer Institute (IST) and were performed
in accordance with the national (Italian) regulations on Animal
Research Resources. Six-week-old female NOD/SCID mice were
obtained from a colony bred in-house under sterile conditions.
Mice were injected subcutaneously with 2×107 human D430B
cells. Two to 3 weeks later, they developed palpable masses of
0.5 to 0.8 cm3.
In a second set of experiments, 2×107 D430B cells per mouse
were injected into the tail vein to induce pseudo-metastases. Mice
were monitored for weight loss every other day and by MRI
starting 3 weeks after inoculum.
To target tumor-expressed human CD70 antigen, 30 µg per
mouse of biotin-labeled LD6 mAb was administered into the
tail vein in 100-µL volume, and MRI was performed immedi-
ately. Four hours after administration of the biotin-labeled
antibody, 8 µmol Fe/Kg per mouse of USPIO-anti-biotin was
injected in the tail vein in 100-µL volume. MRI was performed
again 24 h later. As negative control, groups of mice were
similarly injected with biotin-conjugated CH-L mAb or with
PBS prior to USPIO-anti-biotin.
Magnetic Resonance Imaging
MRI was performed with a clinical 1.5 T MR system (Philips,
Gyroscan NT-Intera).
Test tubes were placed on a surface coil in a prone position and
were analyzed by MR using a coronal plane on their longitudinal axis.
Mice were anesthesized by intraperitoneal injection of a mixture
of xylazine and ketamine and were placed on a surface coil in a
prone position on a support filled with water at 37°C to preserve
body temperature. Imaging was performed before and 24 h after
administration of USPIO-anti-biotin.
The temperature during experiments was 28°C, and the mean
acquisition time was 30 min for each experiment. Images were
obtained on coronal and axial planes.
The following sequences were applied: T1-weighted three-
dimensional fast-field echo sequences (repetition time in milli-
seconds/echo time in milliseconds/flip angle/17/4.6/13°) and T2-
weighted three-dimensional fast-field echo sequences (repetition
time in milliseconds/echo time in milliseconds/flip angle/50/12/7°)
were performed with a field of view of 100×100 mm, a matrix of
256×256 pixels, and a slice thickness of 2 mm. Three-dimensional
balanced gradient echo (3D-b-FFE) sequences (repetition time in
milliseconds/echo time in milliseconds/flip angle/11/4.1/45°) were
performed with a field of view of 150×150 mm, a matrix of 256×
256 pixels, and a slice thickness of 1 mm. In addition, T1-weighted
turbo spin-echo sequences (450/20/90°) and T2-weighted turbo
spin-echo sequences (3111/130/90°) were performed with a field of
view of 100×100 mm, a matrix of 256×256 pixels, and a slice
thickness of 2 mm.
Ex Vivo MRI and Histopathological Analysis
Mice were euthanized by CO2 method immediately after the in vivo
MRI session. Tumors and liver were excised and fixed in 4%
buffered formalin. Ex vivo MRI was subsequently performed.
Specimens were then paraffin-embedded and processed for
histological analysis according to standard techniques. The
presence of iron was detected by Pearl Prussian blue staining
and was qualitatively assessed by an experienced pathologist
(M.T.) with an Olympus BX41 microscope by estimating iron-
positive cells.
Statistical Analysis
Both qualitative and quantitative analyses were performed. Qual-
itative visual analyses were performed by two radiologists (C.E.N.
and G.B.) on a commercially available workstation (DICOMed
Review, EbitAET, 3Mpixel, Barco Monitor). Both observers were
blinded. They selected the imaging sequences and parameters
which provided optimal SI and contrast relative to the USPIO
superparamagnetic properties.
Quantitative analyses were expressed as mean SI ± standard
deviation with SI being measured in tumor and liver by one
investigator using a defined region of interest (ROI) on T2*- and b-
FFE-weighted images. The size of the region of interest depended
on the diameter of the tumor. The same analysis was performed in
the control group.
The SI values were divided by the background noise to yield the
signal-to-noise ratio (SNR) according to the formula SNR=SI/noise
[20].
The difference in SI (ΔSI) was calculated by comparing SI
before and after the administration of USPIO-anti-biotin, as
follows:
SI ¼ SIbeforemicrobeads  SIaftermicrobeadsð Þ=noise:
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Results
Immunofluorescence Analysis of Biotin-
Conjugated Antibodies and USPIO-Anti-biotin
with Human Lymphoma Cells
Biotin-conjugated monoclonal anti-CD70 (LD6) and an
irrelevant mAb (CH-L) were tested for reactivity with
D430B lymphoma, A2774 ovarian carcinoma, and Jurkat
leukemia cells by immunofluorescence analysis using strep-
tavidin-FITC as secondary reagent. As shown in Fig. 1a, mAb
LD6 (continuous line) reacted strongly with D430B cells,
weakly (ten times lower in terms of fluorescence intensity)
with A2774 cells, and showed no reactivity with Jurkat cells.
The isotype-matched mAb CH-L (dotted line) did not bind to
any cell line, showing background fluorescence equal to
streptavidin-FITC without antibody (not shown). Confocal
microscopy confirmed the strong membrane staining of the
monoclonal anti-CD70 on D430B and the low staining on
A2774 cells (Fig. 1b, lower panels).
Purity of antibody preparation was assessed by SDS-PAGE
analysis under non-reducing conditions and Coomassie blue
staining, which showed a single band of approximately
150 kDa (Fig. 1b, upper panel). The degree of biotinylation
was similar in the two mAbs since Western blot analysis of the
two biotin-conjugated mAbs, run in equimolar amounts in
parallel lanes, revealed a similar intensity of the antibody bands
on avidin-peroxidase staining (Fig. 1b, lower panel). The two
mAbs showed a comparable level of biotinylation (3 and 3.4
biotin per antibody molecule for CH-L and LD6, respectively)
also by the use of a biotin quantitation kit.
The suitability of mAbs conjugated in house with Sulfo-
NHS-LC-biotin as a target for USPIO-anti-biotin was then
verified. Figure 1c shows the immunofluorescence profile of
D430B cells challenged with biotin-conjugated monoclonal
anti-CD70 (LD6) plus (continuous line) and minus (gray
profile) USPIO-anti-biotin, followed by FITC-anti-mouse
serum. In the presence of USPIO-anti-biotin bound to biotin-
LD6 mAb, a higher fluorescence signal was detectable due
to the additional murine monoclonal anti-biotin carried by
the magnetic particles.
In Vitro MRI Detection of Biotin-Labeled
Monoclonal Anti-CD70 and USPIO-Anti-biotin
Conjugates Bound to the Cells
Prior to conducting the in vivo experiments, the ability of
MRI at 1.5 T to detect in vitro binding of USPIO-anti-biotin
to cells expressing CD70 at high (D430B) and low (A2774)
levels was investigated. D430B cells challenged with biotin-
labeled mAb LD6 plus USPIO-anti-biotin showed an
evident hypointense signal on T2*-weighted images,
whereas no changes in SI were observed with biotin-CH-L
mAb, as shown in Fig. 1d. A2774 cells treated with biotin-
LD6 plus USPIO-anti-biotin showed only a slightly hypo-
intense signal, and no appreciable signal changes were
observed by treatment with biotin-labeled mAb CH-L and
USPIO-anti-biotin alone (Fig. 1d). As expected, the CD70-
negative Jurkat cell pellets showed no changes in SI under
the same conditions (Fig. 1d). The barely detectable changes
in SI induced by the LD6/USPIO complex on CD70-low
cells suggest that the biotinylated mAb LD6 is suitable only
for the in vivo detection by MRI at 1.5 T of tumors with a
CD70-bright phenotype.
In Vivo MRI of Human Lymphoma Subcutaneous
Xenografts
To assess if the monoclonal anti-CD70 could specifically
target human lymphoma cells in vivo and be detected by
MRI, human D430B cells were subcutaneously injected in
NOD/SCID mice and allowed to grow up to a tumor mass of
Fig. 1. Immunofluorescence analysis of CD70 surface
expression and detection of biotin-labeled monoclonal anti-
CD70 and USPIO-anti-biotin conjugates bound to the cell
surface. a Surface expression of CD70 antigen by D430B
lymphoma, A2774 ovarian carcinoma, and Jurkat leukemia
cells as assessed by indirect immunofluorescence and
cytofluorimetric analysis (upper panels) or confocal micro-
scopy (lower panels). Immunofluorescence profiles of cells
stained with biotin-conjugated monoclonal anti-CD70 (LD6,
continuous line) or with biotin-conjugated mAb CH-L as
isotype-matched negative control (dotted line, ctr), followed
by FITC-streptavidin. MFI mean fluorescence intensity. b
Purity of LD6 and CH-L mAbs (1 μg/lane) resolved by SDS-
PAGE analysis under non-reducing conditions as assessed
by Coomassie blue staining of 8% polyacrylamide gels
(upper panels). As standards, 3 and 1 μg of a commercially
available IgG2b mAb (ctr) were run in parallel lanes. Anti-
bodies LD6 and CH-L display a similar degree of biotinylation
as detected by Western blot analysis of equimolar amounts
and staining with HRPO-streptavidin followed by chemilumi-
nescence. Antibodies were resolved on an 8% acrylamide
gel under non-reducing conditions. Numbers indicate molec-
ular weight markers. c Immunofluorescence profile of D430B
cells challenged with biotin-conjugated monoclonal anti-
CD70 (LD6) plus (continuous line) and minus (gray profile)
USPIO-anti-biotin, followed by FITC-anti-mouse serum. In
the presence of USPIO-anti-biotin bound to biotin-LD6 mAb,
higher fluorescence signal is detectable due to the additional
murine mAb carried by the magnetic particles. Profile of
negative control without primary antibody and with USPIO-
anti-biotin (dotted line, ctr) is shown. Samples were analyzed
on a FACscan flow cytometer. X-axis fluorescence intensity
in log scale, Y-axis cell number. d MRI analysis at 1.5 T of
antibody+USPIO-treated cell pellets in test tubes. Each pellet
contained 2×106 D340B lymphoma, A2774, or Jurkat cells
that had been stained by either biotinylated LD6+USPIO-
anti-biotin (arrows), biotinylated CH-L+USPIO-anti-biotin
(arrowhead), or USPIO-anti-biotin alone (asterisk). Only
D430B cells treated with biotinylated LD6+USPIO-anti-biotin
showed a clearly hypointense signal on T2-weighted three-
dimensional fast-field echo images.
b
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0.5 cm3. Mice then underwent an MRI session to collect
images before treatment and immediately thereafter were
injected i.v. with either biotin-conjugated mAb LD6 or CH-
L followed 4 h later by USPIO-anti-biotin.
The following day, MRI was repeated. As shown in
Fig. 2, 24 h after the administration of biotin-conjugated
monoclonal anti-CD70 (LD6) plus USPIO-anti-biotin, sub-
cutaneous tumors showed a slight and inhomogeneous
decrease in SI on T2*-weighted images (Fig. 2a, b).
Regions of interrest were defined and signal intensity
calculated on the tumor of each mouse before (mean ± SD,
1,894±170) and after (mean ± SD, 1,350±160) USPIO
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administration. Mean values and standard deviations were
calculated in all mice. The SNR of D430B tumor after USPIO-
anti-biotin administration showed a decrease in SI on T2*-
weighted sequences (mean SNRbefore ± SD/meanSNRafter ± SD,
38±3/27±3). Analyses of images confirmed a decrease of about
30% in SI measured after USPIO-anti-biotin administration.
Results are the mean of three independent experiments.
In control groups injected with the biotin-conjugated CH-L
antibody plus USPIO-anti-biotin or with USPIO-anti-biotin
alone, no appreciable differences in SI of the tumor were
observed (Fig. 2c, d). These results were confirmed and
quantified by setting ROIs on tumors before (mean ± SD,
1,494±76) and after (mean ± SD, 1,420±68) USPIO admin-
istration. A non-significant ΔSI (around 5% difference) was
indeed observed. Results are the mean of three experiments.
In Vivo MRI of Human Pseudo-metastatic
Lymphoma Xenografts
A pseudo-metastatic animal model was then set up by i.v.
injection of human lymphoma cells in NOD/SCID mice. As
soon as weight loss, a sign of tumor take, was detected, mice
underwent MRI to collect images before treatment, which
demonstrated the presence of tumor masses in the retroper-
itoneal space, in particular in the kidney.
After MRI mice were injected i.v. with either biotin-
conjugated antibody, LD6 or CH-L followed 4 h later by
USPIO-anti-biotin. The following day, MRI was repeated.
Twenty-four hours after the administration of biotin-conjugated
monoclonal anti-CD70 plus USPIO-anti-biotin, tumors showed
a slight decrease in SI when T2-weighted sequences were
applied, but a significant decrease in SI when b-FFE-weighted
sequences were applied (Fig. 3).
Quantitative analysis was then performed by setting ROIs
on b-FFE-weighted images and measuring SI on the tumor of
each mouse before (mean ± SD, 1,303±635) and after (mean ±
SD, 499±235) USPIO administration. The SNR of D430B
tumor after USPIO administration showed a clear-cut decrease
(mean SNRbefore ± SD/meanSNRafter ± SD, 141±159/60±57).
Analyses of images confirmed a decrease of about 60% in SI
after USPIO-anti-biotin administration.
In control groups injected with the biotin-conjugated CH-L
antibody plus USPIO-anti-biotin, no appreciable differences in
SI of the tumor were observed. Quantitative analysis performed
by setting ROIs on tumors and measuring SI before (mean ±
SD, 230±34) and after (mean ± SD, 257±63) USPIO-anti-
biotin administration confirmed the visual analysis. Also, in
this case, a non-significant ΔSI was observed.
It is noteworthy that 24 h after the administration of
biotin-conjugated LD6 antibody plus USPIO-anti-biotin, the
liver showed a decrease in SI on T2*- and, in particular, on
b-FFE-weighted sequences (Fig. 3).
Quantitative analyses were performed on b-FFE-weighted
images of the liver of each treated mouse by setting ROIs
and measuring SI before (mean ± SD, 1115±66) and after
(mean ± SD, 349±31) USPIO administration. Mean values
and standard deviations were calculated in all mice: the SNR
of liver after USPIO-anti-biotin administration confirmed a
C
B
D
A Subcutaneous Lymphoma Xenograft
T2-3D-FFE before USPIO-anti-biotin 
administration
T2-3D-FFE after USPIO-anti-biotin 
administration
T2-3D-FFE before USPIO-anti-biotin administration
(Control group)
T2-3D-FFE after USPIO-anti-biotin administration
(Control group)
Fig. 2. Axial MR images of subcutaneous lymphoma xenografts. On T2-weighted three-dimensional fast-field echo images
before (a) and 24 h after (b) the administration of biotin-conjugated monoclonal anti-CD70 (LD6) plus USPIO-anti-biotin,
subcutaneous tumors showed a slight and dishomogeneous decrease in SI (arrows). In control groups (c, d) injected with the
biotin-conjugated antibody CH-L plus USPIO-anti-biotin or with USPIO-anti-biotin alone, no appreciable differences in SI of the
tumor were observed (arrows) before (c) and 24 h after (d) administration of the contrast agent.
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significant decrease in SI on b-FFE-weighted sequences
(mean SNRbefore ± SD/meanSNRafter ± SD, 120±16/43±7).
Quantitative analyses of the liver of control mice
inoculated with biotin-conjugated CH-L plus USPIO-anti-
biotin showed a significant ΔSI before (mean ± SD, 214±
25) and after (mean ± SD, 54±12) USPIO administration.
Ex Vivo MR Imaging and Detection of Iron Oxide-
Labeled Cells in Human Lymphoma Xenografts
Since subcutaneous tumors showed a decrease in SI on T2*-
weighted images that was less evident in pseudo-metastatic
tumors, the same T2* sequences to the excised pseudo-
metastatic tumor were applied. Ex vivo MR images of the
pseudo-metastatic tumor showed a higher decrease in SI on T2*-
weighted images (Fig. 4) compared to T2*-weighted images
obtained in vivo (Fig. 3c, d), while this difference was not
evident in the liver which already showed a strong ΔSI in vivo.
To verify if iron particles had been actually delivered to the
tumors, histopathological analysis by Pearl Prussian blue
staining was performed on subcutaneous and pseudo-meta-
static tumors that had been excised from mice after MRI.
Microscope examination showed iron nanoparticles bound
to the reactive tissue and to the tumor cells in the case of
subcutaneous tumors (data not shown). In addition, as shown in
Fig. 5a, iron bound to tumor cells (approximately 10–15%)was
detected also in the case of pseudo-metastatic tumors in mice
that had received treatment with biotin-conjugated monoclonal
anti-CD70 plus USPIO-anti-biotin. No Prussian blue staining
was detectable in the case of treatment with the isotype-
matched negative control (CH-L) plus USPIO-anti-biotin
(Fig. 5b) or USPIO-anti-biotin alone (Fig. 5c). As expected
on the basis of MRI data, Pearl Prussian blue staining was
observed in the liver of mice receiving either LD6 or the
irrelevant control antibody (Fig. 5d) or only the USPIO-anti-
biotin, thereby indicating non-specific uptake by the reticu-
lum–endothelial system in the liver (Fig. 5e).
Discussion
Magnetic nanoparticles formed by iron oxide/dextran com-
plexes are a promising tool for several in vitro and in vivo
applications. Because their unique magnetic features can be
applied to special medical techniques, they can be used as a
A
* *
B-FFE weighted images before and after 
USPIO-anti-biotin administration B
*
DC T2-3D-FFE weighted images before and after USPIO-anti-biotin administration
Pseudo-metastatic Lymphoma Xenograft
Fig. 3. Coronal MR images of pseudo-metastatic lymphoma xenografts. MRI images demonstrated the presence of tumor
masses in the retroperitoneal space, in particular in the right kidney (arrow) with hydronephrosis (hyperintense signal area). On
b-FFE weighted images, before (a) and 24 h after (b) the administration of biotin-conjugated LD6 plus USPIO-anti-biotin,
tumors (arrows) and liver (asterisk) showed an evident and homogeneous decrease in SI. On T2-weighted three-dimensional
fast-field echo images before (c) and 24 h after (d) administration of biotin-conjugated LD6 plus USPIO-anti-biotin, tumors
(arrows) showed a less or not significant decrease in SI, whereas the liver showed a significant decrease in SI (asterisk).
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Fig. 5. Histochemical detection of iron nanoparticles in pseudo-metastatic tumor xenografts (a–c) and in the liver (d, e). In a
and d, the monoclonal anti-CD70 LD6 was used as primary antibody, while in b, the isotype-matched control antibody CH-L
was used. In c and e, only USPIO-anti-biotin was administered to mice. Iron bound to tumor cells was detected (a). No
Prussian blue staining was detectable in the case of treatment with the isotype-matched negative control (b) or with USPIO-
anti-biotin alone (c). As expected on the basis of MRI data, Prussian blue staining was observed in the liver (d) of mice receiving
LD6 or only USPIO (e), indicating non-specific uptake by the reticulum–endothelial system. Tissue sections were stained with
the Prussian Blue method and images were taken using an Olympus BX41 Microscope equipped with Olympus Camedia C-
7070 camera (original magnification ×200 or ×400).
Ex-vivo T2-3D-FFE  weighted images
TUMOR LIVERTUMOR LIVER
Fig. 4. Ex vivo MR images of pseudo-metastatic lymphoma xenografts. Tumor (arrows) and liver (arrowheads) specimens fixed
in 4% buffered formalin showed a clear decrease in SI (arrows) on T2*-weighted images.
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flexible, fast, and simple magnetic sorting system for the
separation of large numbers of cells according to specific
cell surface markers [21].
Moreover, these particles are completely biodegradable
and show no toxic effects or incompatibility with biological
organisms, thereby substantiating their use as contrast agents
for MRI and as carrier systems for therapy [21].
We previously demonstrated that USPIO-anti-CD20 con-
jugates were able to bind to neoplastic B cells in vivo and
were detectable by MRI at 1.5 T, indicating that they could be
used to monitor the disease [19, 22]. However, many
antibodies directed to tumor antigens, potentially useful
especially in experimental settings, are not available as
USPIO conjugates. We therefore sought to evaluate whether
an “indirect” targeting technique, which employs unlabeled
mAbs followed by a common USPIO-conjugated secondary
reagent, could provide an equally suitable contrast agent.
In this study, we assessed the feasibility of targeting
superparamagnetic particles to tumors by means of a
two-step system based on the administration of tumor-
specific biotin-conjugated antibodies followed by USPIO-
anti-biotin. For this purpose, we chose to target the
human CD70 antigen, expressed by lymphoma cells and
only transiently by normal activated lymphocytes, iden-
tified by the murine mAb LD6 [14, 15]. Since LD6 does
not react with murine cells, it seemed suitable for the
monitoring of human lymphoma xenografts in mice. An
isotype-matched murine mAb that does not react with
human lymphoma cells, CH-L, was used as negative
control. The two purified antibodies were both biotin-
conjugated in-house, and labeling was assessed by
Western blot with streptavidin-HRPO and found to be
equal. As common secondary reagent, commercially
available USPIO particles conjugated with monoclonal
anti-biotin were chosen since their physical character-
istics matched those of the USPIO-anti-CD20 contrast
agent successfully used in our previous work [19].
Before in vivo experiments, the reactivity of USPIO-
anti-biotin toward the biotin-labeled monoclonal anti-
CD70 bound to the lymphoma cell surface was checked
in vitro by immunofluorescence.
We initially assessed the combination of biotin-labeled
antibodies with USPIO-anti-biotin in human lymphoma
xenografts induced subcutaneously in immunodeficient mice.
In this set of experiments, visual analysis showed a slight and
dishomogeneous decrease in SI on T2*-weighted images.
Quantitative analysis confirmed a 30% decrease in SI
at the tumor site. Histopathological analysis with Pearl
Prussian blue staining demonstrated that iron nanopar-
ticles were indeed present, in keeping with the MRI
results. The control group was injected with only USPIO-
anti-biotin or with isotype control CH-L mAb and
USPIO-anti-biotin to investigate the possible role of the
non-specific distribution of USPIO in the tumor. The
results obtained suggest that non-specific localization is
low in this type of tumor, indicating that the MR signal
obtained is related to the specific ability of the conjugated
antibodies to target the tumor-associated antigen in vivo.
We also observed an evident localization of iron in the liver
regardless of the primary antibody used for treatment. This
finding may be due to the aspecific phagocytosis of
nanoparticles by liver reticulum–endothelial cells and to
interaction of the Fc component of the antibodies with
surface Fc receptors. The subcutaneous xenograft animal
model was chosen because tumor growth can be easily
monitored.
In a second set of experiments, we developed a pseudo-
metastatic lymphoma model by injecting mice with tumor
cells in the tail vein. In vivo MRI demonstrated a decrease in
SI especially on b-FFE-weighted sequences compared to
T2*-weighted sequences. In ex vivo MR images, tumor
specimens showed a higher decrease in SI on T2*-weighted
images compared to in vivo MR examination.
The magnetic susceptibility of iron nanoparticles produ-
ces magnetic field dishomogeneities that are known to affect
regions in MR images over a far greater area than the actual
particle distribution. Cell-bound large iron nanoparticles can
influence magnetic resonance SI many pixels away and
produce an effect described as “blooming artifact,” the size
of which is pulse-sequence- and field-strength-dependent.
To maximize the ability to visualize this effect, most
imaging studies have used T2- or T2*-weighted spin-echo
and gradient echo sequences and high magnetic field
strengths. The region of signal void in these images is
consequentially larger than the actual area occupied by the
iron-targeted tumor cells.
Our in vivo images of mouse kidneys were acquired with
T2*-weighted and b-FFE-weighted sequences. We observed
that b-FFE-weighted gradient echo sequences displayed high
sensitivity also to small numbers of iron nanoparticles, in
particular in the case of intracellular iron localization.
Indeed, b-FFE-weighted gradient echo imaging sequences
have a number of advantages over other imaging sequences,
above all for cellular imaging fields.
As demonstrated in another study performed with a
different MR instrument at 1.5 T [23], the high sensitivity
to off-resonance effects, which was originally considered
a negative aspect of this imaging sequence, showed that it
was instead very effective for cellular imaging with iron
oxide nanoparticles. Indeed, it was recently demonstrated
for the first time that individual SPIO-labeled cells can be
detected in vivo using this specialized microimaging
approach [24].
While maintaining the sensitivity to iron oxide-labeled
cells intrinsic to gradient echo sequences, balanced gradient
echo-weighted sequence exhibits blooming artifact suppres-
sion traits intrinsic to spin-echo sequences. In addition, the
b-FFE-weighted gradient echo sequence provides substan-
tially enhanced SNR compared to spin-echo and gradient
echo sequences. This improvement in SNR allows micro-
imaging at lower field strengths and acquisition of images at
high spatial resolution with reasonable scan times. These
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two factors were key to visualizing small numbers of iron-
targeted tumor cells.
Our results reflect those obtained in previous studies
which used similar USPIO contrast agents to visualize
inflammatory cell infiltration of the brain in a murine model
of autoimmune encephalomyelitis [11]. However, these
studies used 3.5- to 7-T MRI equipment, while in the
present investigation, the high antigen expression by a
homogeneous population of tumor cells allowed the detec-
tion of cell-bound USPIO by 1.5-T standard equipment.
Our present in vitro data using an anti-CD70 suggest that
MRI at 1.5 T can detect tumor cells and eventually identify
metastases that express the relevant target antigens at high
levels, whereas tumors with low CD70 antigen expression
may not be detected. Thus, the monoclonal anti-CD70 may
represent an additional and molecularly specific contrast
agent in the diagnosis and follow-up of CD70-expressing
tumors. In addition, MRI detection at 1.5 T of lymphoma
masses by monoclonal anti-CD70 in vivo may be suggestive
of a strong antigenic expression and of a good tumor
localization of the CD70 mAb, thus allowing the selection of
those patients that could benefit from CD70 mAb-based
immunotherapy. Indeed, previous data indicate that therapy
with the mAb LD6 inhibits the growth of CD70-expressing
tumors grown as xenografts in immunodeficient mice [2].
One potential limit of the present study may be the iron
concentration in the commercially available USPIO-anti-
body conjugate used (20 mM/L) which, compared to
concentrations in clinically available non-targeted MRI
contrast agents that are non-specifically internalized by
reticulum–endothelial cells, was low. The development of
similar USPIO-targeted antibodies with high iron oxide
content may thus allow improvements in the sensitivity of
detection in order to permit the MR imaging of tumors with
small diameters or with lower target antigen density.
A possible application of superparamagnetic antibody-
targeted MRI technology is the in vivo tracking of cells.
Indeed, previous studies have shown that in vitro cell
labeling by MRI contrast agents can be performed by either
non-targeted nanoparticles, which enter the cell in a non-
specific fashion, or by specific USPIO-antibody conjugates
that specifically bind to a cell surface antigen and can then
eventually be internalized [25, 26].
Conclusion
In this study, we report that a two-step technique based on
tumor-specific biotin-conjugated primary antibodies and
commercially available USPIO-anti-biotin provides a simple
method of molecular imaging using MRI at 1.5 T. Moreover,
this approach contributes to efforts focusing on cell labeling
in vitro and in vivo. The development of new tumor-specific
contrast agents may further improve this technology and
provide a new tool for the diagnosis of tumors and for
cancer-targeting therapies.
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2.1.2. Cell labelling by iron oxide nanoparticles 
 
2.1.2.1. Title of paper 
 
• Neumaier CE, Baio G, Ferrini S, Corte G, Daga A. MR and iron 
magnetic nanoparticles. Imaging opportunities in preclinical and 
translational research. Review Tumori 2008 Mar-Apr; 94:226-33. 
• Baio G, Daga A, Cappelli AM, Derchi LE, Corte G, Neumaier CE. 
“Targeting dei Linfociti NK con ferumoxides mediante una Risonanza 
Magnetica ad 1.5T”. SIRM Rome 2008. Magna cum Laude. P1500. 
2.1.2.2. Objective of the study 
 
To noninvasively label NK cell lymphocytes by using two types of 
superparamagnetic contrast agents (USPIO and SPIO) and different types of 
transfection agents. 
2.1.2.3. What this study added to the literature 
 
Several attempts to image NK cells have been made by different groups 
using direct labelling strategies that involve purifying cells from peripheral 
blood, radiolabelling with 111In-oxine, and re-administering to patients. This 
approach has limitations such as cell manipulation in culture and cell-
function impairment after ex-vivo labelling. Several studies reported the 
high toxicity of 111In-oxine to cells, leading to improper migration into target 
organs. In vitro labelling with unmodified USPIO applied at high 
concentration proved its effectiveness on cells such as monocytes, glioma 
cells, macrophages, or oligodendrocytes. In contrast, the in vitro spontaneous 
endocytosis of dextran-coated particles with non-phagocytic cells remains 
insufficient to allow most applications in cellular MR imaging. There are 
many problems associated with the low endocytosis capacity of some 
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“candidate” cells like lymphocytes. Moreover, cellular toxicity studies 
conducted with high iron concentrations in the labelling medium (e.g., 2mg 
Fe per ml of culture medium) led to the conclusion that free radicals could 
be generated, leading to reduced cell multiplication and even cellular death 
[146]. To improve the endocytosis internalisation of nanoparticles by no 
phagocytic cells, different systems were proposed, such as coupling particles 
to a transfection agent or the modification of their external structure. 
However, these studies are often reserved to the specialised laboratories that 
developed them, and/or represent difficulties for non-specialists. An 
interesting alternative was proposed by our study, by using marketed 
(U)SPIO-like Feridex® or Sinerem®. In the presence of these agents, 
(U)SPIO were internalised in cells via the formation of endosomes. The 
transfection agents involve polycationic dendrimers such as Superfect®, 
poly-L-lysin, or FuGENE®. Given its low price and wide availability, poly-
L-lysin became the transfection agent of choice, as several studies reflect. 
The results of this piece of research were presented during the SIRM 2008 
and awarded with a Magna cum Laude. 
2.1.2.4. What changed as a result of the paper? 
 
The past several years has seen tremendous advances in the engineering of 
immune effector cells as therapy for cancer. Despite this improvement in 
basic science, labelled NK cells are still not applied in the clinical 
environment. Several labelling studies have been carried out on stem cells as 
a novel therapeutic option for cell-death-related diseases, such as myocardial 
infarction by using iron oxide nanoparticles, but most of these are still 
preclinical. 
2.1.2.5. In retrospect, what should have been done differently in this study? 
 
Chapter 2       Original peer reviewed papers 
  
 
P a g e  89 | 136 
 
Looking back at this work, we could have performed the preclinical in vivo 
MR imaging study of (U)SPIO-labelled NK cells in healthy controls and in 
cancer animal models. This set of experiments would have made our cell 
labelling MR protocol stronger. 
2.1.2.6. Future work as a result of this publication    
 
For the development of NK cell-based immunotherapies in solid tumors, the 
ability to accurately and quantitatively assess tumor homing and 
biodistribution by molecular imaging is the key. Imaging of NK cell-based 
therapies allows for an immediate assessment of therapeutic efficacy, off-
target effects, severity of the immunosuppressive microenvironment, and 
quantification of NK cell expansion. Following the research studies on 
preclinical MR application of iron oxide nanoparticles, I was invited to write 
two chapters for one of the first Molecular Imaging books on Probes for 
Cancer research (“Molecular Imaging probes for cancer research”, edited by 
Professor Xiaoyuan Chen, Laboratory of Molecular Imaging and 
Nanomedicine (LOMIN), at NIH Bethesda, USA). 
2.1.2.7. Confirmation of authorship 
 
This is shown at the end of Chapter 2. 
2.1.2.7. External link to the paper on the journal website 
 
https://www.ncbi.nlm.nih.gov/pubmed/18564611
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ABSTRACT
Ultrasmall superparamagnetic iron oxide nanoparticles and magnetic resonance im-
aging provide a non-invasive method to detect and label tumor cells. These nanopar-
ticles exhibit unique properties of superparamagnetism and can be utilized as excel-
lent probes for magnetic resonance imaging. Most work has been performed using a
magnetic resonance scanner with high field strength up to 7 T. Ultrasmall superpara-
magnetic iron oxide nanoparticles may represent a suitable tool for labeling molecu-
lar probes that target specific tumor-associated markers for in vitro and in vivo detec-
tion by magnetic resonance imaging.
In our study, we demonstrated that magnetic resonance imaging at 1.5 T allows the
detection of ultrasmall superparamagnetic iron oxide nanoparticle conjugated anti-
body specifically bound to human tumor cells in vitro and in vivo, and that the mag-
netic resonance signal intensity correlates with the concentration of ultrasmall super-
paramagnetic iron oxide nanoparticle antibody used and with the antigen density at
the cell surface. The experiments were performed using two different means of target-
ing: direct and indirect magnetic tumor targeting. The imaging of tumor antigens us-
ing immunospecific contrast agents is a rapidly evolving field, which can potentially
aid in early disease detection, monitoring of treatment efficacy, and drug develop-
ment. Cell labeling by iron oxide nanoparticles has emerged as a potentially powerful
tool to monitor trafficking of a large number of cells in the cell therapy field. We also
studied the labeling of natural killer cells with iron nanoparticles to a level that would
allow the detection of their signal intensity with a clinical magnetic resonance scan-
ner at 1.5 T.
Magnetic resonance imaging and iron magnetic nanoparticles are able to increase
the accuracy and the specificity of imaging and represent new imaging opportunities
in preclinical and translational research.
Introduction
Magnetic resonance imaging (MRI) offers a non-invasive technique to obtain
anatomic and metabolic/functional information with high spatial and temporal res-
olution. It has two particular advantages over techniques that involve the use of ra-
dionuclides or optical probes: higher spatial resolution, and physiological, molecular
and anatomical information can be extracted simultaneously. For specific detection
of macromolecules using MRI, i.e., molecular imaging, ligands need to be conjugated
to MR contrast agents in order to induce a different signal intensity (SI) from the non-
targeted tissue. Similarly, for MRI detection of the cell populations of interest, i.e., cel-
lular imaging, cells need to be labeled with MR contrast agents in order to make them
stand out from the surrounding tissues. For both applications, gadolinium chelates
may be used, but they have low relaxivity values, which further decrease upon cellu-
Tumori, 94: 226-233, 2008
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lar internalization, are not biocompatible, and very little
is known about their potential toxicity following cellular
dechelation over time.
Superparamagnetic iron oxide particles (SPIO), which
were introduced as contrast agents shortly after the use
of gadolinium chelates1-3, currently appear to be the
preferred material. In particular, ultrasmall superpara-
magnetic iron oxide particles (USPIO) may represent a
suitable tool for labeling molecular probes that target
specific tumor-associated markers for in vitro and in vi-
vo detection by MRI. An important property of USPIO is
the strong T2 relaxivity that produces a decrease in SI on
T2-weighted images4,5 and also a high T1 relaxivity with
an increase in SI on T1-weighted images6,7. The associa-
tion of MRI with specific tumor iron oxide nanoparticles
is able to increase the accuracy and the specificity of im-
aging8.
Monoclonal antibodies (mAbs) represent an impor-
tant emerging tool in cancer therapy, and the study of
specific surface markers on tumor cells has determined
an important development of mAbs for use as targeted
therapeutic agents. Therapeutic mAbs can act by block-
ing growth factors, directly signaling arrest and apopto-
sis, or inducing elimination of mAb-decorated target
cells via activation of host defense mechanisms9.
The preparation and use of magnetically labeled
mAbs seemed to be an extension of the earlier work in
nuclear medicine carried out using radiolabeled anti-
bodies. In this way, the detailed anatomic information
on the MR images can be specifically marked in order to
detect a disease in its earliest stages, particularly tu-
mors. Immunoglobulins can be covalently linked to the
dextran polysaccharide coat of the iron oxide using an
established method10,11. Iron oxide nanoparticles have
been conjugated to polyclonal immunoglobulin G for
the detection of induced inflammation12, to mAb frag-
ments for the specific visualization of myocardial in-
farction13, to intact mAbs for immunospecific detection
of intracranial small cell lung carcinoma14, intracellular
adhesion molecule-1 gene expression on transfected
cell lines15 and oligodendrocyte progenitors16, and to
synaptotagmin I for detection of apoptotic tumor
cells17. Alternative ways of attaching mAbs to magnetic
nanoparticles include glutaraldehyde cross-linking18,
complexing through ultrasonication19,20, using the bi-
otin-streptavidin system21,22 and amine–sulfhydryl
group linkage23,24. The aforementioned studies provide
examples of cases where molecular MRI using iron ox-
ides has proven to be successful. Moreover, most work
has been performed using an MR scanner with high
field strength up to 7 T.
However, cellular imaging aims to visualize cells. It is
a non-invasive method to study cellular processes
which entails proper labeling of cells with appropriate
MR contrast agents25. Cell labeling by SPIO has emerged
as a potentially powerful tool to monitor trafficking of
transplanted cells by magnetic resonance, e.g. in studies
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for tissue repair, but it has also become increasingly im-
portant in the development of oncologic cell therapies.
We report our experience in tumor and cell labeling.
For tumor targeting, we used two different approaches:
direct magnetic tumor targeting by a USPIO conjugated
antibody specifically bound to human tumor cells in
vitro and in vivo, and indirect magnetic tumor targeting
based on a bridge of tumor-specific biotin-conjugated
antibodies in vivo. We demonstrated that the MRI SI
correlates with the concentration of USPIO antibody
used and with the antigen density at the cell surface. We
also studied the possible use of these conjugated mon-
oclonal antibodies as contrast agents for in vivo labeling
of human tumor cells.
For cell labeling, we investigated the possibility of la-
beling human natural killer (NK) T cells with iron
nanoparticles and different types of transfection agents.
We tested these types of targeting at a level that would
allow their SI with a clinical MR scanner at 1.5 T.
Iron oxide nanoparticles
The in vitro magnetic properties of USPIO are report-
ed to be a T1 relaxivity (r1) of 21.6 (mmol/liter·sec)-1 and
a T2 relaxivity (r2) of 44.1 (mmol/liter·sec)-1 at 37 ºC and
0.47 tesla (T), where mmol/liter is the concentration of
iron oxide. Conventional, water-soluble, paramagnetic
contrast agents are generally metal chelates with un-
paired electrons, and they work by shortening both T1
and T2 relaxation times of surrounding water protons to
produce a signal-enhancing effect26. They distribute in
the extracellular fluid and do not cross the intact
blood–brain barrier27. Another approach is the develop-
ment of water-insoluble SPIO nanoparticles that com-
prise iron oxides such as magnetite (Fe3O4), maghemite
(γFe2O3), or other ferrites28,29. Ferromagnetic crystals are
composed of magnetized domains the size of a micron.
Superparamagnetism occurs when the size of the crys-
tals is smaller than the ferromagnetic domain (~30 nm).
SPIO agents typically consist of an iron oxide core and a
hydrophilic coating30. They have very high relaxivities
(R1 and R2), and the significant capacity of these parti-
cles to increase the susceptibility effect of the measured
spin-spin relaxation time (T2*) is especially useful in
MRI. This large T2* effect is the result of the non-homo-
geneous distribution of these superparamagnetic parti-
cles, which accelerates the loss of phase coherence of
the spins contributing to the MRI signal. Clinically, SPIO
are predominantly used for their negative enhancement
effect on T2- and T2*-weighted sequences. This class of
MRI agents includes large oral SPIO (300-3500 nm)
agents, standard SPIO (60-150 nm) agents, USPIO (10-
40 nm) agents, monocrystalline iron oxide (10-30 nm)
nanoparticle agents, and cross-linked iron oxide agents
(a form of monocrystalline iron oxide nanoparticles
with a cross-linked dextran coating)31. Both the size and
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the surface properties of SPIO particles affect their
pharmacokinetics, organ distribution, and intracellular
uptake32. Biologically, SPIO particles are usually taken
up by the reticuloendothelial system and phagocytic
cells. USPIO particles are less prone to liver uptake and
are small enough to migrate across the capillary wall of
tumors33.
Tumor targeting
Direct tumor magnetic labeling
We used commercially available USPIO bound to an
anti-CD20 monoclonal antibody (immunoglobulin G1-
murine) and stabilized with sodium citrate (Miltenyi
Biotech, Bergisch Gladbach, Germany). USPIO-anti-
CD20 mAb is a molecular imaging agent developed for
MRI of CD20 antigen-positive B cell lymphomas. The
particles were composed of a biodegradable, non-toxic,
ferromagnetic matrix (dextran). The overall mean parti-
cle diameter was ~30-50 nm. There were typically 10-
200 antibody molecules/particle (30 nm in diameter).
The in vitro R1 and R2 relaxivities measured at 37 ºC and
1.5 T were 30 and 60 liter·s-1·mmol-1, respectively34. The
CD20 antigen is a 35-kDa, cell-surface non-glycosylat-
ed, hydrophobic phosphoprotein expressed on normal
and malignant B cells, and it does not shed, modulate,
or internalize35,36. It is present on ~9% of the peripheral
blood mononuclear cell (PBMC) fraction and >90% of B
cells from blood and lymphoid organs. Lymphoma cells
from >90% of patients with B-cell non-Hodgkin lym-
phoma express this antigen. Despite the presence of
CD20 on normal B cells, it is a good tumor target for mo-
lecular targeting with antibodies for the management of
non-Hodgkin lymphoma. 
As cell lines, D430B and Raji cells (anaplastic large B-
cell lymphoma) were used. The expression of surface
antigens by D430B and Raji cell lines was analyzed by im-
munofluorescence. The presence of USPIO antibody
bound to the cells was verified by staining with a phyco-
erythrin-labeled anti-mouse immunoglobulin antibody
(Southern Biotec Inc., Birmingham, AL, USA). All samples
were analyzed by cytofluorimetric analysis on a FACScan
(BD Biosciences, Franklin Lakes, NJ, USA).
In vitro study. We incubated five million human
D430B cells37 and Raji Burkitt lymphoma cells (ICLC, In-
terlab Cell Line Collection) with different amounts of
anti-CD20 monoclonal antibody USPIO conjugates. Af-
ter incubation with the USPIO-mAb conjugates, un-
bound conjugates were removed and cells were includ-
ed in a matrigel sponge for MRI imaging with a 1.5-T
MR system (Philips Gyroscan NT-Intera). Immunofluo-
rescence analysis showed that USPIO-anti-CD20 mAb
bound to the cell surface and the D430B cells expressed
five times more CD20 molecules than the Raji Burkitt
cells. USPIO anti-CD20 mAb on D430B cells showed a
decrease in SI on T2*-weighted images and SI enhance-
ment on T1-weighted images (Figure 1). In comparison,
USPIO anti-CD20 mAb on Raji Burkitt cells only showed
a slight hypointensity on T2-weighted images and a
non-homogeneous hyperintensity on T1-weighted im-
ages (Figure 1). Quantitative analysis showed that the
changes in T1 SI (∆SI = SInon-labeled–SI USPIO anti-CD20
mAb/noise) values from the three-dimensional fast-field
echo sequences at 1.5 T for the USPIO anti-CD20 mAb
on D430B cells were -36.6, -12.4, and -6.2 for 0.03 µmol
iron (Fe)/liter, 0.01 µmol Fe/liter, and 0.005 µmol
Fe/liter USPIO anti-CD20 mAb, respectively. The T2 ∆SI
values were -73, -24, and -12 for 0.03 µmol Fe/liter, 0.01
µmol Fe/liter, and 0.005 µmol Fe/liter USPIO anti-CD20
mAb, respectively. In comparison, the T1 ∆SI values of
the USPIO anti-CD20 mAb on Raji Burkitt cells were -25,
-9, and -6 for 0.03 µmol Fe/liter, 0.01 µmol Fe/liter, and
0.005 µmol Fe/liter USPIO anti-CD20 mAb, respectively.
The T2 ∆SI values were -43, -17.7, and -12 for 0.03 µmol
Fe/liter, 0.01 µmol Fe/liter, and 0.005 µmol Fe/liter US-
PIO anti-CD20 mAb, respectively.
In vivo study. Experiments were approved by the Insti-
tutional Review Committee of the National Cancer In-
stitute and were performed in accordance with the Na-
tional Regulations on Animal Research Resources. MRI
Figure 1 - Representative MR images of cell pellets in test-tubes.
Each pellet contains 5x106 D430B lymphoma cells and 5x106 Raji
lymphoma cells on T2*-weighted images (A) and on T1-weighted
images (B), with of USPIO-anti-CD20, respectively. A) D430B cells-
USPIO-anti-CD20 showed an important decrease of SI on T2*-
weighted images that is more evident in the pellet treated with 0.03
µmol Fe/l of USPIO-anti-CD20, whereas Raji cells-USPIO-anti-
CD20 showed a slight hypointensity in the same sequences (dou-
ble arrow). B) D430B cells-USPIO-anti-CD20 showed a SI en-
hancement on T1-weighted images and Raji cells-USPIO-anti-
CD20 an inhomogeneous hyperintensity on T1-weighted three-di-
mensional fast field echo images (double arrow).
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studies were performed in NOD-SCID mice bearing s.c.
D430B or the Raji Burkitt tumors (0.5-1 cm2). Each
mouse received an i.v. dose of 8 µmol Fe/kg 24 h before
imaging with a 1.5 T-MR system34.
The D430B tumors showed a non-homogeneous SI
decrease on T2*-weighted images (Figure 2) and a slight
SI enhancement on T1-weighted images. In compari-
son, the Raji Burkitt tumors showed slight non-homo-
geneous hypointensity on T2*-weighted images and
slight nonhomogeneous hypertensity on T1-weighted
images. Quantitative analysis studies were conducted
with the region-of-interest technique to obtain the sig-
nal/noise (SNR) ratios. The T2*-weighted ∆SI value
(SNRbefore/SNRafter) of the D403B tumor (n = 5) was 35 ±
7% (82 ± 9%/57 ± 11%), whereas the T2*-weighted ∆SI
value of the Raji Burkitt tumor was 15 ± 8% (47 ± 10%/40
± 13%). In comparison, tumors in mice injected with a
non-specific standard SPIO agent ferumoxide (17 µmol
Fe/kg) showed a T2*-weighted ∆SI value of 5 ± 6% (1,392
± 86%/1,322 ± 80%).
Indirect tumor magnetic labeling
We used commercially available USPIO bound to an
anti-biotin monoclonal antibody (immunoglobulin G1-
murine) and stabilized with sodium citrate (Miltenyi
Biotech). The r1 and r2 relaxivities were 30 L·sec-1·
mmol-1 and 60 L·sec-1·mmol-1, respectively34. Anti-CD70
murine mAb, clone LD6, was purified from culture
medium by affinity chromatography on Sepharose-Pro-
tein A (GE Healthcare, Chalfont, St Giles, UK) and sub-
sequently conjugated with EZ-Link Sulfo-NHS-LC-bi-
otin (Pierce®, Rockford, IL) according to the manufac-
turer’s instructions38,39. Surface expression of the CD70
antigen by the D430B line was analyzed by immunoflu-
orescence and flow cytometry. To detect the binding of
USPIO anti-biotin to the biotin-conjugated antibodies,
D430 B cells were incubated with biotin-LD6 and bi-
otin-CH-Leo. After washes, cells were challenged with
10 ml of the USPIO anti-biotin suspension, and the
presence of USPIO-anti-biotin bound to the cells carry-
ing biotin-conjugated anti-CD70 mAb was verified by
staining with a FITC-labeled anti-mouse immunoglob-
ulin antibody (Caltag) followed by flow cytometric
analysis. Mice were injected s.c. with 2 x 107 human
D430B cells (palpable masses of 0.5 to 1 cm2). In a sec-
ond set of experiments, 2 x 107 D430B cells per mouse
were injected into the tail vein to induce pseudo-metas-
tases, in particular localized in kidney and retroperi-
toneum. To target tumor-expressed human CD70 anti-
gen, 30 µg per mouse of biotin-labeled LD6 mAb was
administered via the tail vein and MRI was performed
with an MR scanner at 1.5 T. Four hours after adminis-
tration of the biotin-labeled antibody, 16 µmol Fe/kg
per mouse of USPIO anti-biotin was injected in the tail
vein. MRI was performed again 24 h later. As negative
control, a group of mice was similarly inoculated with
biotin-conjugated CH-Leo mAb. We performed the his-
tological analysis according to standard techniques.
Iron oxide-labeled cells were stained with Perl’s Pruss-
ian blue stain. The D430B s.c. tumors showed a nonho-
mogeneous SI decrease on T2- and T2*-weighted im-
ages 24 h after USPIO anti-biotin administration (Figure
3); the D430B pseudo-metastases showed an important
decrease in SI on T2* (Figure 4) and on balanced fast-
field, echo-weighted images. Histopathological analysis
using the Prussian blue stain demonstrated a significant
iron localization in the D430B pseudo-metastases in
comparison to s.c. D430B tumor.
Cell labeling
NK cells were generated from PBMC obtained from
healthy donors. The PBMC were enriched for NK cell
populations by negative depletion using immunomag-
netic beads (NK cell isolation kit II; Miltenyi Biotec).
PBMC were incubated with a biotin-conjugated anti-
body mix containing anti-CD3, anti-CD4, anti-CD14,
anti-CD15, anti-CD19, anti-CD36, anti-CD123 and anti-
235a (glycophorin A). Cells were washed and cen-
Figure 2 - Direct magnetic tumor targeting in vivo. On T2*-weight-
ed images before (A) and after (B) USPIO-anti-CD20 antibody ad-
ministration. The CD20 high D430B tumor showed a non-homo-
geneous decrease of signal.
Figure 3 - Indirect tumor targeting in D430B subcutaneous lym-
phoma. On T2-weighted images, before (A) and after (B) USPIO-
anti-biotin administration. There was a nonhomogeneous de-
crease in signal.
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trifuged. The supernatant was discarded and the cell
pellet was resuspended in 0.1% phosphate-buffered
saline human AB serum and incubated at 4 °C for 10
min after the addition of depletion anti-biotin mi-
crobeads. The cell suspension was loaded on a column
in the magnetic field of a magnetic-activated cell sorter.
NK cell purity was determined by flow cytometry. En-
riched NK cells were expanded as bulk NK cell popula-
tions in RPMI containing 10% heat-inactivated fetal calf
serum and 500 IU/ml of interleukin-2.
As a targeted contrast agent, we used a commercially
available ferumoxide suspension (Endorem, Guerbet,
Paris), which has a total iron content of 11.2 and 28
mg/ml, respectively. As a transfection agent, protamine
sulfate (Pro, 6 mg/ml) or polylysine (PLL, 1.5 mg/ml)
was added. The final FE-Pro or FE-PLL suspensions
were added directly to the cells and incubated
overnight. For the assessment of labeling efficiency and
to study the SI on an MR scanner at 1.5 T, four groups
were compared: unlabelled cells; NK-ferumoxides
alone; NK-feromoxides plus protamine; NK-ferumox-
ides plus PLL (Figure 5). Cell viability was measured in
single cell suspensions by trypan blue exclusion. Perl’s
Prussian blue stain was performed to show iron local-
ization in NK cells. On T2-weighted images, we ob-
served a decrease in SI in all three groups due to iron in
NK cells (Figure 5), but in the quantitative analysis, we
calculated a significant decrease in SI in human feru-
moxides-PLL-NK-labeled cells (60%) compared with
human ferumoxide-Pro-NK-labeled cells (30%). Perl’s
Prussian blue stain demonstrated that the hypointensi-
ty on MRI was due to ferumoxides in NK cells. Moreover,
there were no toxic effects after labeling cells, and with
our doses no apoptosis or necrosis was observed.
Discussion
SPIO particles appear to be the preferred material for
the targeting of tumor and cells. The popularity of SPIO
particle labeling is mainly because: 1) they provide a
strong change in signal (hypointensity) per unit of met-
al (on T2*-weighted images), 2) they are composed of
biodegradable iron (biocompatible and can be recycled
by cells using biochemical pathways for iron metabo-
lism), 3) their surface coating (dextran) allows chemical
linkage of functional groups and ligands, 4) they can be
easily detected by light and electron microscopy, and 5)
they can be manipulated and change their magnetic
properties according to size. Iron nanoparticles can be
conjugated to specific mAbs in order to label tumor and
cells. These “molecular probes” are able to induce a dif-
ferent SI in tumor tissue compared to normal tissue.
Many promising probes are being, or will be, applied to
the diagnosis of cancer and may also facilitate cancer
therapy. Furthermore, many antibodies directed to tu-
mor-associated antigens are available for clinical use. A
wide spectrum of commercially available SPIO antibod-
ies used for cell-separation techniques is available, and
some of them are also available as clinical-grade
reagents8. They may be a promising tool for several in
vitro and in vivo applications.
In our studies, we demonstrated the successful use of
a commercially available USPIO antibody conjugate for
MRI in vitro and in a murine model. In medicine, many
Figure 4 - Indirect tumor targeting in D430B pseudo-metastases
lymphoma. On T2-weighted images, before (A) and after (B) US-
PIO-anti-biotin administration. There was a decrease in signal in-
tensity in D430B.
Figure 5 - T2-weighted images of USPIO natural killer labeled cells
and natural killer cells. A) Unlabelled natural killer cells. B) Feru-
moxides Pro-NK-labeled cells. C) Ferumoxides PLL-NK-labeled
cells. D) NK-ferumoxides 
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approaches have been investigated for diagnosis and
therapy and have offered a large variety of applications:
magnetic cell separation, MRI, magnetic targeted drug
delivery, and magnetically induced hyperthermia. Such
particles do not have any toxic effect or incompatibility
with biological organisms, therefore they have a poten-
tial use as contrast agents for MRI and as a carrier sys-
tem for drugs40.
Our in vitro study was designed to assess the feasibil-
ity of the use of an MR scanner at 1.5 T to detect USPIO
antibodies bound to tumor cells at potentially suitable
doses for small animal models in a pre-clinical setting.
We demonstrated that commercially available USPIO
antibody conjugates specific for a B-cell lymphoma-as-
sociated antigen binding to the human D430B cells or to
the Raji Burkitt lymphoma cell line can be visualized on
MRI at 1.5 T. We also demonstrated through in vitro as-
says that there is a dose-response relationship between
the different amounts of USPIO anti-CD20 bound to the
cells and the DSI on T2*-weighted images. This effect is
more evident on cells expressing high levels of the target
antigen (D430B) than on cells with a lower expression
(Raji), indicating that the magnitude of DSI observed
depends on the dose of the immunospecific contrast
agent and on the target antigen expression of the cells.
Indeed, in vivo experiments indicated that the intra-
venous administration of a single dose of USPIO anti-
CD20 antibody conjugate 24 h before performing MRI
at 1.5 T is sufficient to induce detectable changes of SI in
a reproducible fashion (35% ± 7). Our results are consis-
tent with those obtained in previous studies using simi-
lar USPIO contrast agents to visualize inflammatory
cells infiltrating the brain in a murine model of autoim-
mune encephalomyelitis41. However, these previous
studies used a 3.5-7 T MR scanner, whereas in the pres-
ent investigation the high antigen expression by a ho-
mogeneous population of tumor cells allowed the de-
tection of cell-bound USPIO by a 1.5 T standard scan-
ner. With indirect magnetic tumor targeting, we as-
sessed the feasibility of targeting superparamagnetic
particles to tumors by a bridge of tumor-specific biotin-
conjugated antibodies. We demonstrated that the com-
bination of specific biotin-labeled antibodies with the
USPIO anti-biotin as the common secondary reagent
was able to target two types of murine models: the
xenotransplant (s.c.) and the pseudo-metastases lym-
phoma tumors. In particular, the D430B pseudo-metas-
tasis was localized in the kidney and retroperitoneum.
These tumor sites are more vascularized than s.c. tu-
mors. In fact, the decrease in SI at MRI visualization was
more evident in D430B pseudo-metastases, and Perl’s
Prussian blue staining demonstrated a significant iron
concentration in this type of tumor model.
A potential limitation of these molecular probes may
be related to the relatively low iron concentration com-
pared with the clinically available non-targeted MRI
contrast agents, which are non-specifically internalized
by the reticular-endothelial cells. Thus the develop-
ment of similar USPIO-targeted antibodies with high
iron oxide content may enhance the sensitivity of de-
tection, in order to allow MRI of tumors with small di-
ameters or with lower target antigen density. We believe
that this indirect method opens the possibility to target
any cell surface antigen, thus becoming a useful tool in
MRI.
Another possible application of iron nanoparticles
and MRI is to label cells. In our cell labeling experi-
ments, we illustrated the possibility to label NK cells
with ferumoxides and different kinds of transfection
agents. NK cells are a subpopulation of lytic effector
lymphocytes that represents the first line of defense
against tumor progression and metastasis. More studies
were performed with stem cells, which have a signifi-
cant phagocytic activity. This characteristic is less evi-
dent in NK cells. For this reason, we used different kinds
of transfection agents. The complex ferumoxides-PLL-
NK cells showed a substantial decrease in SI on T2*-
weighted images, and Perl’s Prussian blue staining con-
firmed the presence of ferumoxides in NK cells, thus
proving that PLL is more efficient than Pro as a transfec-
tion agent for the internalization of ferumoxides by NK
cells.
We have shown that significant changes in T2-weight-
ed MRI SI can be achieved in human NK lymphocytes
with a short incubation of iron oxide nanoparticles at
concentrations that do not have deleterious effects on
cellular viability or function. The detected contrast
change lasted for at least 24 h and raises the possibility
that iron oxide nanoparticle labeling of lymphocytes
could be used to track these cells in tumors and other
tissues using high spatial resolution MRI. Iron nanopar-
ticles might be a type of targeting to study in vivo NK
cell migration at a level that would allow the detection
of their SI with a clinical MR scanner at 1.5 T. We believe
that by optimizing molecular-targeted contrast agents,
MRI technology and the generation of new USPIO or
SPIO antibodies, or other USPIO or SPIO ligands, may
provide useful immunospecific contrast agents for the
diagnosis of tumors and for targeting cells for cell ther-
apy. In this way, it promises to provide new methods for
the early detection of cancer and support for personal-
ized cancer therapy. Nevertheless, there has been suffi-
cient experience with specifically targeted contrast
agents and high-resolution techniques for MRI and oth-
er modalities that we must begin moving these new
technologies from the laboratory to the clinic.
Conclusions
MRI combined with iron oxide contrast agents is able
to increase the accuracy and specificity of imaging and
represents a new imaging opportunity in preclinical and
translational research.
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2.2. Investigation of tumour imaging by using MEMRI 
 
2.2.1. Title of paper 
 
• Baio G, Fabbi M, Emionite L, Cilli M, Salvi S, Ghedin P, Prato S, 
Carbotti G, Tagliafico A, Truini M, Neumaier CE. In vivo imaging of human 
breast cancer mouse model with high level expression of calcium sensing 
receptor at 3T. Eur Radiol. 2012 Mar; 22(3):551-8. 
2.2.2. Objective of the study 
 
To demonstrate that MEMRI can be applied to visualise human breast CaSR-
expressing cancer cells using a prototype birdcage with a clinical 3T human 
scanner. 
2.2.3. What this study added to the literature 
 
Most of the studies published during this period applied MEMRI to 
investigate overexpressed manganese-superoxide dismutase tumours. Our 
aim was to target tumours with high CaSR expression levels and to find the 
best MR contrast agents to target this type of tumour. This was a novel 
application certainly of value for the scientific literature. The application of 
a clinical human scanner with a prototype birdcage coil was something novel 
too, since all previous studies used ultra-high field MR preclinical scanners. 
2.2.4. What changed as a result of the paper? 
 
Manganese is not commercially available as an MR contrast agent, thus 
clinical applications cannot be explored. However, several preclinical 
imaging studies extensively demonstrated the interesting role of this ion 
combined with MR imaging, which could find a new interesting application 
and potentially come back into the clinical market soon. 
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2.2.5. In retrospect, what should have been done differently in this study? 
 
Looking back to this work, silencing CaSR expression in the breast cancer 
cell lines would have strengthened the link between CaSR expression levels 
and manganese uptake at MRI. The application of Verapamil as Calcium 
antagonist is not specific for CaSR and any calcium receptors/channels could 
participate to the manganese uptake that we observe at MRI. 
2.2.6. Future work as a result of this publication 
 
Following this paper, we further explored the role of manganese as a contrast 
agent to investigate tumour calcium metabolism. We investigated if the 
manganese uptake we had observed on MRI was due to extracellular or 
intracellular internalisation of manganese. The results of this experiment are 
discussed in the following section. However, we also performed further 
research exploring different  calcium receptors (CaSR and TRPV6) in 
different types of cancer animal models (breast and prostate), which is not 
included in this thesis because it has recently been submitted to a journal for 
review, and is not published as yet. 
2.2.7. Confirmation of authorship 
 
This is shown at the end of Chapter 2. 
2.2.8. External link to the paper on the journal website 
 
https://www.ncbi.nlm.nih.gov/pubmed/21947485
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Abstract
Objectives To demonstrate that manganese can visualise
calcium sensing receptor (CaSR)-expressing cells in a
human breast cancer murine model, as assessed by clinical
3T magnetic resonance (MR).
Methods Human MDA-MB-231-Luc or MCF7-Luc breast
cancer cells were orthotopically grown in NOD/SCID mice to
a minimum mass of 5 mm. Mice were evaluated on T1-
weighted sequences before and after intravenous injection of
MnCl2. To block the CaSR-activated Ca
2+ channels, verap-
amil was injected at the tumour site 5 min before Mn2+
administration. CaSR expression in vivo was studied by
immunohistochemistry.
Results Contrast enhancement was observed at the tumour
periphery 10 min after Mn2+ administration, and further
increased up to 40 min. In verapamil-treated mice, no
contrast enhancement was observed. CaSR was strongly
expressed at the tumour periphery.
Conclusion Manganese enhanced magnetic resonance
imaging can visualise CaSR-expressing breast cancer cells in
vivo, opening up possibilities for a new MR contrast agent.
Key Points
• Manganese contrast agents helped demonstrate breast
cancer cells in an animal model.
• Enhancement was most marked in cells with high calcium
sensing receptor expression.
• Manganese uptake was related to the distribution of
CaSR within the tumour.
• Manganese MRI may become useful to investigate human
breast cancer.
Keywords Magnetic Resonance Imaging .Manganese
chloride . Breast cancer . Calcium receptor . In vivo small
animal MRI
Introduction
Calcium (Ca2+) ion is required to maintain normal structure
and function in all living cells [1, 2] and occupies a
prominent position in the signal transduction system of the
cell, participating in a variety of physiological and
biological events such as proliferation, apoptosis [3, 4]
and differentiation [5]. The role of Ca2+ as a second
messenger has received great attention, as a multitude of
growth factors and cytokines signal through this ubiquitous
molecule [6]. Moreover, in the past decade the role of Ca2+
as extracellular first messenger in causing or preventing
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cancer has been under active investigation [7] since the
cloning of plasma membrane calcium-sensing receptor
(CaSR) from the parathyroid gland [8]. CaSR is a seven-
transmembrane G-protein-coupled receptor [7], capable of
sensing changes in extracellular calcium concentration,
which inhibits secretion of parathyroid hormone (PTH)
following binding with its physiological ligand Ca2+ [9].
The CaSR is expressed at different levels in normal human
breast duct cells, in the duct cells of fibrocystic breast
tissue, and also in ductal carcinomas of the breast [10]. In
addition, calcium ions play key roles not only in normal
breast physiology but also in various pathological con-
ditions. For instance, Ca2+ is an important constituent of
milk, which has a Ca2+ content of 200 mg/litre [11].
Furthermore, a diagnostically important characteristic of
breast cancers, that can be very useful during mammo-
graphic screening, is their tendency to form microcalcifica-
tion within ducts [12]. In vitro studies have shown that
increased Ca2+ levels induce terminal differentiation of
normal human breast epithelial cells in culture [13].
Breast cancer has a marked tendency to spread to bone
[14]. The observation that numerous cells within the bone
marrow express the CaSR under normal circumstance [15],
leads to hypothesise that the presence of CaSRs on
metastatic cells may contribute to their propensity to reside
in bones, where locally high levels of Ca2+ are present
during resorption processes. The local Ca2+ level at
resorption sites has been reported to rise as high as
40 mM [16].
Indeed, high Ca2+ levels (5, 7.5 and 10 mM) stimulate
the secretion of parathyroid hormone related protein
(PTHrP) in some breast cancer cell lines in vitro,
presumably via a CaSR-mediated mechanism [17]. Excess
PTHrP could contribute to the massive osteolysis caused by
breast cancers’ bone metastases by promoting a feed-
forward mechanism in which release of Ca2+ from the
bone, stimulates further PTHrP production and more bone
resorption [18–20]. Interruption of this cycle by blockade
of CaSR activity [21] could potentially offer substantial
therapeutic benefit in this situation. Therefore, given the
importance of Ca2+ in both the physiology and pathophys-
iology of the breast and bone, the CaSR could play
different roles in these processes.
Moreover, the interest in CaSR has been refreshed by the
finding that in a selected group of patients with advanced
breast cancer, CaSR expression assessed by immunohisto-
chemistry is high, predominantly in tissue specimen from
patients who developed bone metastases [22].
Clinically useful MR contrast agents are generally
gadolinium based, however, there has been a renewed
interest in combining the strong magnetic resonance (MR)
relaxation effects of manganese ions (Mn2+), to develop
imaging techniques sensitive to specific molecular processes,
such as Ca2+ mobilisation. Indeed, Mn2+ can enter cells via
the same transport systems in the same way as Ca2+ and can
bind to a number of intracellular structures because of its
high affinity for Ca2+ and Mg2+ binding sites on proteins and
nucleic acids [23, 24]. Mn2+ ion is increasingly used for MRI
in animals and it has been found to be a good contrast
medium for MRI of the brain [25, 26] and the heart [27, 28].
Finally, the olfactory [29], visual [30, 31], and somatosen-
sory pathways of rat and mouse brain have been visualised
in detail after direct injection of MnCl2 into a specific brain
region [32–34].
Manganese-enhanced (ME)-MRI is developed with the
aim to achieve unique tissue contrast, assess tissue viability,
find a surrogate marker of Ca2+ influx into cells and trace
neuronal connections [35]. Previous reports explored the
use of a paramagnetic metalloporphyrin that chelates Mn2+
as MR contrast agent in murine models of breast cancer
[36, 37].
Here, we address the possibility of using free MnCl2 as a
contrast agent in MRI of in vivo human breast cancer. This
hypothesis is supported by previous observations showing
that activation of CaSR by divalent cations such as Ca2+
and Mn2+ [38, 39] triggers ion influx through non-selective
cation channels [4, 40, 41]. Therefore, we speculated that
Mn2+ may accumulate in CaSR-positive breast cancer cells
and allow their imaging.
In addition, human breast cancer cell lines MDA-MB-
231 and MCF-7, which give rise to tumours if transplanted
in immunocompromised mice, express CaSR at different
levels and secrete PTHrP upon stimulation [10, 42, 43].
Here we show that tumours formed by human breast
cancer cells orthotopically implanted in the mammary fat
pad of NOD/SCID mice maintain high CaSR expression
and that intravenous injection of MnCl2 allows tumour
imaging by a 3T MR scanner. The involvement of CaSR in
MnCl2 contrast enhancement was suggested by the study of
its distribution in the tumour tissue and by blockade of ME-
MRI through the Ca2+-antagonist drug verapamil.
Materials and methods
Animal models and contrast agents
In vivo experiments were approved by the Institutional
Review Committee of the National Cancer Institute (IST),
and were performed in accordance to the National Regula-
tion on Animal Research Resources (D.L. 116/92).
Six-week old female NOD/SCID mice (n=6) were
obtained from a colony bred in house under sterile
conditions in the animal facility. Mice were injected in the
lower left mammary fat pad with 2×106 luciferase-
transduced human breast cancer MDA-MB-231-luc-D3H1
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or MCF-7-luc-F5 cells (Xenogen Corporation). When the
tumour mass diameter was approximately 5 mm, as assessed
by palpation and measurement with a caliper, mice were
subjected to MR examination. The pre-clinical MR imaging
protocol was developed for an experimental mouse-dedicated
volume coil with a diameter of 55 mm applied within a
commercially available 3T clinical system (Signa
EXCITE®HDxT, GE, Milwaukee, USA). A solution of
5 mM MnCl2·4H2O (Sigma Chemical Co., St. Louis, MO,
USA) in 0.9% NaCl, was prepared and 180 microL were
injected intravenously per mouse (i.e. a dose range between
7.4 mg/kg in a 24 g mouse and 8.5 mg/kg in a 21 g mouse).
In a control group (n=2), in order to block the CaSR-
activated Ca2+ channels, 0.3 mg/kg of verapamil solution
(Isoptin, Abbott, Italy) was injected subcutaneously at the
tumour side, 5 min before MnCl2 administration, and MRI
carried out as described above.
Magnetic resonance imaging and mouse dedicated coil
Magnetic resonance imaging was performed with a clinical 3T
MR system (Signa EXCITE®HDxT, GE, Milwaukee, USA).
Micewere anaesthetised by intraperitoneal injection of xylazine
(30 mg/kg) and ketamine (100 mg/kg) and were positioned in a
prototype coil (birdcage linear coil, transmit/receive coil, 100
mm long, 55 mm diameter, tuned at 127.6 MHz, GE,
Milwaukee, USA) placed on a support filled with warm water
to preserve mice from hypothermia. The room temperature
during experiments was 23°C, and the mean acquisition time
was limited to 50 min, by the spontaneous awakening of mice.
The imaging parameters are listed in Table 1.
Both qualitative and quantitative analyses were per-
formed on T1-gradient-echo weighted images. Qualitative
visual analyses were performed by two radiologists (A.T.
and G.B.) on a commercially available workstation (AW
Volume Share 2, ADW 4.4, GE, Milan, Italy). Both
observers were blinded. They selected the imaging sequen-
ces and parameters, which provided optimal signal intensity
(SI) and contrast relative to the manganese properties.
Quantitative analyses were expressed as SI±standard
deviation of each mouse, with SI being measured in tumour
and muscle of contralateral leg by one investigator using a
defined region of interest (ROI). The size of the region of
interest depended on the diameter of the tumour (8 mm).
The same analysis was performed in the control group. We
also performed a ROI only on the ring of contrast
enhancement at the tumour periphery at 10 and 40 min of
manganese administration.
The SI values were divided by the background noise to
yield the signal-to-noise ratio (SNR) according to the
formula [44]:
SNR ¼ SI=noise
The difference in SI (ΔSI) before and 40 min after
MnCl2 administration, was calculated as follows:
ΔSItumour ¼ SItumour after Mn2þ  SItumour before Mn2þ=noise
ΔSImuscle ¼ SImuscle after Mn2þ  SImuscle before Mn2þ=noise
Histopathological analysis
Mice were euthanised using the carbon dioxide method
shortly after the MRI session, always before the onset of
signs of distress and when the tumour reached the
maximum diameter of 1 cm. Breast tumours were excised
and fixed in 10% buffered formalin. Specimens were then
paraffin-embedded and processed for histological analysis
according to standard techniques. The specimen sections,
which were best representative of tumour areas, were
identified through Hematoxylin-Eosin staining. The sec-
tions (3 μm) were immunostained using a BenchMark XT
automated immunostainer (Ventana Medical Systems,
Strasbourg, France). Briefly, the sections were deparaffined,
antigen-retrieval was performed with high pH citrate buffer
for 30 min and samples were challenged with a 1:200
dilution of the anti-calcium sensing receptor polyclonal
rabbit antibody (code PA1-934A, AffinityBioReagents,
Golden, CO, USA) or with buffer only, as negative control,
for 30 min at 37°C. Parathyroid cancer specimens were
used as positive staining control. The antibody complex
was revealed with the Polymeric System UltraView DAB
Detection kit (Ventana Medical Systems). The sections
were then counterstained with modified Gill’s hematoxylin,
mounted in Eukitt (Bio-Optica, Milano, Italy) and observed
with a light microscope (Olympus, Tokyo, Japan) using
10X, 20X, 40X and 63X objectives.
Table 1 Parameters utilised for MRI at 3T with a 55 mm birdcage linear coil
Plane TR (ms) TE (ms) FA Bandwidth FoV (mm) Frequence Phase Thickness (mm)
T1-GRE Coronal 13.4 3.6 15° 19.23 60 288 288 1.20
T1-3D-GRE Coronal 7.3 2.5 20° 50 100 320 320 1.00
T2-TSE Coronal 4000 85 90° 31.25 100 320 320 1.00
T1-GRE T1-weighted gradient-echo sequences; T1-3D-GRE T1-weighted three dimensional gradient-echo sequences; T2-TSE, T2-weighted
turbo-spin-echo sequences; TR (ms) repetition time in milliseconds; TE (ms) echo time in milliseconds; FA flip angle; FoV field of view
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The immunohistochemical results were qualitatively
classified according to intensity and pattern of the staining
by two experienced pathologists (S.S. and M.T.), blind to
the in vivo imaging results. A 6-point scale was used to
score the intensity of the CaSR staining, going from score 0
(absent expression) to score 5 (intense, widespread expres-
sion), as described in the literature [22].
Results
Manganese-enhanced MRI at 3T of breast cancer in vivo
When tumour xenotransplants reached a diameter of
approximately 5 mm, mice (n=6) were examined by
MRI following injection i.v. with MnCl2 as contrast
agent. Ten minutes after MnCl2 administration, a ring of
contrast enhancement on T1-weighted images, was
observed at the tumour periphery (Fig. 1b–e). Full
contrast enhancement at the tumour site was reached
around 40 min after MnCl2 injection, with persistence of
a brighter peripheral area (Fig. 1c–f). Similar results were
obtained in all mice, independently of the xenografted
breast cancer cell line.
To evaluate the relationship between manganese-
driven SI increase and divalent cations channels’ activity,
two mice, which had shown good manganese-enhanced
imaging of their tumours few days before, were inocu-
lated with the calcium-antagonist drug verapamil at the
tumour site 10 min before the i.v. administration of
MnCl2. As shown in Fig. 2, blockade of divalent cations
dynamics prevented manganese-enhanced imaging of
tumours, supporting a key role for CaSR and the
functionally related non-selective cation channels in
MnCl2-mediated tumour imaging.
Quantitative analysis was then performed by setting
ROIs on T1-gradient-echo-weighted images of each mouse
and measuring SI on the tumour before and 40 min after
manganese administration. The same sampling was per-
formed on the muscle of the contralateral leg before and
40 min after manganese administration. Data, expressed as
SNR and ΔSI, are listed in Table 2. Paired student’s t-test
analysis of SNR values before and 40 min after Mn2+
administration yielded a significant P value for tumour (P<
Fig. 1 Manganese enhanced
MR imaging (MEMRI) of the
orthotopic human breast cancer
xenografts. a–f MRI of the same
mouse at two different time
points. The tumour dimension
was 5 mm at the first determi-
nation and 10 mm the week
after. On T1-weighted gradient
echo images recorded before
and after Mn2+ administration,
tumours showed a hyperintense
area at their periphery (ring of
manganese enhancement)
10 min after Mn2+ administra-
tion (b–e) and full contrast
enhancement 40 min, with
persistence of a brighter
peripheral area (c–f)
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0.05) but not for muscle (P=0.2). Analysis of images
confirmed an increase of 23% of ΔSI in the tumour after
manganese administration, whereas the muscle showed
only a 4% increase. In control groups treated with
verapamil, no appreciable differences in ΔSI of the tumour
were observed.
When quantitative analysis was performed by setting
ROIs only on the ring of contrast enhancement, visible at
the tumour periphery both 10 and 40 min after injection of
manganese on T1-GRE-weighted images, the ΔSI showed
an average increase of 50% (mean of six independent
experiments).
Immunohistochemical analysis of CaSR
To correlate manganese-enhanced MR images with CaSR
expression by tumour cells in vivo, mice were euthanised
after the MRI session, and tumours were excised, fixed and
paraffin embedded for subsequent immunohistochemical
analysis. CaSR was expressed at very high levels (staining
score 4–5) in all tumour xenografts grown from both MDA-
MB-231-luc (Fig. 3) and MCF-7-luc (not shown). The
highest expression of CaSR molecules was found at the
periphery of the tumour mass (Fig. 3a, b), consistently with
the ring of contrast enhancement observed in MRI short
time after MnCl2 administration. These data suggest that
manganese as contrast agent could be useful in detecting
tumours with high expression of CaSR, which seems an
indicator of bone metastasis potential [22].
Discussion
The biology of Mn2+ ion combined with its ability to act as
an MR contrast agent opens the possibility of using
manganese-enhanced MR imaging (MEMRI) to visualise
tissue function. Manganese can enter cells via a number of
transport systems, which can be regulated by the plasma
membrane calcium sensing receptor (CaSR).
We therefore set up an animal model to assess whether it
is possible to visualise human breast cancer cells with high
expression levels of CaSR in vivo, using Mn2+ as a contrast
agent and a 3T clinical MR scanner equipped with an
experimental birdcage linear coil with a diameter of 55 mm.
In vivo MRI was performed on mice carrying a few mm
tumour masses.
In all mice tested, T1-weighted MR images showed a
characteristic ring of manganese enhancement in the
tumour 10 min after the injection of MnCl2. The full
Fig. 2 a, b Coronal MR images of the orthotopic human breast cancer
xenograft in a verapamil-treated control. MR images show no signal
intensity increase after Mn2+ administration in the mouse treated with
verapamil
Table 2 Quantitative analysis of each tumour before and 40 min after MnCl2 i.v. injection correlated with the signal intensity of muscle of the
contralateral leg at the same time points. Signal intensity values are calculated on T1-gradient echo weighted images
Mouse Tumour beforea Tumour afterb Muscle before Muscle after
SNRc SNR ΔSId SNR SNR ΔSI
1 7.2 10.4 3.2 7.2 8.4 1.2
2 6.9 8.8 1.9 7.1 7.2 0.1
3 7.8 8.8 1.0 6.1 6.7 0.6
4 7.4 8.9 1.5 8.1 8.9 0.8
5 6.4 7.1 0.7 6.8 6.1 −0.7
6 6.9 8.6 1.7 7.5 7.6 0.1
a Before MnCl2 administration
b 40 min after MnCl2 administration
c SNR SI/noise; SI signal intensity
dΔSItumour = SI tumour 40 min after Mn2+ - SI tumour before Mn2+/noise, ΔSImuscle = SI muscle 40 min after Mn2+ - SI muscle before Mn2+/noise
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manganese contrast enhancement was observed approxi-
mately 40 min after MnCl2 injection with persistence of a
brighter peripheral area. We considered the possibility that
the early appearance of a ring of contrast enhancement
could relate to the presence of a neoangiogenic rim at the
tumour periphery. However, this hypothesis seems unlikely,
because we did not observe a ring of contrast enhancement
during the vascular phase occurring within the first min
from injection. In addition, the observation that verapamil
pre-treatment abolished the formation of the ring, rather
supports a role for CaSR-mediated activation of cation
channels leading to Mn2+ intracellular influx.
Moreover, the possibility that the body temperature
could alter the pharmacokinetics of the contrast agent has
to be taken into account. However, a slight hypothermia
was reached only toward the end of the MRI session.
When tumour sampling was performed by setting a ROI
only on the ring of contrast enhancement at the tumour
periphery, a 50% increase in ΔSI, both 10 and 40 min after
manganese administration, was reached. Immunohisto-
chemistry showed a higher CaSR molecule expression at
the periphery of the tumour than in its centre. The lower
CaSR density at the tumour centre may therefore be
responsible for the lower increase of ΔSI (average 23%),
when the whole tumour was analysed 40 min after
manganese administration on T1-gradient-echo-weighted
images. We do not know whether the particular distribution
of CaSR within the tumour is related to the tumour invasive
front or it is specifically related to the human-murine front
line in xenotransplants, and whether it is peculiar to this
cancer model or shared by others.
We chose to correlate the MRI results with the signal
intensity obtained in the muscle because of the presence of the
calcium channels that allow the manganese uptake in such
tissue. Nonetheless, we did not observe an important change in
signal intensity in the muscle after manganese administration.
These differences may be due to the previously reported
interaction of CaSRs with the transient cation channels
(TRPC) in breast cancer cell lines, where the high
expression levels of CaSRs determine a higher calcium
influx by such cation channels [45, 46].
To further correlate manganese contrast enhancement of
the tumour mass with divalent cations receptor and channel
activity, the calcium antagonist drug verapamil was injected
next to the tumour site 5 min before MnCl2 administration.
As no contrast enhancement (see Fig. 2), and no quantita-
tive changes in SI, were observed in the tumours of
verapamil pre-treated mice, it is likely that the manganese
enhancement of the tumour was due to activation of
divalent cations’ dynamics triggered by Mn2+ interaction
with CaSR. Verapamil was injected at the tumour side to
achieve high local concentration without systemic toxic
effects.
A potential drawback to the use of Mn2+ as a contrast
agent is its cellular toxicity, which limits the dose
administered. Recently it was described that a dose of
30 mg/kg MnCl2·4H2O did not interfere with the animals’
well-being [47]. Nevertheless, MR relaxation rates are
proportional to the effective concentration of Mn2+ in
tissue, thus significant amounts of Mn2+ are required to
produce robust and detectable contrast.
In our study, a single maximum dose of 8.5 mg/kg
MnCl2 was administered per mouse, well below the toxicity
threshold described, and still allowed to achieve good
signal intensity in the MR images.
The goal of this study was to give a proof of principle
that Mn2+ could accumulate in breast cancer, possibly as
result of CaSR expression in vivo. Of course, CaSR is
Fig. 3 Immunohistochemical
analysis of CaSR in human
breast cancer MDA-MB-231
cells xenograft (a–c). A CaSR is
detected in tumour cells
(score 4–5) and displays more
intense staining at the tumour
periphery, as detailed in b and
c. Original magnification 200×
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expressed in many different tissues, as described by the
literature and a subcutaneous murine model represented an
ideal situation, with little interference from normal tissue.
However, a recent study reports that CaSR expression
levels, are higher in human breast cancer cell lines than in
normal breast cells, and that such higher levels are
associated to an higher concentration of Ca2+ in the
extracellular space [48]. On these bases, we hypothesised
that breast cancer cells could accumulate Mn2+ more
efficiently than normal breast cells. Moreover, we could
expect that human breast cancers expressing high levels of
CaSR (score 5) take up manganese more efficiently than the
ones expressing low CaSRs levels (score 0–1). Further
studies with CaSR-specific inhibitors in animal models
where larger amounts of normal tissue surround tumour
cells, will be required to fully address this point.
We also considered that the expression of CaSR in other
tissues could determine a high background and a decrease
in contrast noise ratio (CNR), and thus represent a potential
limit for a possible future application of Mn2+ to MR
imaging. However, several studies indicate that Mn2+
uptake is related to the specific function of CaSR in a given
tissue [25–34]. This implies that manganese-enhanced
magnetic resonance imaging (MEMRI) of human breast
cancer, could take advantage from a careful, tissue-specific
timing of MRI acquisition and from improved post-
processing of images.
In summary, this preliminary investigation reports that
MEMRI at 3T can visualise CaSR-expressing human breast
cancer xenotransplants in vivo, opening the exploration of a
potential MR contrast agent to study human breast cancer
into clinic.
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2.2.2. Objective of the study 
 
To set-up a simple method to evaluate the contribution of Mn2+ ions in the 
intra- and extracellular tumour compartments in a MEMRI experiment. 
2.2.3. What this study added to the literature 
 
This work provided interesting information regarding manganese ion 
distribution not only in tumours but also in healthy organs, such as liver, 
kidneys, and muscles, and how this can affect MR imaging analysis and 
interpretation, especially in experiments that aim to demonstrate calcium 
metabolism in tumours. 
2.2.4. What changed as a result of the paper? 
 
As stated above, manganese is not commercially available as MR contrast 
agent, thus clinical applications cannot be explored. However, the 
publications and preclinical experimental studies with manganese are overall 
increasing in the scientific community, exploring new interesting 
applications for this contrast agent which could come back into the clinical 
market soon. 
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Looking back to our experiments, we could have explored the calcium 
receptors expression level on a different type of cancer cell line (such as 
B16F10 murine melanoma cells) to strengthen our previous in vivo studies 
performed on breast cancer cell lines, and thus explore a further role of CaSR 
in a different type of tumour, such as melanoma by MEMRI. 
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Following this work, we developed a new set of preclinical investigations on 
the application of MEMRI in cancer animal models and brown adipose 
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MEMRI and tumors: a method for the evaluation
of the contribution of Mn(II) ions in the
extracellular compartment
Eliana Gianolioa, Francesca Arenaa, Enza Di Gregorioa, Roberto Pagliarinb,
Martina Delbiancob, Gabriella Baioc,d and Silvio Aimea*
The purpose of the work was to set-up a simple method to evaluate the contribution of Mn2+ ions in the intra- and
extracellular tumor compartments in a MEMRI experiment. This task has been tackled by “silencing” the relaxation
enhancement arising from Mn2+ ions in the extracellular space. In vitro relaxometric measurements allowed assess-
ment of the sequestering activity of DO2A (1,4,7,10-tetraazacyclododecane-1,7-diacetic acid) towards Mn2+ ions, as
the addition of Ca-DO2A to a solution of MnCl2 causes a drop of relaxivity upon the formation of the highly stable
and low-relaxivity Mn-DO2A. It has been proved that the sequestering ability of DO2A towards Mn2+ ions is also fully
effective in the presence of serum albumin. Moreover, it has been shown that Mn-DO2A does not enter cell
membranes, nor does the presence of Ca-DO2A in the extracellular space prompt migration of Mn ions from the
intracellular compartment.
On this basis the in vivo, instantaneous, drop in SE% (percent signal enhancement) in T1-weighted images is taken
as evidence of the sequestration of extracellular Mn2+ ions upon addition of Ca-DO2A. By applying the method to
B16F10 tumor bearing mice, T1 decrease is readily detected in the tumor region, whereas a negligible change in
SE% is observed in kidneys, liver and muscle. The relaxometric MRI results have been validated by ICP-MS measure-
ments. Copyright © 2015 John Wiley & Sons, Ltd.
Additional supporting information may be found in the online version of this article at the publisher’s web site.
Keywords:MEMRI; cellular and molecular cancer imaging; molecular and cellular probes; DO2A; calcium receptors; relaxivity
INTRODUCTION
Mn2+ ions are used as positive contrast agents in manganese-
enhanced MRI (MEMRI) to mimic Ca2+ transport in biological sys-
tems. Although MEMRI has been proposed for tracing neuronal
connections, recently it has also been considered useful for
tumor detection, as uptake of Mn2+ ions may be up-regulated
in cancer cells (1–8). Upon i.v. administration of MnCl2, the detec-
tion of hyperintense regions in T1-weighted MR images allows us
to trace the distribution of the paramagnetic metal ions, as Mn2+
ions markedly affect the relaxation times of water protons.
Unfortunately, it is not straightforward to relate signal enhance-
ment (SE) to the local concentration of the metal ions, as the
relaxivity of Mn2+ containing species may cover a very wide
range of values.
Mn2+ is an endogenous metal ion, and it can be coordinated
by a number of naturally occurring molecules to form small or
large complexes, each characterized by its own relaxivity. Among
the small complexes that can be formed in biological fluids, one
may list the following: [Mn(hydrogen-carbonate)]+, [Mn(citrate)],
[Mn(carbonate)] and [Mn(oxalate)] (9). Their relaxivities are, in
general, low, both because of their small size and because of the
small number of water molecules in the inner coordination sphere
of the paramagnetic metal ion. In contrast, binding to macromole-
cules may generate very high relaxivities at the imaging fields. For
instance, Mn2+ bound to human serum albumin has been reported
to have a relaxivity of 97.2/(mM s) at 0.47 T, 25 °C and pH 7 (10). On
this basis, whereas it appears very difficult, if not impossible, to
extract precise information on the actual speciation of Mn2+ ions
in living systems, the occurrence of high SE can be taken as an
indication of coordination to macromolecular systems.
Moreover, we deemed it interesting to seek a method that
provides information on the relative distribution of Mn2+ ions
* Correspondence to: Silvio Aime, Department of Molecular Biotechnologies and
Health Sciences & Molecular Imaging Center, University of Torino, Torino, Italy.
E-mail: silvio.aime@unito.it
a E. Gianolio, F. Arena, E. Di Gregorio, S. Aime
Department of Molecular Biotechnologies and Health Sciences & Molecular
Imaging Center, University of Torino, Torino, Italy
b R. Pagliarin, M. Delbianco
Department of Chemistry, University of Milano, Milano, Italy
c G. Baio
Diagnostic Imaging and Senology Unit, National Cancer Institute – IST,
Azienda Ospedaliera Universitaria San Martino – IRCCS, Genova, Italy
d G. Baio
Aberdeen Biomedical Imaging Centre, University of Aberdeen, Aberdeen, UK
Abbreviations used: MEMRI, manganese-enhanced magnetic resonance im-
aging; DO2A, 1,4,7,10-tetraazacyclododecane-1,7-diacetic acid; EDTA, ethyl-
ene diamine tetraacetic acid; SE, signal enhancement; BSA, bovine serum
albumin; DMEM, Dulbecco’s modified Eagle’s medium; PBS, phosphate-buff-
ered saline; ROI, region of interest.
Research article
Received: 08 September 2014, Revised: 21 May 2015, Accepted: 29 May 2015, Published online in Wiley Online Library: 14 July 2015
(wileyonlinelibrary.com) DOI: 10.1002/nbm.3349
NMR Biomed. 2015; 28: 1104–1110 Copyright © 2015 John Wiley & Sons, Ltd.
1104
in the intracellular and in the extracellular compartment. In the
context of tumor detection and staging, it is relevant to assess
whether the observed SE has to be assigned to the intracellular
or the extracellular compartment. To tackle this task, a procedure
was set up based on sequestering all the Mn2+ ions in the extra-
cellular compartment into a highly stable chelate characterized
by a low relaxivity (“MRI silent”, Fig. 1). Then, the comparison of
the signal intensities of the region of interest (ROI) before and
after the “sequestering” step allows the identification of the
relative contributions from intra- and extracellular compartments
in a MEMRI experiment.
EXPERIMENT
Relaxometric characterization
The longitudinal water proton relaxation rate was measured at
0.47 T (20 MHz proton Larmor frequency) by a Stelar SPINMAS-
TER (Stelar, Mede, Pavia, Italy) spectrometer using the standard
inversion-recovery technique. The temperature was controlled
with a Stelar VTC-91 air-flow heater equipped with a copper–
constantan thermocouple (uncertainty 0.1 °C). Relaxivities were
measured at both 25 °C and 37 °C in water and in serum,
respectively.
In vitro cellular uptake
B16F10 murine melanoma cells and MDA-MB-231 and MCF7
human breast cancer cells were cultured in 75 cm2 flasks in a
humidified incubator at 37 °C and in CO2/air (5:95 v/v) in
Dulbecco’s modified Eagle’s medium (DMEM) containing 10%
fetal bovine serum, 100 U/ml penicillin and 100 mg/ml strepto-
mycin. About 8 × 105 cells were seeded in 6 cm Petri dishes.
Twenty-four hours after seeding, cells were washed and
incubated with different concentrations (0.5 or 1 mM) of MnCl2
and Mn-DO2A (1,4,7,10-tetraazacyclododecane-1,7-diacetic acid)
for 1 h or 7 h at 37 °C in a CO2 incubator. After this incubation
time, the cells were washed three times with 5 ml ice-cold
phosphate-buffered saline (PBS), detached with trypsin–EDTA
(ethylene diamine tetraacetic acid), and, for the acquisition of
MR images, collected in 50 μL of PBS and transferred into glass
capillaries, that were centrifuged at 1500 g for 5 min. The
resulting cellular pellets were placed in an agar phantom and
underwent MRI acquisition. After imaging, the labeled cells were
suspended in 200 μl PBS and sonicated to obtain cell lysates. Mn
content was measured by ICP-MS analysis (Element-2; Thermo-
Finnigan, Rodano, Italy). The preparation of the samples for
ICP-MS analysis was carried out as follows: (i) 150 μl of each cell
lysate was mineralized with 1 ml of concentrated HNO3 (65%)
under microwave heating at 160 °C for 40 min (Milestone
MicroSYNTH microwave lab station equipped with an optical
fiber temperature control and HPR-1000/6M six-position high-
pressure reactor, Bergamo, Italy); (ii) after mineralization, the
volume of each sample was brought to 2 ml with ultrapure water
and the sample was analyzed by ICP-MS. The calibration curve
was obtained using four manganese absorption standard
solutions (Sigma-Aldrich) in the range 0.005–0.2 μg/ml.
The protein content of cells lysates was determined by the
Bradford method using bovine serum albumin (BSA) as standard.
A specific experiment has been carried out in order to assess
whether the presence of Ca-DO2A in the extracellular compart-
ment could drive the delivery of Mn2+ ions from the intracellular
space. After the incubation (1 h) of B16F10 cells with MnCl2
(1 mM), cells were washed twice with PBS and re-incubated
for increasing times (30 min, 1 h, 2 h, 4 h) with fresh culture
medium containing Ca-DO2A (1 mM). The control experiment
was carried out re-incubating the labelled cells with culture
medium without Ca-DO2A. Mn content was measured by
ICP-MS analysis as reported above.
MRI in vitro
The MR images were acquired with a standard T1-weighted
spin-echo sequence and recorded on a Bruker Avance 300
spectrometer operating at 7.1 T equipped with a micro-imaging
probe (TR/TE/NEX 250/3.9/8, FOV 1 cm, one slice, 1 mm).
MRI in vivo
Tumor bearingmice were prepared by inoculating subcutaneously
about 1 × 106 B16F10 cells into the flank of 10 weeks old female
C57B1/6 mice of about 25 g. The mice underwent MRI analysis
7–10 days after cell inoculation. All tumors were approximately
the same size at the time of image acquisition (250 ± 50 mm3).
Tumor development was followed by palpation and caliper
measurement. Tumor volume was calculated according to the
formula (L × W2)/2, where L and W are the maximum length and
width of the tumor. The investigation complied with national
legislation about the care and use of laboratory animals.
Mice were divided into three groups (n = 3 each) and each
group was treated i.v. with one of the following solutions:
(1) MnCl2 (0.058 mmol/kg) + Ca-DO2A (0.116 mmol/kg)
(2) MnCl2 (0.058 mmol/kg)
(3) Mn-DO2A (0.058 mmol/kg).
In the first group, Ca-DO2A was injected i.v. 30 min after the
administration of MnCl2.
MR images were acquired on the Aspect M2 scanner (Aspect
Imaging, Shoham, Israel) operating at 1 T equipped with a hori-
zontal bore MRI magnet using a standard T1-weighted multislice
spin echo sequence (TR = 250 ms, TE = 7.0 ms, NEX = 10, FOV = 3.5
cm, six slices, 1 mm). During the experiments, animals were
anaesthetized with isofluorane gas (0.5–2%) in O2; anesthesia
was maintained by adjustment of gas level as a function of
breath rate, kept close to 70 breaths/min. For the measure of
SE%, ROIs were selected on different slices of the investigated
organs throughout the organ’s volume. ROIs were selected to
include the tumor margins as defined in T2W images. SE of each
organ was calculated as percentage signal increase with respect
to the image acquired before the administration of MnCl2.
Intensity normalization was achieved by using an external
reference (ProHance® 0.5 mM).
Figure 1. Schematic representation of the formation of Mn-DO2A
complex.
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Determination of manganese content in tissues
Mn content was measured by ICP-MS analysis. The preparation
of the samples for ICP-MS analysis was carried out as follows: (i)
tissue samples were freeze-dried, weighed and digested with
1.5 ml (kidneys, tumor and muscle) or 3 ml (liver) of concen-
trated HNO3 (65%) for 24 h; (ii) 1 ml of digested tissues were
mineralized under microwave heating at 160 °C for 40 min;
(iii) after mineralization, the volume of each sample was
brought to 3 ml with ultrapure water and the sample was ana-
lyzed by ICP-MS. Data are presented as mg of Mn per gram of
dry tissue.
RESULTS
The “sequestering agent”
The relaxivity (defined as the paramagnetic contribution to the
observed proton relaxation rate of a solution in which the
paramagnetic agent is present at 1 mM concentration) of MnCl2
and Mn-DO2A was measured at 25 °C and 37 °C in water and in
serum at the magnetic field strength of 0.47 T. The obtained
values are reported in Table 1. Thanks to the six coordinated
water molecules around the Mn(II) ion, MnCl2 is endowed with
a relatively high water relaxivity. A further remarkable increase
in relaxivity is achieved in serum, as a consequence of the
formation of an adduct with albumin (10). In contrast, Mn-DO2A
is endowed with very low relaxivity values both in water and in
serum (Table 1).
Figure 2(A) reports the relaxivity changes observed upon
addition of aliquots of Ca-DO2A to a solution of MnCl2 (1 mM)
in the presence and in the absence of BSA. For both systems,
the addition of Ca-DO2A quickly leads to the asymptotic value,
corresponding to the relaxivity of Mn-DO2A. To get more insight
into the relationship between the stability of Mn-DO2A and the
release of Mn2+ to endogenous macromolecules, we investi-
gated the titration of a Mn-DO2A solution (0.58 mM) with BSA.
The titration has been followed by 1H-relaxometry by measuring
the observed proton relaxation rate (R1obs) at 0.47 T as a function
of the BSA concentration (Fig. 2(B)). At each data point the
measured R1obs value is given by
R1obs ¼ R01 þ rMnDO2A1p Χ MnDO2A þ rMnBSA1p Χ MnBSA [1]
and
Χ MnDO2A þ Χ MnBSA ¼ 1 [2]
where ΧMnDO2A and ΧMnBSA are the molar fractions of Mn bound
to DO2A and to BSA respectively, rMnDO2A1p and r
MnBSA
1p are the
relaxivities of Mn-DO2A and Mn-BSA at 0.47 T and 25 °C reported
in Table 1 (1.8 and 72.5/(mM s), respectively) and R01 is the
diamagnetic contribution measured for the BSA-containing
solutions in the absence of Mn-DO2A.
Equations [1] and [2] allow us to calculate, for each experimen-
tal data point, the percentage of Mn that has been transferred to
BSA (Fig. 2(B)). Even with a large excess of BSA the amount of Mn
bound to the protein remains very low.
Uptake studies of MnCl2 and Mn-DO2A in tumor cells
About 1 × 106 B16F10, MDA-MB-231 andMCF7 cells were incubated
in DMEM medium containing 0.5 or 1 mM MnCl2 or Mn-DO2A,
respectively. At the end of the incubation period (1 h or 7 h), cells
were extensively washed and the obtained cellular pellets
underwent the determination of Mn content and MR image
acquisition. The amounts of internalized Mn, assessed by
ICP-MS, are reported in Fig. 3(A) for B16F10 cells, and in Fig. S1
for MDA-MB-231 and MCF7 cells. The reported data have been
obtained by subtracting the naturally occurring Mn content
measured for the same number of unlabeled cells.
In Fig. 3(B) the MR images of pellets of labelled B16F10 cells,
recorded at 7.1 T, are reported. The amount of internalized metal
is much higher (6–10-fold depending on the incubation time) in
the case of cells incubated in the presence of MnCl2 with respect
to those incubated with Mn-DO2A. Similar results were obtained
Table 1. Relaxivity values of MnCl2 and Mn-DO2A measured
at 0.47 T, in water and serum, at 25 °C and 37 °C
Relaxivity (/(mM s)) at 0.47 T
Water Serum
25 °C 37 °C 25 °C 37 °C
MnCl2 7.8 ± 0.11 6.5 ± 0.21 72.5 ± 0.35 55.2 ± 0.23
Mn-DO2A 1.5 ± 0.13 1.3 ± 0.11 1.8 ± 0.15 1.5 ± 0.12
Figure 2. (A) Variation of the relaxivity of a solution of MnCl2 as a function of the addition of increasing concentrations of Ca-DO2A in water and in the
presence of BSA. (B) Variation of the observed proton relaxation rate of a solution of Mn-DO2A (0.58 mM) as a function of the addition of increasing
concentrations of BSA in PBS. On the same graph the percentages of BSA-bound manganese calculated from R1obs values are also reported as a func-
tion of BSA concentration. Measurements were made at 25 °C, 20 MHz and neutral pH.
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for MCF7 cells, whereas MDA-MB-231 turned out to be even
more effective in the Mn2+ uptake (Fig. S1).
Figure 3(B) reports the MR images obtained from pellets of
B16F10 cells labelled with MnCl2 (3,4) and with Mn-DO2A (4,5).
In the case of MnCl2 labeling the pellets are highly hyperintense,
whereas the pellets of cells labelled with Mn-DO2A are not
distinguishable from control cells (1).
In order to assess whether the presence of an excess of
Ca-DO2A in the extracellular compartment may enhance the
efflux of manganese from the intracellular space, B16F10 cells
previously labelled with MnCl2 were re-incubated, for increasingly
longer intervals, in culture media containing Ca-DO2A (1 mM) or
not, and the amount of intracellular Mn determined by ICP-MS.
The data, reported in Fig. 4, reveal that the presence of Ca-DO2A
in the culture medium does not affect the decrease of the intracel-
lular Mn concentration with time with respect to the control exper-
iment. Apparently there is a slow efflux of Mn ions from the cellular
cytoplasmatic compartment that is independent of the presence
or absence of Ca-DO2A in the cell suspension medium.
In vivo MRI experiments on B16F10 tumor bearing mice
In vivo MRI experiments were carried out at 1 T. Mice were
divided into three groups and each group was treated i.v. with
MnCl2 + Ca-DO2A, MnCl2 or Mn-DO2A.
In the first group, the dose of Ca-DO2A was injected i.v. 30 min
after the administration of MnCl2. In analogy to what is seen
in vitro, the added Ca-DO2A undergoes a transmetallation reaction
with Mn2+ ions present in the vascular and extracellular
compartments, leading to a steady SE% (Fig. 5(A)). In the tumor
region, the formation of Mn-DO2A corresponds to a net decrease
of SE (Figs. 5(B) and 6). In kidneys, liver and muscle no significant
change in the signal intensity occurs (Fig. 5(A) and Fig. S2). In the
group administered with Mn-DO2A, the tumor SE remained low
(24.2 ± 2.4%) for the two hours of the study (Fig. 5(B)). Conversely,
the administration of MnCl2 yielded to a strong tumor SE that
steadily decreased during the first hour to reach a value (70%) that
is about three times the enhancement observed for Mn-DO2A. The
difference in SE% observed in theMR images ofmice administered
with MnCl2, before and after Ca-DO2A injection, indicates that the
contribution arising fromMn2+ in the extracellular compartment is
important only in the tumor region (25 ± 5%).
After 2 h from the administration of the MnCl2 or Mn-DO2A
solutions, the animals were sacrificed and the Mn content in
liver, kidney, muscle and tumor tissues was determined by
ICP-MS. Figure 7 compares the SE% values (taken immediately
before sacrifices) and the Mn content determined by ICP-MS.
From these data it is evident that most of the administered
manganese can be found in kidneys and liver. Upon comparing
ICP and MRI SE% values measured in experiments with either
MnCl2 or (MnCl2 + Ca-DO2A), one can conclude that the relaxa-
tion enhancement observed in tumors appears significantly high
with respect to the amount of Mn found in the analytical
determination.
DISCUSSION
Mn2+ ion is known to form highly stable complexes with
hexacoordinating ligands, e.g. EDTA, whose Mn2+ complex is
characterized by a Kf value of 7.94 × 10
13 (11). Interestingly, EDTA
does not wrap perfectly around the metal ion and leaves room
for the coordination of one water molecule (12). This causes
the relaxivity of Mn-EDTA to be rather high (r1p = 2.9/(mM s) at
0.47 T and 35 °C) (13). Therefore, EDTA has not been considered
suitable as sequestering agent for the intended aim of the project.
Conversely, DO2A (Fig. 1) appears to be a good candidate for
this application. It forms a highly stable complex with Mn2+ ions
(Kf= 1.35 × 10
16) (14) whose water relaxivity, at 0.47 T and 25 °C,
is 1.5/(mM s) (Table 1). In fact DO2A wraps perfectly around the
Mn2+ ion, yielding an octahedral geometry by using the six
available donor atoms (four nitrogens and two oxygens) (Fig. 1)
with no inner-sphere water molecule.
The observed relaxivity arises from the outer sphere contribution
due to water molecules diffusing at the surface of the paramagnetic
complex. For our purpose Mn-DO2A complex can be considered
“MRI silent”. In order to be minimally invasive it was deemed useful
to use the Ca2+ complex of DO2A rather than the sodium salt or
the free acid. The equilibrium reaction depicted in Fig. 1 was first
followed in vitro through relaxometric measurements. Thanks to
the difference in relaxivity between MnCl2 and Mn-DO2A, it is
possible to follow the exchange reaction through the
relaxometric measurement of a solution of MnCl2 titrated with
Ca-DO2A (Fig. 2(A)).
When Ca-DO2A is added to a solution of MnCl2, Mn
2+ ions are
readily sequestered by the DO2A ligand to form the highly stable
Mn-DO2A, as the latter complex is much more stable than
Ca-DO2A (log Kf = 7.16) (15).
Figure 3. (A) Amount of internalized Mn2+ in B16F10 cells incubated with MnCl2 and Mn-DO2A for 1 and 7 h. Error bars represent standard deviations
(statistical analysis: *** P < 0.01; *** P < 0.001). (B) MR images at 7.1 T of pellets of B16F10 cells labelled as follows: (1) control; (2, 3) MnCl2 1 mM and
0.5 mM respectively; (4, 5) Mn-DO2A 1 mM and 0.5 mM respectively.
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Both when Mn2+ ions are dissolved in pure water and when
they are bound to serum albumin, the addition of Ca-DO2A leads
to a marked and sudden decrease in the observed relaxivity due
to the formation of the almost “silent” Mn-DO2A complex. It is
worth noting that, in the presence of high concentrations of
albumin, as it might be the case of the extracellular tumor matrix,
the amount of Mn which is transferred from Mn-DO2A to the
protein remains quite low (Fig. 2(B)). On this basis it is evident
that in blood (albumin concentration 0.6 mM), at a dose of
0.058 mmol/kg (0.58 mM, considering an average mouse weight
of 20 g and a blood volume of 2 ml) the amount of Mn that has
been transferred to albumin from Mn-DO2A is only 0.7%.
However, the high relaxivity of the Mn–albumin system strongly
amplifies this contribution in the observed SE%. Moreover, in the
tumor extracellular matrix, due to the extravasation through the
hyper-permeable tumor vessels, the local concentration of
Albumin is markedly higher than in the blood thus further
enhancing the attainable SE%.
In order to assess the differences in the biodistribution of Mn2+
ions and Mn-DO2A complexes, it has been deemed useful to
investigate the uptake of these species in tumor cells. First, B16F10
cells were considered, and the data reported in Fig. 3 clearly allow
us to draw the conclusion that, while MnCl2 enters cells, likely
through calcium channels and calcium receptors, Mn-DO2A does
not appear to have any active pathway to enter cells (16).
The B16F10 tumor cell line was not selected for a specific
ability to take up Mn2+ ions, but for the ease of obtaining an
in vivo subcutaneous tumor model. Actually, we compared the
uptake efficiency of MnCl2 and Mn-DO2A in B16F10 cells with
that in MCF7 and MDA-MB-231 (both human breast cancer cell
lines), which are frequently used in MEMRI of tumor cells (Fig. S1)
(3,4,6,7). The ability of B16F10 cells to take upMnwas only slightly
lower than that of MCF7 cells, while in the highly metastatic MDA-
MB-231 cells the amount of accumulated Mn was doubled. The
amount of Mn accumulated by B16F10 cells is well above the
threshold for MRI visualization, and these cells were chosen to
obtain the subcutaneous tumors for the in vivo experiments.
The in vivo tumor model was easily obtained in C57B1/6 mice,
while expensive nude mice would have been required in the case
of use of MCF7 or MDA-MB-231 human cancer cells.
The very low internalization efficiency shown by Mn-DO2A is
crucial for the intended aim of the work, as it demonstrates that
Mn2+ ions, once sequestered by DO2A ligand, will not be able to
be taken up by tumor cells. Moreover, the addition of Ca-DO2A
to Mn-labelled cells does not influence the efflux of Mn ions from
the intracellular compartment.
The method was validated in vivo through the acquisition of
MR images of mice sequentially administered with MnCl2 and
Ca-DO2A. Control experiments were carried out on mice
administered with MnCl2 or Mn-DO2A. As can be noticed in
Figure 4. Amount of internalized Mn2+ in B16F10 cells labelled with
MnCl2 as a function of the re-incubation time with fresh medium contain-
ing (■) or not (○) 1 mM Ca-DO2A.
Figure 5. (A) 1 T MR SE in liver, kidney, muscle and tumor of B16F10 tumor bearing mice administered with MnCl2 and, after 30 min, with Ca-DO2A. (B)
Tumor SE in mice administered with MnCl2 + Ca-DO2A compared with that obtained in mice administered with MnCl2 or Mn-DO2A only. Error bars
represent standard deviations. The vertical black line on the graph represents the time point at which Ca-DO2A was administered.
Figure 6. 1 T MR images of B16F10 tumor bearing mice administered
with MnCl2 before (left) and after (right) the administration of Ca-DO2A.
The tumor region is circled in white.
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Fig. 5(B) and 6, in the tumor region, the arrival of Ca-DO2A
corresponds to a net and sudden decrease of signal intensity,
indicating that a significant number of the administered Mn2+
ions were coordinated to biomolecules in the extracellular
matrix. Conversely, the i.v. administration of Ca-DO2A has a
low effect on SE% in the kidney region, and it is negligible
in the muscle tissue. In the liver it appears to cause a slight
increase of the observed SE%, likely reflecting an increase in
the hepatobiliary excretion route of Mn-DO2A. The peculiar
behavior observed in the tumor region may be accounted
for by the presence of a relatively large extracellular region
(17–19) where an important fraction of the Mn(II) ions finds
suitable coordination to the endogeneous biomolecules during
the MEMRI experiment. Interestingly, 45% of SE in the tumor
region is still maintained up to 2 h after the administration
of Ca-DO2A. This contribution is ascribable to the Mn2+ ions,
which have already been internalized by tumor cells in the first
30 min. This finding appears in contrast with the in vitro re-
sults reported in Fig. 4 that suggest a steady efflux of Mn2+
ions from the labeled cells. Likely, the in vivo conditions main-
tain a higher level of integrity of the cellular membranes.
Other considerations may also be made comparing the results
obtained upon the administration of MnCl2 and of Mn-DO2A.
Two hours after the administration (Fig. 5(B)), the values of
SE% in the tumor region correspond to 70% in the case of
administration of MnCl2 (intra- + extracellular contributions)
and 24% for Mn-DO2A (extracellular contribution), respectively.
The three sets of experimental data, with an estimation that 30%
of the MRI signal is lost for the clearance of the paramagnetic
manganese ions (either free or as Mn-DO2A), allow us to establish
that 45% and 25% of the observed SE are respectively due to the
intra- and extracellular contributions in B16F10 xenografted
tumors. Considering that only 70% of SE is maintained after 2 h,
due to clearance of the probe, these values were recalculated to
be 64% and 36%, respectively for the intra- and extracellular con-
tributions. These values appear to be coherent with the intra- and
extracellular volume fractions reported for tumor tissues (Table 2).
This analysis was restricted to the tumor region because in the
other investigated organs the addition of Ca-DO2A had almost
no effect on SE%. Even considering that healthy organs are
characterized by a reduced extracellular volume fraction (Table 2)
with respect to tumor, the behavior observed for kidney, liver and
Figure 7. 1 T MRI SE and manganese content determined through ICP-MS analysis in tissues of mice administered with MnCl2, Mn-DO2A or MnCl2 +
Ca-DO2A, 2 h after the administration. Error bars represent standard deviations (statistical analysis: *** P < 0.01; *** P < 0.001).
Table 2. Intra- and extracellular contributions to MR signal (measured as SE%) upon MnCl2 administration compared with intra-
and extracellular volume fractions estimated by other methods
Intracellular Extracellular Reference
Tumor MR signal contribution 64a 36a this work
Volume fraction 73–71 27–29 17
65 35 17
51–45 49–55 20
75–55 25–45 19
Liver MR signal contribution ND ND this work
Volume fraction 85 15 21
83.4 16.6 17
Kidney MR signal contribution ND ND this work
Volume fraction 85 15 23
Muscle MR signal contribution ND ND this work
Volume fraction 91–81.4 9–18.6 18
91.8–81.1 8.2–18.9 22
aThese values were recalculated from the values reported in the text (45% and 25%) to account for the 30% SE which is lost in the
first 2 h due to clearance of the probe.
ND, values not detectable by the method used in this work.
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muscle is difficult to rationalize. In principle, one may forward two
alternative explanations: (i) Mn-DO2A does not reach the
extravascular space, i.e. the vessels’ fenestration is not suitable
for the leakage of the added metal complex whereas the passage
of Mn2+ ions has occurred through other transport routes
(e.g. calcium channels); (ii) Mn2+ ions do not accumulate in the
extracellular regions of these healthy tissues as they are avidly
taken up by the parenchyma cells. Option (i) has to be excluded
as small paramagnetic complexes show a rapid extravasation
(distribution half-lives of 5–15 min) into the extracellular space in
most body organs with the exception of brain (24). Option (ii)
remains a tentative explanation to account for the observed
behavior. The chemical composition of the extracellular microenvi-
ronment in healthy tissue may be very different from that one
present in tumors. The latter may contain large amounts of serum
albumin that can temporarily “sequester” Mn2+ ions.
The observed MR SE%, compared with the effective amounts
of Mn2+ found in the investigated organs (liver, kidneys and
muscle) by ICP-MS analysis, turned out to be well correlated. In
tumor, the intracellular Mn (about 5 μg/g tissue) yields a good
SE% (45 ± 10.4%), suggesting an important contribution arising
from the presence of high relaxivity species, likely represented
by macromolecular Mn(II) complexes.
In summary, the method reported herein may represent a
useful tool to differentiate the extracellular contribution from
cellular uptake in aMEMRI experiment. This approachmay further
strengthen the MEMRI approach for early detection and charac-
terization of tumors (4–7).
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2.3 Exploring a new role of MEMRI to visualize Brown adipose tissue 
 
2.3.1. Title of the abstract 
 
• Rosa F, Basso L, Pace D, Secondini L, Boccardo S, Neumaier CE, 
Baio G. In vivo Non-invasive Detection of Brown Adipose Tissue through 
Manganese Enhanced Magnetic Resonance Imaging (MEMRI). WMIC 
2015. P688. 
 
2.3.2. Objective of the study 
 
To demonstrate the feasibility of in vivo MEMRI to visualise and quantify 
brown adipose tissue (BAT) activity in healthy controls and cancer animal 
models. 
2.3.3. What this study added to the literature 
 
This study was a novel imaging approach to investigate brown adipose tissue 
in cancer animal models. The results of this study are not published yet; 
however, they were awarded during the World Molecular Imaging 
Conference in 2015 and highlighted by Prof. G Gore as high impact research 
during his plenary lecture. 
2.3.4. In retrospect, what should have been done differently in this study? 
 
Looking back at this work, it would have strengthened our results if we had 
distinguished adipose tissue manganese uptake from beige adipose tissue 
uptake, considering the significant biological role of beige adipose tissue and 
its activation. However, this will be part of a future research project. 
2.3.5. Confirmation of authorship 
 
This is shown at the end of Chapter 2. 
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2.3.6. External link to the paper on the journal website 
 
http://www.wmis.org/wp-
content/uploads/2015/09/WMIC2015_ProgramBook.pdf
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Thus, neutralization of PTHrP might hold promise for ameliorating cancer cachexia and improving patient survival.
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2.4. Application of in vivo proton MR spectroscopy in breast cancer 
expressing different level of Calcium sensing receptors. 
 
2.4.1. Title of papers 
 
• Baio G, Rescinito G, Rosa F, Pace D, Boccardo S, Basso L, Salvi S, 
Calabrese M, Truini M, Neumaier CE. Correlation between Choline Peak at 
MR Spectroscopy and Calcium-Sensing Receptor Expression Level in 
Breast Cancer: A Preliminary Clinical Study. Mol Imaging Biol. 2015 Aug; 
17(4):548-56. 
• Baio G, Valdora F, Pace D, Salvi S, Villosio N, Truini M, Calabrese 
M and Neumaier CE. The key role of correlation between MR spectroscopy 
choline peak and calcium sensing receptor for breast cancer: Diagnosis by a 
3T MR scanner. Journal of Clinical Oncology, ASCO 2013 Vol 31, No 
15_suppl (May 20 Supplement). 
 
2.4.2. Objective of the study 
 
To explore the possible correlation between total choline peaks in breast 
cancer lesions as measured by in vivo proton magnetic resonance 
spectroscopy ((1)H-MRS) and CaSR expression levels in surgical 
specimens. 
2.4.3. What this study added to the literature 
 
In vivo proton magnetic resonance spectroscopy represents a useful 
technique for quantifying phosphocholine (P-Cho) concentration levels and 
for characterising tumour types (e.g., mass vs. diffuse) of breast cancer, but 
it may have limitations for small lesions. Our understanding of the molecular 
mechanisms that regulate the production of P-Cho compound is still 
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incomplete. This study explored a new approach to the interpretation of 1H-
MRS and proposed a novel role of CaSR in P-Cho production and 
interpretation of 1H-MRS imaging of breast cancers. Part of the results of 
this study were also presented during the ASCO conference meeting in 2013. 
Following our publication, a review published by Bhujwalla ZM et al, one 
of the main experts in MRS, cited our paper as novel clinical imaging study 
on breast cancer MRS [144]. 
2.4.4. What changed as a result of the paper? 
 
In vivo MRS is not routinely applied for breast cancer diagnosis because the 
results obtained by MRS are not easy to reproduce between imaging centres. 
However, following our investigation on CaSR in breast cancer there has 
been an increased number of publications supporting the important role this 
receptor has in cancer and response to treatment, also in other types of 
cancer, making this protein an interesting tumour target. 
2.4.5. In retrospect, what should have been done differently in this study? 
 
Looking back we might have increased the number of patients we 
prospectively analysed, especially for benign lesions. This would have 
improved the significance of our findings, as well as the correlation between 
P-Cho and CaSR. The opportunity to explore also the value of 1H-MRS and 
CaSR before and after chemotherapy would have been beneficial for the 
understanding of CaSR in breast cancers during treatment. 
2.4.6. Future work as a result of this publication 
 
We have not performed further investigations on this topic but, as stated 
above, further investigation of the potential role of CaSRs in breast cancers 
and the opportunity to investigate by 1H-MRS before and after chemotherapy 
might be an interesting future research work. 
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Abstract
Purpose: The calcium-sensing receptor (CaSR) is overexpressed in many pathological states
including breast cancer. Since choline kinase may be activated in breast cancer cells by CaSR
resulting in increased phosphocholine production, we sought to correlate the total choline peak
in breast lesions as measured by in vivo proton magnetic resonance spectroscopy (1H-MRS)
with the CaSR expression levels in surgical specimens.
Procedures: Thirty-six patients with breast lesions were MR scanned at 3T scanner. Tumour
morphology and DCE-MR kinetics were evaluated. 1H-MRS was applied for Cho detection and
compared with the CaSR immunohistochemistry analysis (score 0–5) on surgical breast
specimens.
Results: Thirty-four lesions demonstrated a DCE malignant kinetics curve (types 2 and 3),
while two lesions showed a benign (type 1). Twenty of the 23 breast cancer lesions
(87 %) with a consistent Cho peak expressed a CaSR score of 3–5, and ten of the 11
breast lesions negative for Cho (91 %) had a CaSR score of 1–2. The two benign lesions
showed a non-uniform/weak intense expression of the CaSR (score 3) with a consistent
Cho peak.
Conclusions: The presence or absence of choline peak evaluated by 1H-MRS, well
correlated with the expression of CaSR in patients with breast lesions (pG0.01),
supports the hypothesis that CaSR may play an important role in the production of
choline in breast cancer.
Key words: Calcium-sensing receptor, MR spectroscopy, Breast cancer, Posphocholine,
3T MR, Magnetic resonance imaging, G protein-coupled receptor, Calcium channels, MRI breast,
Molecular imaging cancer
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Introduction
One important multimodal sensor to maintain systemiccalcium homeostasis is the calcium-sensing receptor
(CaSR), a member of the G protein-coupled receptor
(GPCR) superfamily [1]. Calcium ions (Ca2 +) play an
important role in the control of many important cellular
functions such as proliferation, differentiation and secretion.
It has been recently documented that CaSR is expressed in a
variety of tissues in the body where it does not play an
obvious role in calcium homeostasis, based on its ability to
respond to a variety of ligands, including polyvalent cations
and amino acids [2]. The different ligands may stabilise the
CaSR in an activation state that allow stimulation of
different pathways (the so called ligand-based signalling)
[3]. Consequently, the alteration in the signalling is
correlated with a number of pathophysiological states. In
cancer, the role in the over or low expression of this receptor
is still in discussion and could be related on the type of
cancer, stage and grade. In particular, CaSR in breast cancer
seems to have an important role in the development of bone
metastasis as recently demonstrated [4]. Further studies
might confirm the use of the CaSR expression as a
prognostic marker for the risk of skeletal metastases in
patients diagnosed with breast cancer.
At present, in the clinical setting, breast cancer prognosis
is assessed by TNM (tumour, node and metastasis) staging,
histologic type, histologic grade, mitotic figure count and
hormone receptor status, by pathology examination. Breast
magnetic resonance imaging (MRI) has been established as a
powerful tool with a high sensitivity for breast cancer
detection [5–7]. However, this technique has a low speci-
ficity, due to overlapping enhancement patterns that we
obtain after gadolinium administration (quantitative analysis
of the time-intensity curves in dynamic contrast-enhanced
MRI). With the advances in technology and the faster
sequences imaging, this limit can be overcome by measuring
kinetic parameters, such as, for example, the transit of the
contrast (transfer constant: Ktrans) [8].
In addition, in vivo proton magnetic resonance spectros-
copy (1H-MRS) is increasingly being used in the clinical
evaluation to characterise the cellular chemistry of breast
cancer. The phosphocholine (PCho) compound evaluated by
MRS may represent an imaging biomarker for cell prolifer-
ation thus allowing non-invasive molecular analysis of
biologic tissue. Its value has been associated with the
aggressiveness of the breast cancer phenotype [9]. Differ-
ences in its concentration between invasive and in situ breast
lesions may reflect a different histological grade and
receptor status [10].
However, the understanding of the molecular mecha-
nisms that regulate the production of PCho compound is
very limited. In vitro studies on breast cancer cells
demonstrated the important role of the CaSR in the pathway
of choline kinase (ChoK) activity and PCho. Calcium ions
induce a significant increase in extracellular PCho produc-
tion in breast cancer cells primarily related to CaSR-induced
ChoK activation and not from degradation of choline
phospholipids [11]. Since a high level of CaSR expression
induces a high concentration of calcium ions that activate
ChoK in breast cancer cells, resulting in increased PCho
production, we hypothesised that 1H-MRS may detect
elevated choline peak levels in breast cancer patients related
with CaSR activity and expression levels demonstrated at
the immunohistochemistry analysis.
In this study, we prospectively correlated the clinical
results of breast MRI-MR spectroscopy obtained with a 3T
MR scanner and CaSR-positive and negative breast speci-
mens at the immunohistochemistry analysis.
The aim of this preliminary study is to evaluate a possible
role of the CaSR in choline metabolism in breast lesion.
Material and Methods
Patient Selection
Thirty-six patients (range 34–70 years old; mean age 52 years)
scanned with MRI/1H-MRS protocol were included in this study.
Patients with a suspicious findings at the clinical examination (such as,
e.g., a lump in the breast) and/or at imaging evaluation (mammogra-
phy or ultrasonography of the breast) were recruited from medical or
surgical oncologists. All the suspicious lesions were biopsied and
classified by the Breast Imaging Reporting and Data System (BI-
RADS). Lesions greater than 1.5–2 cm were scanned with the 1H-
MRS protocol and included in this study, while lesion smaller than 1–
1.5 cm or with the presence of a breast hematoma adjacent to the
suspicious lesion were excluded. This study was approved by the
institutional review board of our Institute. The informed consent was
obtained from each patient prior to the study.
Dynamic Contrast Enhanced MR Imaging
The MR imaging protocol consisted of high-resolution imaging,
dynamic contrast-enhanced MR imaging and single voxel MR
spectroscopy was applied to all the patients recruited in the study. A
clinical 3T whole body scanner (Signa EXCITE®HDxT, GE,
Milwaukee, USA) with a dedicated software and channel phased-
array breast coil (HD 8 Channels VIBRANT® Breast Array by GE,
Milwaukee, USA) was used for both MR imaging and MR spectros-
copy. All patients were examined in prone position with the breasts
gently cushioned with rubber foam in order to reduce patient motion.
After tri-plane calibration scans, axial pre-contrast T2-weighted images
were acquired (see Table 1 for MR parameters details).
One set of images was acquired before contrast (2 ml/kg for
2 ml/s; ProHance® Bracco Imaging, Italy) and other five image
stacks after bolus i.v. administration using an automatic injection
system (Medrad Spectris Solaris EP) followed by a saline (30 cc) to
flush the contrast medium. For quantitative analysis of contrast
enhancement, the signal intensity was measured by a region of
interest (ROI) selectively placed into the area of a lesion with the
earliest contrast enhancement. Initial enhancement was quantified
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by calculating the percent enhancement using the formula [(SI post
−SI pre)/SI pre] × 100, where SI post is the average SI within the
ROI on the first post-contrast image and SI pre is the average SI
within the ROI on the pre-contrast images. The time course of
signal intensity was assessed visually using a graphic in which the
x-axis represents the temporal resolution and the y-axis represents
the signal intensity of the target area. For the post-processing
analysis, the GE software application Functool 9.4.05a was used.
The subtraction images were generated on the scanner console
(Advantage Workstation Volume Share 2 GE (AW 4.4)), subtract-
ing pre-contrast images from each post-contrast image, pixel by
pixel.
MR Spectroscopy (1H-MRS)
The subtraction images were used for placing the volume of interest
(VOI) for the subsequent 1H-MRS. The VOI was a rectangular
prism, which included the entire contrast enhanced lesion and
adjusted to avoid the non-enhancing gland parenchyma or the
surrounding fat. By this method, the theoretical filling factor was
obtained comparing the lesion volume (calculated as an ellipsoid)
with that of the VOI (calculated as a rectangular prism), ranged
from 0.38 to 0.70. A radiologist with 2 years of experience in breast
MRI/1H-MRS was responsible of the VOI position and size.
For 1H-MRS, single-voxel water and fat suppressed point-
resolved spectroscopy (BREASE) was acquired after contrast
administration. The hypothesis was that the post-contrast localiza-
tion of the lesion would yield a better consideration of its
morphology including as much of the lesion as possible while
avoiding surrounding adipose tissue.
The BREASE sequence was based on a PRESS single voxel
acquisition, including a water suppression pulse and VSS sat bands.
The acquisition is TE-averaged (4 to 8 echoes) to minimise the side bands
effects from the lipid peak. The sensitive volume in PRESS localization
was selected by applying a frequency-selective 90° pulse followed by two
frequency-selective 180° pulses to generate a spin echo from the ROI.
Before 1H-MRS was performed, the channel contralateral to the
lesion site was automatically switched off. Automated parameter
optimization was consisted of frequency and receiver gain adjustment
and gradient tuning. An automatic shimming adjustment was also
performed to reach a full width at half maximum (FWHM) of the
unsuppressed water peak lower than 30 Hz (for voxel size
20×20×20 mm). For values greater than 30 Hz, the automated
shimming procedure was repeated. In the case of a value of FWHM
greater than 30 Hz, the voxel was readjusted to the region of interest.
The 1H-MRS sequence was acquired with the following parame-
ters: TR/TE=2000/144 ms, number of excitations (NEX)=32 for voxel
size 8 cm3 (2×2×2 cm), NEX=56 for voxel size greater than 3.375 cm3
and NEX=82 for voxel size 3.375 cm3 (1.5×1.5×1.5 cm).
Table 1. Parameters utilised for breast MRI and 1H-MRS by a 3T MR scanner
Sequence Plane TR (ms) TE (ms) FoV (cm) Matrix Spacing PD Thickness (mm) Slices AT (min)
T2 FSE FSE XL AXIAL 4020 120 34×34 512×384 0 R/L 4 45 1:50
VIBRANT VIBRANT AXIAL 5.3 2.4 32×32 320×320 0 R/L 1.2 144 1:35×7
1H-MRS GRE 3D
BREASE
AXIAL 2000 155 24 – – A/P 20 – 5:00
TR Repetition time, TE Echo time, FoV Field of view, PD Phase direction, AT Acquisition time
Fig. 1. Immunohistochemical analysis of CaSR expression in human breast cancers specimens (score 0–5).
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This relatively long TE was chosen to increase the visibility of
the Cho resonance because of the longer T2 of Cho (9350 ms) in
comparison to that of lipids (∼100 ms). Voxel size was chosen not
less than 3.375 cm3 (1.5×1.5×1.5 cm) and not greater than 8 cm3
(2×2×2 cm), and it was carefully adjusted to the lesion.
The Cho resonance in breast spectra was qualitatively determined,
and the criteria for determining the presence or absence of Cho were
that a peak should be clearly identifiable at 3.2 ppm within the lesion
(range 3.19–3.26 ppm). See Table 1 for MR parameters details.
BREASE is a specific spectroscopy sequence optimised to enhance
breast choline concentration. It is a TE-averaged, PRESS spectroscopy
acquisition compatible with a 4-, 7- or 8-channel breast coil.
Immunohistochemistry
Immunohistochemistry (IHC) was performed by staining formalin-
fixed, paraffin-embedded 3-μm-thick tissue sections representative of
the tumour. The sections were deparaffinised, rehydrated and treated
using the automatic immunostaininer Benchmark XT (Ventana
Medical Systems, SA Strasbourg, France). Antigen retrieval was
performed with citrate buffer high ph for 30 min. Then, the antibody
was incubated for 1 h at 37 °C followed by addition of the polymeric
detection system Ventana Medical System Ultraview Universal DAB
Detection Kit. Finally, the sections were counter-stained
(automatically) with Gill’s modified haematoxylin and then cover-
slipped in Eukitt. The primary antibody, anti CaSR, was commercially
available (PA1-934A, Affinity BioReagents, Inc., Thermo scientific
INC Rockford, IL USA), polyclonal; dilution 1:200, visualisation:
membrane/citoplasmatic As positive tissue control, parathyroid was
used. Immunohistochemistry on adjacent sections in the absence of the
primary antibody was performed for the negative control. The sections
were analysed with an Olympus light microscope using 10× and 40×
objectives. Two independent observers, blinded to clinical details of
individual patients, evaluated the immunohistochemical analysis of
CaSR reactivity, using a scoring system. Expression of CaSR (Fig. 1)
was quantified using a visual grading system based on the extent of
staining (percentage of tumour cells) graded on a scale of negative
(score 0), weak (score 1), moderate (score 2), intense (score 3) and
strong (score 4), as described in the literature [4].
Statistical Analysis
Demographic data are presented as means±standard deviation (range).
Number of patients in different groups was compared using Fisher’s
exact text. For concern CaSR expression, we used twomain categories:
CaSR+ if score was 3–4 and CaSR− if the score was 0, 1 or 2.
Results
MR Dynamic Contrast enhancement
and Spectroscopy analysis
Of all 36 patients, 25 showed one breast lesion as mass-nodule
type morphology, nine patients showed a multifocal and
multicentric morphology and two lesions appeared as ill-
defined nodule type at MR imaging. No contralateral breast
cancers were observed. A total of 34 of the 36 breast
demonstrated malignant type kinetics with rapid enhancements
in the initial phase followed bywashout or reaching a plateau in
the late phase (types 2 and 3), while two lesions showed the
benign enhancement kinetics with the persistent enhancement
pattern (type 1). A total of 23 of the 34 malignant lesions
(68 %) showed a positive choline peak at MRS, while in 11 of
the 34 (32 %), the choline peak was absent or not consistent
from a qualitative analysis. In the two lesions with benign
enhancement kinetics, the choline peak was consistent.
Histological Results and Calcium Sensing
Receptor Expression at Immunohistochemistry
Analysis
At histological analysis, 25 lesions were invasive ductal
carcinoma, eight lesions invasive lobular carcinoma, one
Table 2. Correlation breast cancer histotypes, hormone receptors, ki67, and
CaSR-choline results
Histotype Er Pr Ki67 Erb 2 CaSR Cho
Invasive ductal carcinoma 98 99 66 2 4 +
Invasive ductal carcinoma 96 3 5 1 3 +
Invasive ductal carcinoma 99 5 10 1 4 +
Invasive ductal carcinoma 80 0 18 2 5 +
Invasive ductal carcinoma 99 46 10 1 3 +
Invasive ductal carcinoma 94 59 21 0 3 +
Invasive ductal carcinoma 90 93 12 0 5 +
Invasive ductal carcinoma 0 40 50 0 4 +
Invasive ductal carcinoma 66 0 20 3 4 +
Invasive ductal carcinoma 12 0 10 0 5 +
Invasive ductal carcinoma 34 0 8 0 3 +
Invasive ductal carcinoma 2 0 58 0 4 +
Invasive ductal carcinoma 61 9 32 0 3 +
Invasive ductal carcinoma 0 0 30 0 1 −
Invasive ductal carcinoma 93 96 0 1 2 +
Invasive ductal carcinoma 75 82 16 0 1 +
Invasive ductal carcinoma 57 83 10 0 3 −
Invasive ductal carcinoma 0 0 44 3 2 −
Invasive ductal carcinoma 2 0 92 0 1 −
Invasive ductal carcinoma 91 0 15 0 1 −
Invasive ductal carcinoma 0 0 15 3 3 +
Invasive ductal carcinoma 99 7 44 2 2 −
Invasive ductal carcinoma 99 98 11 0 1 −
Invasive ductal carcinoma 99 86 22 0 1 −
Invasive ductal carcinoma 0 0 56 3 2 −
Apocrin carcinoma 0 0 14 0 4 +
Invasive lobular carcinoma 98 0 24 2 3 +
Invasive lobular carcinoma 99 5 10 1 4 +
Invasive lobular carcinoma 95 10 43 3 3 +
Invasive lobular carcinoma 94 73 20 1 5 +
Invasive lobular carcinoma 99 38 22 0 5 +
Invasive lobular carcinoma 0 0 19 0 1 −
Invasive lobular carcinoma 97 97 12 0 2 −
Invasive lobular carcinoma 99 6 27 0 2 +
Papillary hyperplasia/
apocrine metaplasia
0 0 0 0 3 +
Papillary hyperplasia/
apocrine metaplasia
0 0 0 0 3 +
Er Estrogen receptor, Pr Progesterone receptor, Ki67 Antigen KI-67 cellular
proliferation index, Erb2 Receptor tyrosine-protein kinase, CaSR Calcium-
sensing receptor, Cho Choline peak at 1H-MRS (+), no choline peak at 1H-
MRS (−), TR Repetition time, TE Echo time, FoV Field of view, PD Phase
direction, AT Acquisition time
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lesion apocrine carcinoma, two lesions with papillary
hyperplasia/apocrine metaplasia (Table 2).
For the evaluation of CaSR, parathyroid was used as a gold
standard, since its strong CaSR expression, while the negative
control consisted of performing immunohistochemistry on
adjacent sections in the absence of the primary antibody. The
intense expression corresponds to the plasma membrane/
citoplasmatic localisation of CaSR in parathyroid cells [4].
All breast lesions expressed the CaSR at the immunohis-
tochemistry analysis, but at different levels. The predomi-
nant staining was membrane/citoplasmatic. The intensity of
the CaSR expression was different between the malignant
and benign lesions. Twenty-one of the 34 breast cancer
lesions (62 %) showed a high level expression of CaSR with
a score between 3 and 5 (five invasive lobular carcinoma,
one apocrine carcinoma and 15 invasive ductal carcinoma).
In 13 of the 34 malignant lesions (38 %), the CaSR patterns
were between 1 and 2 (three lobular carcinoma and 10
invasive ductal carcinoma). The two benign lesions, with
papillary hyperplasia/apocrin metaplasia, showed a score 3
for CaSR expression. For CaSR expression level interpreta-
tion, please see Fig. 1.
Choline peak and Calcium Sensing Receptor
expression correlation
Twenty of the 23 breast lesions with a consistent choline
peak at 1H-MRS expressed a score of CaSR 3–5 (87 %) and
ten of the 11 breast lesions negative at 1H-MRS showed a
score 1–2 of CaSR 91 % (Figs. 2, 3 and 4). No significant
correlation was found between the different level expression
of CaSR and hormone status (Er/Pr) of the different lesions
(pG0.977), nor between CaSR expression and morphology
of the lesions at the DCE-MRI (mass-type cancers compared
to non-mass-type cancers) (pG0.167). An overview of the
results is listed in the Table 2 and Figs. 5 and 6.
Discussion
Recently, a lot of interest has arisen in the activity of
calcium-sensing receptor, in particular in tissues, such as
breast cancer, that are not directly involved in the systemic
mineral ion homeostasis, where the receptor probably acts in
different kind of roles [12]. In patients with breast cancer,
traditional anatomical imaging using size and morphological
Fig. 2. Proton MR spectroscopy choline peak and calcium-sensing receptor (CaSR) correlation. A 58-year-old woman with an
invasive lobular carcinoma. a Axial VIBRANT (Volume Imaging for BReast AssessmeNT) contrast-enhanced magnetic
resonance (MR) image (repetition time/echo time [TR/TE] 5.3/2.4 ms; 1.2 mm slice thickness) shows an enhancing irregularly
multifocal and muticentric lesion in the right breast. b Malignant type kinetics intensity curve with rapid enhancements in the
initial phase followed by a plateau in the late phase. c MIP reconstruction image of the lesion in the right breast. d–e Single-
voxel MR spectroscopy (BREASE sequence): VOI localization on the axial VIBRANT contrast-enhanced magnetic resonance
MR image and the resonance peak of total composite choline compounds (tCho) that was evident at 3.2 ppm. f
Immunohistochemical analysis of CaSR expression in human breast cancer specimen (score 5).
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criteria for diagnosis does not provide information on
functional characteristics of the primitive tumours. The
current challenge is to move towards a more molecular
assessment of tumour for response evaluation that can be
correlated with functional changes after neoadjuvant che-
motherapy. Magnetic resonance imaging combines the
morphological and functional assessment of breast tumours
improving the diagnostic confidence and providing early
surrogate markers of disease response [13]. Furthermore,
in vivo1H-MRS represents a useful technique for quantifying
Cho concentration levels and characterising tumour types
(e.g., mass vs. diffuse) of breast cancer, but it may have
limitations for characterising small lesions [14]. Understand-
ing the molecular mechanisms that regulate the production
of P-Cho compound is still incomplete. Recent studies on
breast cancer cells demonstrated how CaSR could play an
important role in the pathway of choline kinase (ChoK)
activity and PCho production [11].
The extracellular calcium-sensing receptor (CaSR) is a
cell surface receptor that binds calcium ions and mediates
cellular responses to extracellular-free calcium. In the breast,
the expression of the CaSR is localised in the ductal
epithelial cells and during lactation it promotes Ca2+
transport into milk [15]. We know that Ca2+ plays an
important role in both normal physiological function and
pathologic states in breast tissue. High level of CaSR
expression induces a high concentration of calcium ions
that activate ChoK in breast cancer cells, resulting in
increased PCho production [11].
In our study, we prospectively correlated the presence or
absence of choline peak at 1H-MRS with the different
expression levels of CaSR in breast lesions. A total of 34 of
the 36 breast lesions demonstrated malignant type kinetics at
DCE-MRI. A 68 % of these lesions showed positive choline
peak (range of 3.19–3.26 ppm), while 32 % where negative.
It is extensively showed that total choline concentration can
be used as a marker of malignancy and, combined with
DCE-MRI, increases the specificity up to 88 % (100 % after
the inclusion of a single slice T2* perfusion measurement)
[16], indeed, the tCho levels are significantly higher in mass-
type cancers compared to non-mass-type cancers [14].
However, in our study, we had 32 % of breast cancers
negative for total choline with MR spectroscopy, showing,
in our opinion, an important limit of this technique, in the
breast cancer detection. This “limit” maybe explained by
other reasons beyond the technological aspects of the
Fig. 3. Proton MR spectroscopy choline peak and calcium-sensing receptor (CaSR) correlation. A 62-year-old woman with an
invasive lobular carcinoma. a Axial VIBRANT (Volume Imaging for BReast AssessmeNT) contrast-enhanced magnetic
resonance (MR) image (repetition time/echo time [TR/TE] 5.3/2.4 ms; 1.2 mm slice thickness) shows an enhancing nodule in
the left breast. b Malignant type kinetics intensity curve with rapid enhancements in the initial phase followed by washout. c
MIP reconstruction image of the lesion in the left breast. d–e Single-voxel MR spectroscopy (BREASE sequence): VOI
localization on the axial VIBRANT contrast-enhanced magnetic resonance MR image and the resonance peak of total
composite choline compounds (tCho) that was not evident at 3.2 ppm. f Immunohistochemical analysis of CaSR expression in
human breast cancer specimen (score 1).
G. Baio et al.: Correlation between Choline and Calcium-Sensing Receptor Expression at MR Spectroscopy 553
technique (such as, e.g., the quantity of fat included in the
VOI or the dimension of the lesion) [14].
In our opinion, the results of this study, correlating MRI-
MRS results and immunohistochemistry, could explain the
negative results of choline in some breast cancer patients.
Indeed, 87 % of the breast lesions with choline peak at
3.2 ppm showed high level expression of CaSR (score 3–5).
In 91 % of the lesions negative for choline, CaSR expression
Fig. 4. Proton MR spectroscopy choline peak and calcium-sensing receptor (CaSR) correlation. A 54-year-old woman with an
invasive ductal carcinoma. a Axial VIBRANT (Volume Imaging for BReast AssessmeNT) contrast-enhanced magnetic
resonance (MR) image (repetition time/echo time [TR/TE] 5.3/2.4 ms; 1.2 mm slice thickness) shows an enhancing polilobulated
lesion in the right breast. b Malignant type kinetics intensity curve with rapid enhancements in the initial phase followed by
washout. c MIP reconstruction image of the polilobulated lesion in the right breast, showing multifocal disease. d–e Single-
voxel MR spectroscopy (BREASE sequence): VOI localization on the axial VIBRANT contrast-enhanced magnetic resonance
MR image and the resonance peak of total composite choline compounds (tCho) that was evident at 3.2 ppm. f
Immunohistochemical analysis of CaSR expression in human breast cancer specimen (score 4–5).
Fig. 5. Correlation between choline peak at 1H-MRS and
calcium-sensing receptor expression in breast lesions. Cho+
Choline peak at 1H-MRS, Cho− No choline peak at 1H-MRS,
CaSR+ calcium-sensing receptor score 3–5, CaSR− calcium-
sensing receptor score 1–2.
Fig. 6. Histopathology correlation between choline peak at
1H-MRS and calcium-sensing receptor expression in breast
lesions. IDC Invasive ductal carcinoma, ILC Invasive lobular
carcinoma, APC Apocrine carcinoma, HY/MT Papillary
hyperplasia/apocrine metaplasia, Cho+ Choline peak at
1H-MRS, Cho− No choline peak at 1H-MRS, CaSR+ Calcium-
sensing receptor score 3–5, CaSR− Calcium-sensing receptor
score 1–2.
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was very low (score 1–2). The Fischer exact test statistic
value was 0.001 with a significance limit at pG0.01.
Our preliminary results could address a possible correla-
tion between the expression of this receptor in breast lesions
and how this expression is influencing the choline produc-
tion within the tumour subsequently detected with 1H-MRS.
We did not observe a correlation of hormone receptors and
morphology of the lesions (mass-type cancers compared to
non-mass-type cancers) with CaSR expression and choline
peak (data not shown). From our results, we may deduce that
the mechanism behind the production of choline is complex
and influenced by other important factors, for example, as
very recently described how Cho production and gene
expression profiles are correlated and different, between
cancers subtypes [17].
Furthermore, we also had two unexpected benign lesions
at DCE-MR imaging, diagnosed as papillary hyperplasia/
apocrine metaplasia, at the histology examination (“border-
line benign lesion”). It is interesting that the MR spectros-
copy examination of these two lesions showed a consistent
choline peak and immunohistochemistry analysis confirmed
the expression of CaSR with a score 3. Although the sample
size is insufficient in this group for clear conclusions, this
result is consistent with the idea that this receptor is
expressed and probably differently regulated in both benign
and malignant conditions [18], thus influencing the 1H-MRS
results. However, more examinations on benign lesion
should be done in order to confirm this result (e.g., on
breast fibroadenoma).
The physiological mechanism behind the CaSR-choline
pathway confirms the importance of the role of this receptor
in breast tumour. DCE-MRI plus 1H-MRS could play
together an important role in the study of breast cancer and
CaSR, in particular, if this receptor has a special role in bone
metastases development [4]. From a clinical point of view, it
would be very important to perform a “molecular imaging
diagnosis” of a group of patients with high risk to develop
bone metastases, using a non-invasive imaging technique
such as MRI-1H-MRS.
Many clinical studies used 1H-MRS to monitor the
response of locally advanced breast cancer, showing that
the change in tCho concentration can serve as an indicator
for predicting clinical response to therapy [19, 20]. On the
basis of our results and considering the link between CaSR
and choline, we believe that it would be challenging to
investigate more how the receptor expression changes
under chemotherapy and how this relates to the choline
peak changes. Recent investigation of BRCA1 and CaSR
showed how these two factors together suppress the
expression of survinine and promote sensitivity to
paclitaxel in human breast cancer cell [21]: This is
another example of how CaSR could influence not only
the therapy effects (may promote aggressive behaviour
and resistance to cytotoxic drugs?), but also the imaging
results when using a technique such as 1H-MRS (CaSR-
choline production).
Furthermore, in our cohort of patients, five triple negative
breast cancers were expressing different level of CaSR. We
believe that this is another important point of our results,
considering that actually the treatment of these patients is
challenging and CaSR may represent an independent
receptor suitable for a tumour targeting therapy of triple
negative breast cancer.
The future in biomarkers research for the evaluation of
treatment response will be the correlation of gene expression
and MR imaging: Gene arrays and immunohistochemistry
analysis of CaSR-Cho pathways could help to better
understand which gene expression is related to specific
changes in the aggressiveness of the disease, assessed by
MRI.
A large cohort of patients is mandatory to confirm our
preliminary results and to perform the next step in the
analysis of CaSR-Cho during treatment. Furthermore, a
larger sample of benign lesions would allow better under-
standing of CaSR in the “non-malignant” condition and its
possible role in the progression to cancer.
The ongoing research and the development of new
functional MR techniques applied into the routine of clinical
care indicate that the prospects for substantial improvements
in monitoring therapeutic response as well as for early
detection of breast cancer are promising [13]. A key factor to
success will depend in the rigorous reproducibility of the
qualitative and quantitative measurements performed by an
imaging technique, such as MRI-1H-MRS.
Conclusions
Our findings suggest that 1H-MRS presence or absence of
choline peak correlates with different expression levels of
CaSR in patients with breast lesions. These results support
the hypothesis that CaSR plays an important role in the
production of choline in breast cancer and that the CaSR-
Cho signalling is important in breast cancer cell biology,
suggesting the possibility that this pathway may represent a
potential tumour imaging targeting strategy.
Acknowledgments. The authors thank Mrs Teresa Morris, Coordinator of
Aberdeen Biomedical Imaging, University of Aberdeen, UK, for his helpful
revision of the manuscript, in particular for English editing.
Conflict of Interests. The authors declare that they have no conflict of
interests.
Ethical Approval. All procedures performed in studies involving human
participants were in accordance with the ethical standards of the institutional
and/or national research committee and with the 1964 Helsinki declaration
and its later amendments or comparable ethical standards.
References
1. Ward DT, Riccardi D (2012) New concepts in calcium-sensing receptor
pharmacology and signalling. Br J Pharmacol 165:35–48
2. Diez-Fraile A, Lammens T, Benoit Y et al (2013) The calcium-sensing
receptor as a regulator of cellular fate in normal and pathological
conditions. Curr Mol Med 13:282–295
G. Baio et al.: Correlation between Choline and Calcium-Sensing Receptor Expression at MR Spectroscopy 555
3. Ward DT (2004) Calcium receptor-mediated intracellular signalling.
Cell Calcium 35:217–228
4. Mihai R, Stevens J, McKinney C et al (2006) Expression of the calcium
receptor in human breast cancer-a potential new marker predicting the
risk of bone metastases. Eur J Surg Oncol 32:511–515
5. Warner E, Plewes DB, Shumak RS et al (2001) Comparison of breast
magnetic resonance imaging, mammography, and ultrasound for
surveillance of women at high risk for hereditary breast cancer. J Clin
Oncol 19:3524–3531
6. Warner E, Messersmith H, Causer P et al (2008) Systematic review:
using magnetic resonance imaging to screen women at high risk for
breast cancer. Intern Med 148:671–679
7. Houssami N, Hayes DF (2009) Review of preoperative magnetic
resonance imaging (MRI) in breast cancer: should MRI be performed
on all women with newly diagnosed, early stage breast cancer? Cancer J
Clin 59:290–302
8. Su MY, Yu HJ, Carpenter PM et al (2005) Pharmacokinetic parameters
analyzed from MR contrast enhancement kinetics of multiple malignant
and benign breast lesions detected in the same patients. Technol Cancer
Res Treat 4:255–263
9. Aboagye EO, Bhujwall ZM (1999) Malignant transformation alters
membrane choline phospholipid metabolism of human mammary
epithelial cells. Cancer Res 59:80–84
10. Lean C, Doran S, Somorjai RL et al (2004) Determination of grade and
receptor status from the primary breast lesion by magnetic resonance
spectroscopy. Technol Cancer Res Treat 3:551–556
11. Huang C, Hydo LM, Liu S et al (2009) Activation of choline
kinase by extracellular Ca2+ is Ca(2+)-sensing receptor,
Galpha12 and Rho-dependent in breast cancer cells. Cell Signal
21:1894–1900
12. Brown EM, MacLeod RJ (2001) Extracellular calcium sensing and
extracellular calcium signaling. Physiol Rev 81:239–297
13. O’Flynn EA, DeSouza NM (2011) Functional magnetic resonance:
Biomarkers of response in breast cancer. Breast Cancer Res 13:405
14. Baek HM, Lee YJ (2014) Feasibility of MR spectroscopy for
characterizing malignant breast lesions using a clinical 3-T scanner.
Breast Cancer Jan 4. [Epub ahead of print]
15. Cheng I, Klingensmith ME, Chattopadhyay N et al (1998) Identification
and localization of the extracellular calcium-sensing receptor in human
breast. J Clin Endocrinol Metab 83:703–707
16. Huang W, Fisher PR, Dulaimy K et al (2004) Detection of breast
malignancy: Diagnostic MR protocol for improved specificity.
Radiology 232:585–591
17. Grinde MT, Skrbo N, Moestue SA et al (2014) Interplay of choline
metabolites and genes in patient-derived breast cancer xenografts.
Breast Cancer Res 16:R5
18. Brennan SC, Thiem U, Roth S et al (2013) Calcium sensing receptor
signalling in physiology and cancer. Biochim Biophysa Acta
1833:1732–1744
19. Meisamy S, Bolan PJ, Baker EH et al (2004) Neoadjuvant chemother-
apy of locally advanced breast cancer: predicting response with
in vivo1H MR spectroscopy a pilot study at 4T. Radiology 233:424–431
20. Kumar M, Jagannathan NR, Seenu V et al (2006) Monitoring the
therapeutic response of locally advanced breast cancer patients:
Sequential in vivo proton MR spectroscopy study. J Magn Reson
Imaging 24:325–332
21. Promkan M, Liu G, Patmasiriwat P et al (2011) BRCA1 suppresses the
expression of survivin and promotes sensitivity to paclitaxel through the
calcium sensing receptor (CaSR) in human breast cancer cells. Cell
Calcium 49:79–88
556 G. Baio et al.: Correlation between Choline and Calcium-Sensing Receptor Expression at MR Spectroscopy
 
   
 
P a g e  104 | 136 
 
 
2.5. A non-invasive approach to investigate chronic lymphocytic 
Leukaemia by using iron oxide nanoparticles. 
 
2.5.1. Title of papers 
 
• Valdora F, Cutrona G, Matis S, Morabito F, Massucco C, Emionite L, 
Boccardo S, Basso L, Recchia AG, Salvi S, Rosa F, Gentile M, Ravina M, 
Pace D, Castronovo A, Cilli M, Truini M, Calabrese M, Neri A, Neumaier 
CE, Fais F, Baio G, Ferrarini M. A non-invasive approach to monitor 
chronic lymphocytic leukaemia engraftment in a xenograft mouse model 
using ultra-small superparamagnetic iron oxide-magnetic resonance imaging 
(USPIO-MRI). Clin Immunol. 2016 Jul 15. 
• Cutrona G, Matis S, Colombo M, Massucco C, Baio G, Valdora F, 
Emionite L, Fabris S, Recchia AG, Gentile M, Neumaier CE, Reverberi D, 
Massara R, Boccardo S, Basso L, Salvi S, Rosa F, Cilli M, Zupo S, Truini 
M, Tassone P, Calabrese M, Negrini M, Neri A, Morabito F, Fais F, Ferrarini 
M. Effects of miRNA-15 and miRNA-16 expression replacement in chronic 
lymphocytic leukaemia: implication for therapy. Leukaemia. 2017 Sep; 
31(9):1894-1904. 
 
2.5.2. Objectives of the studies 
 
 To demonstrate noninvasively that iron oxide nanoparticles can be 
applied in in vivo MR imaging to monitor chronic cell leukaemia (CLL) 
engraftment. 
 
 To investigate in in vivo the effects of replacement of miR-15a and 
miR-16-1 into CLL cells by using USPIO-MRI. 
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2.5.3. What these studies added to the literature 
 
The temporal window between early disease detection and the subsequent 
steps (either mouse death or CLL cell engraftment rejection) provides a tool 
to evaluate more precisely treatment efficacy and the possible emergence of 
therapy resistant clones. Examples of the potential use of the USPIO-MRI 
approach that we developed are provided by observations in which CLL-
engrafted mice could, in part, be “cured” by the administration of the anti 
CD20 mAb rituximab. This MRI approach may be used for a more precise 
staging of patients with CLL and possibly other lymphoproliferative 
disorders. 
2.5.4. What changed as a result of the papers? 
 
A novel MR imaging approach was developed to investigate in vivo CLL 
engraftment and to evaluate response to treatment. This study included a 
scientific collaboration with Viscover™ Imaging Agents 
(https://www.miltenyibiotec.com/GB-en/products/macs-imaging-and-
microscopy/viscover-imaging.html). 
2.5.5. In retrospect, what should have been done differently in these 
studies? 
 
Looking back we might have considered applying 18FDG-PET/CT to one of 
the CLL group of animal models in order to compare the sensitivity and 
specificity of our technique versus 18FDG-PET/CT, since this technique has 
been applied by other research groups. This may have further strengthened 
our method. 
2.5.6. Future work as a result of these publications 
 
The research here described was concluded after the paper was published. 
No further research was carried out on this topic by our research group. 
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miRNAs are a “hot topic” in both the field of haematological malignancies 
and autoimmunity, since these two conditions are often concomitant in 
patients because a causal bidirectional relationship exists between them. 
Considerable effort has been made to understand the proteins that have a 
relevant role in both processes; literature advances demonstrate that miRNAs 
surface as the epigenetic regulators of those proteins and control networks 
are linked to both autoimmunity and haematological malignancies. 
Furthermore, in solid malignancies, a different expression signature of 
miRNA has recently been validated in oral squamous cell carcinoma 
(OSCC).  
2.5.7. Confirmation of authorship 
 
This is shown at the end of Chapter 2. 
2.5.8. External link to the paper on the journal website 
 
https://www.ncbi.nlm.nih.gov/pubmed/27430522 
https://www.ncbi.nlm.nih.gov/pubmed/28053325 
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Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia among adults. Despite its indolent nature,
CLL remains an incurable disease. Herein we aimed tomonitor CLL disease engraftment and, progression/regres-
sion in a xenograft CLLmousemodel using ultra-small superparamagnetic iron oxide-magnetic resonance imag-
ing (USPIO-MRI). Spleen contrast enhancement, quantified as percentage change in signal intensity upon USPIO
administration, demonstrated a difference due to a reduced USPIO uptake, in the spleens of mice injected with
CLL cells (NSG-CLL, n= 71) compared to controls (NSG-CTR, n= 17). These differences were statistically signif-
icant both after 2 and 4 weeks from CLL cells injection. In addition comparison of mice treated with rituximab
with untreated controls for changes in spleen iron uptake confirmed that it is possible to monitor treatment ef-
ficacy in this mouse model of CLL using USPIO-enhanced MRI. Further applications could include the preclinical
in vivo monitoring of new therapies and the clinical evaluation of CLL patients.
© 2016 Elsevier Inc. All rights reserved.
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1. Introduction
Chronic lymphocytic leukemia (CLL) is the most common form of
adult leukemia in Western countries [1,2]. CLL is characterized by the
clonal expansion of mature CD5+/CD23+ lymphocytes that can
infiltrate multiple organs including lymph nodes, the bone marrow,
spleen, and liver. CLL is highly heterogeneous in terms of therapy-free
interval, response to treatment and overall survival, ranging from
rapid disease progression requiring early and frequent treatment, to
survival for decades with minimal or no treatment. Staging of CLL
patients involves periodical evaluation of lymph nodes, spleen, and
liver infiltration and is used to define risk and treatment. Follow-up
generally includes a blood cell count and palpation of lymph nodes,
liver, and spleen every 3–12 months [3,4]. In daily clinical practice, a
common modality for evaluating changes in spleen size is to assess if
the spleen is palpable, which means that the spleen generally requires
an enlargement of at least two folds in order for changes to be detected.
In addition, unlike superficial lymph nodes, deep nodes cannot be
evaluated by simple palpation alone.
Several mouse models for the study of CLL development have been
established [5]. These encompass transgenic models in which key
genes have been altered [6–9]or xenograft models that use immunode-
ficientmice that are engraftedwith human leukemic cells [10–12]. In all
instances, development of the CLL clone can be followed bymonitoring
peripheral blood for the presence of leukemic cells, but the evaluation of
lymphoid tissues (i.e. the spleen, in immunodeficient mice as lymph-
nodes are mostly atrophic), where the leukemic cells have to seed to
begin their proliferative phase, requires sacrificing the animals. Thus,
sensitive and safe imaging techniques to monitor disease development
may beuseful in preclinicalmodels and,more importantly also based on
the above considerations, may find application in routine clinical
practice.
Computer tomography (CT) is used as the first-linemodality for im-
aging of lymphoidmalignancies [13]. The role of CT has not been clearly
defined in CLL patients, although CT routine disease monitoring for CLL
has been largely discouraged [3,14,15]. CT scans are recommended for
baseline and final assessment in clinical trials and is not the method of
choice to be used in clinical staging [16,17]. Magnetic resonance imag-
ing (MRI) has a high sensitivity in the diagnosis of the disease and
also plays an important role in the assessment of disease activity with-
out the need for exposure to ionizing radiation. The success of MRI
in vivo highly depends on the molecular imaging agent used. With the
help of efficient imaging agents, it is possible for MRI to precisely detect
early-stage disease and to monitor the response to drug therapy.
Superparamagnetic iron oxide (SPIO) or ultra-small super-
paramagnetic iron oxide (USPIO) nanoparticles are now primarily
used and are becoming increasingly attractive as the precursor for the
development of a target-specific MRI contrast agent in molecular MRI.
The efficacy of iron oxide nanoparticles used as specific contrast agent
in MRI for liver, spleen, and lymph node has been demonstrated in
experimental and clinical studies. Several studies have shown that
these particles can significantly improve the detection and characteriza-
tion of focal lesions within these organs [18–20]. Due to their size-
dependent properties and their applicability in non-invasive imaging
methods, these materials are promising candidates for research,
diagnostic, and therapeutic applications in various fields such as cancer,
neurodegenerative diseases (e.g. multiple sclerosis, [21–23], stroke [24,
25]), as well as in inflammatory diseases (e.g. rheumatoid arthritis [26]
and atherosclerosis [27]). Iron oxide particles can be used as contrast
medium in MRI because they are agents of high relaxivity able to
enhance the contrast in T2/T2*-weighted MRI in tissues in which they
accumulate. USPIO are taken up by the cells of the liver, spleen, bone
marrow, and lymph nodes. Because of their small size (mean size 10–
20 nm), they diffuse freely through capillaries and are phagocytized
by tissue-resident inflammatory cells of the reticulo-endothelial system
(RES), which predominantly consists of macrophages, although neutro-
phils may also take up USPIO [28–30].
In this study we aimed to establish a non-invasive specific MRI
method to better visualize and to quantify the presence of CLL disease
by USPIO within the spleen in a pre-clinical setting. In particular, we
used a mouse xenogeneic transplantation model, NOD/Shi-scid,γcnull
(NSG) mice, a NOD/SCID-derived strain that lacks the IL-2 family
commoncytokine receptor gammachain gene (γc) [10,11]. A secondary
goalwas tomonitor CLL disease evolution using imaging strategies in an
attempt to reduce the overall number of mice necessary for the
evaluation of CLL cell engraftment over several time points, limiting
their sacrifice and suffering during experimental protocols.
2. Materials and methods
2.1. CLL patients
Newly diagnosed CLL patients from participating Institutions were
enrolled within 12 months from diagnosis (O-CLL1 protocol
clinicaltrial.gov identifier NCT00917540). Diagnosis was confirmed by
flow cytometry (FC) analysis centralized at theNational Institute of Can-
cer Laboratory in Genoa, Italy, together with the determination of CD38
Abbreviations
MRI magnetic resonance imaging
ROI region of interest
CLL chronic lymphocytic leukemia
USPIO ultra-small superparamagnetic iron oxide
SNR signal-to-noise ratio
CT computed tomography
SD standard deviation
sem standard error of mean
SI signal intensity
ΔSNR% percentage signal-to-noise ratio change
i.v. intravenous injection
i.p. intraperitoneal injection
RES reticulo-endothelial system
PBMC peripheral blood mononuclear cells
FC flow cytometry
MHz megahertz
FIESTA Fast Imaging Employing Steady State Acquisition
FA Flip Angle
FoV field of view
TR repetition time
TE echo time
T1 longitudinal relaxation time
T2 transverse relaxation time
ROC receiver-operating characteristic
CI confidence interval
IGHV immunoglobulin heavy chain variable region
FISH fluorescent in situ hybridization
Units
mm millimeter
g gram
mg milligram
kg kilogram
μL microliter
μmol micromole
ms millisecond
nm nanometer
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°C centigrade
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and ZAP-70 expression and IGHV mutational status as previously
described [31,32]. Cytogenetic abnormalities involving deletions at
chromosomes (11)(q22.3), (13)(q14.3) and (17)(p13.1), and trisomy
12were evaluated by fluorescent in situ hybridization (FISH) in purified
CD19+ population as previously described [32] (Table 1).
PBMC from patients with CLL were isolated by Ficoll-Hypaque
(Seromed, Biochrom) density gradient centrifugation.
2.2. Murine model
Six to eight week old female NOD/Shi-scid,γcnull (NSG) mice (The
Jackson Laboratory), a xenograft model for CLL growth in vivo [10,11],
were housed in sterile enclosures under specific pathogen-free condi-
tions. All procedures involving animals were performed respecting the
current National and International regulations and were reviewed and
approved by the licensing and Animal Welfare Body of the IRCCS-AOU
San Martino-IST National Cancer Research Institute, Genoa, Italy.
NSG mice were infused by intravenous injection (i.v.) with 30–
50 × 106 PMNCs/mouse from 18 CLL cases (see Table 1) and the
presence of CD19+CD5+ leukemic cells were checked after 2 and 4-
weeks from the date of injection in blood samples taken from the
retro-orbital vein.
2.3. Preparation of USPIO particles-contrast agent and dosage
The USPIO contrast agent (Feraspin XS, Miltenyi Biotech GmbH,
Germany) used, consists of commercially available USPIO nanoparticles
with a mean particle size of 10–20 nm, able to circulate in the
bloodstream and be taken up by RES macrophages. All animal groups
were imaged before, and 24 h after i.v. injection of 100 μL/25 g mouse
of USPIO, corresponding to a dose of 40 μmol Fe/kg body weight.
2.4. In-vivo MRI experiments
The mice were anesthetized by intraperitoneal injection (i.p.)
with a combination of xylazine (30 mg/kg) and ketamine
(100mg/kg) and were positioned in a prototype coil (birdcage linear
coil, transmit/receive coil, 100 mm in length, 55 mm in diameter,
tuned at 127.6 MHz, Flick Engineering Solutions BV, Milwaukee,
USA). The room temperature during experiments was 23 °C and the
mean acquisition time was limited to 20 min by the spontaneous
awakening of mice. In vivo MRI was performed on a 3T clinical
system (Sigma® EXCITE® HDxT, GE Healthcare, Milwaukee, USA).
The approved imaging protocol is described in Table S1. The saline
solution was administrated before and after MRI scanning in order
to rehydrate the mice and to alleviate pain. After completion of the
MRI, all mice were sacrificed in a saturated CO2 chamber and autop-
sies were performed. The spleens were collected for IHC analysis and
cytofluorimetric analysis.
2.5. MRI signal intensity analysis
All animal groups were imaged before and 24 h after USPIO
administration as described above. Both qualitative and quantitative
analyses were performed with FIESTA (Fast Imaging Employing Steady
State Acquisition)-weighted sequences [33]. Quantitative analyses
were expressed as signal intensity (SI) ± standard deviation (SD) for
each mouse, calculated 24 h after Feraspin XS administration, with SI
being measured in the spleen, and the background noise was deter-
mined by drawing a region outside the anatomy of the mice, using an
operator-defined region of interest (ROI). Circular ROIs were manually
drawn and the size of the ROIs weremeasured by consistently acquiring
the same size in the control group and in mice injected with CLL cells.
After defining the ROIs, the SI in the spleen of eachmousewas acquired.
A circular ROI, positioned as indicated in Fig. 1, was used to calculate the
signal-to-noise ratio (SNR) and ΔSNR% as follows [34,35]:
SNR ¼ SItissue=SInoise
ΔSNR% ¼ SNRafterUSPIOð Þ− SNRbeforeUSPIOð Þ=SNRbeforeUSPIO½   100
2.6. Histopathological analysis
Formalin-fixed and paraffin-embedded spleen specimens were ana-
lyzed for the presence of human CLL infiltrates. The sections were
deparaffinized and antigen-retrieval was performed with citrate buffer
high pH for 8 min. Double staining with CD20 and Ki67 by IHC was
performed by incubation (32 min at 37 °C) with a specific anti-human
Ki67 antibody (MIB-1, DAKO Cytomation, dilution 1:25) and followed
by addition of the polymeric detection system Ultraview Universal
DAB Detection Kit (Roche, Ventana). Automatic dispensing of the sec-
ond antibody (anti-CD20, L26-Roche Ventana Medical System) for
20 min at 37 °C, was followed by addition of the polymeric detection
system (Ultraview Universal RED Detection Kit). An appropriate
positive tissue control was used for each staining run; the negative
control consisted of performing the entire IHC procedure on adjacent
sections in the absence of the primary antibody. The sections were
counter-stained (automatically using a user-defined protocol) with
Gill's modified hematoxylin and then cover-slipped. All sections were
quantitatively evaluated by two observers with an Olympus light
microscope using 10×, 40× and 63× objectives. All the sections were
analyzed under a Leica DM3000 DMLB optical microscope (Leica
Microsystems, Germany) and microphotographs were collected using
a Leica DFC320 DMD108 digital microimaging camera (Leica
Microsystems, Germany). Perls' Prussian blue staining (Histological
staining Kit, code 010236, Diapath) was performed to detect ferric
(Fe3+) iron.
2.7. Treatment with rituximab
CLL engraftment was achieved as described above. The anti-CD20
MAb, Rituximab, was donated by the pharmacy of our Institution from
remnants of the patients' sack therapy. Rituximab treatment was
started using a dosage of 50 μg/mouse/dose (four treatments every
3 days) in 200 μL of saline solution by i.v. injection [36]. The control
group was injected with an equal volume of saline solution. Basal MRI
was performed after four weeks of PBMC CLL injection before starting
Table 1
Biologic and molecular characteristics of CLL patients included in the
study.
Prognostic parameters n (% of total)
CD38
Negative 13 (72.2)
Positive 5 (27.8)
Total 18 (100)
ZAP-70
Negative 6 (33.3)
Positive 12 (66.7)
Total 18 (100)
IGHV
Mutated 13 (72.2)
Unmutated 5 (27.8)
Total 18 (100)
FISH
Negative 3 (16.6)
del(13)(q14) 15 (83.3)
Trisomy 12 0 (0)
del(11)(q22.3) 0 (0)
del(17)(p13) 0 (0)
Total 18 (100)
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therapy and thereafter, at therapy completion [treated mice (n = 3),
control mice (n= 3)] treated with saline solution as detailed in Supple-
mentary Fig. 1.
After three days of the last dose of antibody, animals were sacrificed
in a saturated CO2 chamber and autopsies were performed. Blood, and
different samples of the spleens were evaluated by both FC and by IHC
as described above. Fresh spleen tissue samples were mechanically
resuspended with gentleMACS™ Dissociator (Miltenyi). The spleens
were previously enzymatically digested using the Spleen Dissociation
Kit (Miltenyi). The single-cell suspensions were evaluated by flow
cytometry analysis with FACSCanto (BD Biosciences) and DIVA 6 (BD
Biosciences) or FLOWJO V.9.8.3 software (Treestar Inc.) for: anti-
human (hu) CD45 FITC, CD19 PECy7, CD5 APC antibodies (BD
Biosciences).
2.8. Statistical analysis
The Mann-Whitney U statistical test was used for testing statistical
differences between more than two groups of samples and the
Wilcoxon test for matched-pairs groups.
In order to identify the best cut-off value to be used in our experi-
ments able to discriminate engrafted disease from engraftment failure,
a diagnostic threshold of the relative enhancement measurements
was sought by constructing receiver operating characteristic (ROC)
curves. In an ROC curve, the true-positive rate (sensitivity) is plotted
as a function of the false-positive rate (100 specificity) for different
cut-off points. Each point on the ROC plot represents a sensitivity and
specificity pair that corresponds to a particular decision threshold. The
area under the ROC curve (AUROC) was analyzed to define the
performance of the applied methods. The 95% confidence intervals
(CI) were calculated (see Supplementary Fig. 2). A value of P b 0.05
was considered significant for all statistical calculations. Values are
given as means ± sem.
3. Results
3.1. MRI signal measurements and histopathological correlations
NSG mice were inoculated with CLL cells and autologous T cells
(defined as NSG-CLL) to favor the engraftment of the leukemic clones.
USPIO-enhanced MRI was performed after two weeks and/or after
four weeks in control mice (NSG-CTR, mice that did not receive any
human cells), and in the NSG-CLL mice; results were expressed as
ΔSNR%.
Overall, 24 h after USPIO administration we observed an increase in
SI in the NSG-CLL at two weeks (n = 41) and at four weeks (n = 28)
compared to the NSG-CTR mice. In Fig. 2 two representative
experiments of mice analyzed at four weeks are shown. Fig. 2A and D
show MRI images of NSG-CTR and NSG-CLL after 24 h of USPIO
administration. Fig. 2B and E show spleen IHC analysis of the same
mice displaying the absence of CD20+ cells in NSG-CTR mice and the
presence of focal aggregates of CD20 positive cells in NSG-CLL spleen
surrounded by CD3+ cells (not shown). In addition, Perls' Prussian
blue staining (used to detect USPIO nanoparticles) indicated that ferric
iron particles were excluded from the focal lesions (Fig. 2F) whereas a
randomdistribution of USPIO nanoparticleswas observed in the spleens
of NSG-CTR mice (Fig. 2C).
Fig. 3 summarizes the data obtained from all NSG mice analyzed
including those that did not achieve engraftment [defined as NSG
non-engrafted mice (NSG-CLL-ne)] as demonstrated by the absence of
CD20+ and CD3+ cells when sacrificed for IHC and FC examination
of the spleen at four weeks (data not shown). In addition, at this time,
their peripheral blood did not show presence of huCD45+ cells (data
not shown). The Mann-Whitney U statistical test found a significant
difference (P b 0.0001) comparing the group of NSG-CTR mice to
NSG-CLL mice at four weeks. Interestingly, a significant difference was
also observed when comparing the NSG-CLL mice at two weeks
(P b 0.0001) (Fig. 3A). Significant differences were also observed
comparing measurements of the same NSG-CLL mice at two and four
weeks from PBMC CLL injection (Fig. 3B).
3.2. Cut-off determination
ROC analysis was utilized in order to identify the best cut-off for
ΔSNR% to be used in our experiments for discriminating NSG-CLL mice
from NSG-CTR. The best cut-off values were −4.8 (AUC = 0.97 [95%
CI 0.92–1.0]) at 2 weeks and−6.0 (AUC = 0.99 [95% CI 0.97–1.0]) at
4 weeks (Supplementary Fig. 2).
3.3. Measurements of CLL disease regression in NSG engrafted mice
In order to investigate whether this technique would be useful for
evaluating CLL disease regression upon therapy, NSG-CLL mice were
treated with rituximab. Four mice were treated four times at three-
day intervals using a dosage of 50 μg/mouse, and compared with five
mice injectedwith an identical volume of saline solution (mock-treated
mice).
MRI was carried out in three mock-treated NSG-CLL mice and in
three NSG-CLL treated with rituximab and the relative signal
measurements obtained at therapy start were compared with those
obtained at therapy completion (Fig. 4). The ΔSNR% values showed a
clear reduction in animals treated with rituximab compared to mock-
treated animals (Fig. 4C and D). Differences did not reach statistical
significance likely due to the limited number of animals investigated.
The general strategy of treatments and spleen evaluations is shown in
Supplementary Fig. 1.
Spleen IHC analysis for expression of CD20, Ki67, CD3, and Perls'
Prussian blue staining of mice treated with rituximab or with saline
solution are shown in Fig. 5A and B. Spleen tissue IHC indicates that
the decreasedMRI signal observed in rituximab-treated mice correlates
Fig. 1. Representative slices of the sequence protocol used to measure the signal intensity
(SI) in tissues of interest. The regions of interest (ROIs, white circles) were drawn in the
tissues of interest, spleen and in the region outside the anatomy of the mice
(background noise) in order to measure the signal intensity (SI), as mean ± standard
deviation (SD) and to calculate the signal-to-noise ratio (SNR) as described in Materials
and methods section.
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with the loss of CD20+ cells organized in follicles (clearly observable in
the spleen of mock-treated NSG-CLL mice). In addition, follicle residues
are clearly infiltrated by T cells andUSPIOnanoparticles (Fig. 5B). Spleen
FC analysis showed that huCD45/CD19/CD5+ cells were significantly
less represented in rituximab-treated mice compared to mock-treated
mice. In contrast, the percentage of CD3-positive cells was significantly
higher in mock-treated mice, compared to NSG-CLL mice treated with
rituximab (Fig. 5C and D).
4. Discussion
MRI is a well-suited imaging modality for noninvasive cell tracking
because of its tissue characterization, excellent image quality, and high
spatial resolution, although currently nuclear imaging is a more
sensitive technique. Furthermore, MRI advantages include lack of ioniz-
ing radiation, flexible image contrast, and the ability to assess localized
function, perfusion, and necrosis. MRI offers the potential of tracking
cells in vivo using innovative approaches and contrast media as well
as cell labeling and image acquisition.
In this study, we used MRI to track CLL cell seeding in a xenograft
mouse model. We first observed that changes in spleen organization
could be identified four weeks after CLL cell inoculation and analyzed
by means of a high field 3T clinical scanner and USPIO nanoparticles.
We used FIESTA acquisition because our previous observations
indicated that it was suitable and also high sensitive in conditions of
very low iron oxide nanoparticle concentrations [37] rendering this
sequence the best option for the study of single cell iron oxide nanopar-
ticles [33]. Histologic examination of the same spleens confirmed the
presence of CD20+ nodular structures (see Fig. 2) surrounded by
CD3+ cells (not shown). In addition, Perls' Prussian blue staining
demonstrated that iron particles were excluded from the nodular
areas occupied by lymphoid cells, providing a rational explanations for
the MRI signals observed. The combination of extracellular with
intracellular iron oxide nanoparticles compartmentalization within the
CLL spleen, affected iron oxide proton relaxivity, which sometimes
resulted in an increase rather than in the usual and expected SI
decrease. This high T2-USPIO effect has also been reported by Simon
G.H. et al. [38].
Fig. 2.Magnetic resonance image signal determination and histological analysis in control (NSG-CTR) compared to engrafted (NSG-CLL) mice. The figure shows representative in vivo
USPIO magnetic resonance images (MRI) obtained after 24 h of USPIO administration in a NSG-CTR (A) and NSG-CLL mouse (D). The position of the spleen is indicated by the red
outline. Matched histology sections (magnification, 100×) show the absence (B) or the presence (E) of CD20 (red) and Ki67 (brown) positive cells; Perls' Prussian blue ferric iron
staining (C and F) allows the detection of USPIO nanoparticles.
Fig. 3. Comparison of magnetic resonance image signal intensity change in the spleen of control (NSG-CTR), engrafted (NSG-CLL) at 2 and 4 weeks and non-engrafted (NSG-ne) mice.
(A) The scatter dot plot represents percentage signal-to-noise ratio change (ΔSNR%) of the MRI acquisition analysis comparing NSG-CLL mice at 2 weeks (red dots) and 4 weeks (blue
dots) from peripheral blood mononuclear cell (PBMC) CLL injection, NSG-CTR mice (black dots) and NSG-ne (grey dots, evaluated at 4 weeks from PBMC CLL injection). Values of
ΔSNR% are expressed as mean ± sem. NSG-CTR mice: −42.16 ± 5.6; NSG-CLL at 2 weeks: +16.32 ± 3.95; NSG-CLL at 4 weeks: +30.49 ± 4.0; NSG-CLL-ne mice: −37.21 ± 5.5.
Statistical comparisons were carried out using the Mann-Whitney U test. A P-value b 0.0001 is indicated by *** and P = 0.017 by *. (B) Comparison of MRI signals detected in the same
mice 2 weeks (red dots) or 4 weeks (blue dots) from PBMC CLL injection (P = 0.02 Wilcoxon-matched pair test).
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FC analyses of splenic cell suspensions showed that huCD45+
cells were comprised of CD19/CD5+ cells and a variable proportion
of CD3+ cells (not shown). An analogous approach of using FC to
measure circulating T and B cells can be employed to assess the
take of CLL engraftment in NSG mice although this method may be
misleading, as leukemic cells can be difficult to track due to their
extremely low number in peripheral blood. In addition, when
tracked, the leukemic cells may represent cells merely surviving
after the injection. Indeed, 17/19 non engrafted mice showed the
presence of huCD45/CD19/CD5 cells (representing the bona fide
the leukemic clone). In contrast USPIO enhancedMRI spleen analysis
was able to consistently assess the engraftment of CLL cells two
weeks after their injection (see Fig. 3), as could also be confirmed
by IHC evaluation.
A reliable assessment of CLL engraftment two weeks after leukemic
clone inoculation is most advantageous given that this animal model
does not allow long term persistence/expansion of the inoculated
leukemic cells beyond 6–8 weeks. Thereafter, mice can develop a
graft-versus-host disease that may cause also the reduction and even
disappearance of the leukemic cells [11]. In addition, leukemic cells
can mature into plasmablasts/plasma cells [39]. The above limitations
might impair the experimental data, particularly when drug treatments
are evaluated, because this time-framemay not be sufficient to provide
information on the long term effect of drugs.
We also report the possibility of identifying a cut-off value for
ΔSNR% able of discriminating NSG-CLL from NSG-CTR or NSG-ne mice.
A similar cut-off value was used to identify the different disease
extension at two and four weeks after inoculum in NSG-CLL mice. The
identification of a relatively precise cut-off value allows investigators
to reliably define when a single mouse can be considered engrafted or
not and make decisions regarding the subsequent experimental
procedures. This analysis however requires standardization on the
instrument(s) used for the image acquisition.
USPIO-enhanced MRI also was able to detect CLL disease regression
after rituximab treatment of engrafted mice. MRI images, acquired be-
fore and following treatment, MRI images detected definite changes
with an inversion of the ΔSNR% value (see Fig. 4). IHC showed a radical
change in the architecture of the spleen of treated animals compared to
controls. Following treatment, lymphoid infiltrates were mainly repre-
sented by unorganized T lymphocytes with the loss of the typical
Fig. 4.Representative experiment of treatmentwith rituximab. Thefigure shows a representative in vivoUSPIOmagnetic resonance image (MRI) obtained 24 h after USPIO administration
in a NSG-CLL mouse treated with saline solution (A) and a NSG-CLL mouse treated with rituximab (B). The position of the spleen is indicated by the red outline. MRI images show
acquisition at therapy start (T.S.) and at therapy completion (T.C.). The scatter dot plots (C) and (D) display data for each mouse and percentage signal-to-noise ratio change (ΔSNR%)
mean values are calculated for each treatment-mice group (n = 3) and the control NSG-CTR group.
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CD20+ nodular areas. Tissue Perls' Prussian blue stain confirmed the
diverse disposition of USPIO nanoparticles (Fig. 5). Thus, this technique
clearly distinguishes between the different types of lymphoid infiltrates
on the basis of their organization.
Another point that should be underlined is that the use of this tech-
nique limits the number of animals to be tested and sacrificed. This is
important for several reasons: first, it requires fewer leukemic cells for in-
jection thus sparing other cells for additional experimental procedures.
Although a large number of CLL cells can generally be recovered from
CLL patients, a typical experiment may require more than half a billion
cells, a quantity often obtained from selected patients only. Second, this
approach facilitates clearance of animal experimentation protocols by
ethics committees. Currently, animal testing regulations pay increasingly
more attention to the procedures and the experimental settings applied,
encouraging the use ofmethods that limit animal sacrifice (and ultimate-
ly suffering of animals). A related point is the control of experimental
variability, as only animals with evidence of disease are used to complete
the experimental procedures with no additional trauma.
5. Conclusions
In summary, we present here an in vivo imaging approach for mon-
itoring CLL disease evolution in a pre-clinical model of CLL using
xenografted immunodeficientmice.MRI is a valuable, non-invasivemo-
dality to predict progression in our CLL-model. In addition, by anticipat-
ing the timing of CLL engraftment, applications of MRI may include
in vivo monitoring of new therapies thus allowing a longer temporal
window to evaluate treatment efficacy and the possible emergence of
therapy resistant clones.
Finally, this method may have potential application in the clinical
setting and may be used to evaluate organ involvement in CLL disease,
allowingmore accurate staging without exposing patients to additional
radiation.
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Fig. 5. Representative immunohistochemistry and flow cytometry analysis of mouse spleens from a rituximab experiment. The figure shows the histologic analysis carried out for the
presence of CLL cells (CD20, red), proliferating cells (Ki67, brown), T cells (CD3, red) and USPIO nanoparticles (Perls' Prussian blue) in the NSG-CLL mice treated with saline solution
(A) and in NSG-CLL mice treated with rituximab (B). Magnification 40× (left panels) and 200× (right panels). In panels C and D, the scatter-plots show the presence of CLL cells and
autologous T-cells, respectively, evaluated by flow cytometry (CD45+/CD19+/CD5+ or CD45+/CD19−/CD5+), indicating a significant decrease of the percentage of CLL cells in the
group of mice treated with rituximab (n = 4) compared to the control group treated with saline solution (n = 5). Statistical comparisons were carried out by Wilcoxon test.
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Introduction
The efficacy of iron oxide nanoparticles as a macrophage-
monocytic phagocytic system (MMPS)–specific contrast 
agent for liver, spleen, and lymph node MRI has been 
demonstrated in experimental and clinical studies. Several 
studies have shown that these particles can significantly 
improve the detection and characterization of focal lesions 
within these organs¹. Due to their size-dependent 
properties and their applicability in non-invasive imaging 
methods, these materials are promising candidates for 
research, diagnostic, and therapeutic applications in various 
fields such as cancer, neurodegenerative diseases (e.g. 
multiple sclerosis, stroke) as well as inflammatory diseases 
(e.g. rheumatoid arthritis, atherosclerosis)². In our study, we 
focused on a specific mouse xenogeneic transplantation 
model, NOD/LtSz-scid/scid (NOD/SCID), of chronic 
lymphocytic leukemia (CLL)³. CLL is a type of slow growing 
leukaemia, characterized by a gradual increase in the 
number of B lymphocytes, first in the blood and bone 
marrow and, as the disease progresses, in the lymph nodes, 
liver, and spleen. In particular, computed tomography (CT) 
is used as the first-line modality for imaging of lymphoid 
malignancies but, specifically for CLL, the role of CT has not 
yet been clearly defined⁴. In order to prevent the exposure 
of the CLL patient to irradiation, we aimed to establish a 
specific MRI method to better visualize the presence of the 
disease within the spleen using a pre-clinical setting.
Materials and methods
FeraSpin™ XS consisting of USPIO nanoparticles, with a 
mean particle size of 10–20 nm, was used as MRI contrast 
agent. Upon intravenous injection, FeraSpin XS 
nanoparticles circulate in the bloodstream and are taken up 
by macrophages, including those in the liver and spleen 
(reticulo-endothelial system, RES). Two groups of mice were 
injected with the contrast agent: one group of healthy NOD/
LtSz-scid/scid (NOD/SCID) mice (NSG; n=2) and another 
group of NOD/SCID mice injected with chronic MG0248-CLL 
cells (NSG-CLL; n=4), which served as a xenogeneic mouse 
transplantation model³. Scanning was performed on a 
clinical 3T MR scanner (Signa® EXCITE® HDxT, GE Healthcare, 
Milwaukee, USA) and the mice were positioned in a 
prototype coil (linear birdcage transmit/receive coil, 
100 mm length, 55 mm diameter, tuned at 127.6 MHz, Flick 
Engineering Solutions B.V., Netherlands; General Electric 
Company) placed on a warm plate to prevent animal 
hypothermia. Imaging was performed on both animal 
groups before and 24 hours after administration of 
100 μL/25 g mouse of FeraSpin XS, corresponding to a dose 
of 40 μmol Fe/kg body weight. In the healthy animal group 
(NSG) imaging was also performed 6 days and 14 days after 
contrast agent injection. Both qualitative and quantitative 
analyses were performed with a FIESTA sequence (fast 
imaging employing steady state acquisition) as described in 
literature⁵. Regions of interest (ROI) were defined and the 
signal intensities in  
the liver and spleen of each mouse were calculated. 
Histological analysis was performed according to standard 
techniques on the NSG and NSG-CLL mice, 28 days and  
6 days post injection (p.i.) of FeraSpin XS, respectively. 
Immunohistochemistry of the spleen using anti-
human-CD20 antibody was performed to demonstrate the 
human CD20+ CLL cell aggregates. Perls’ Prussian blue 
staining was conducted for the detection of iron.  
A quantitative assessment by estimation of iron-positive 
cells was performed using an Olympus BX4l microscope.
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Results and discussion
NSG mice (control)
In the NSG mice, at 24 hours p.i. of FeraSpin XS, a strong 
decrease in signal intensity (SI) in the liver (80%) and spleen 
(50%) has been observed (figure 1A,B). In order to 
investigate the time-dependent SI in the healthy animal 
group, we repeated the imaging acquisition at 6 and 14 
days after contrast agent administration. While the SI of the 
liver was found to increase and reach a baseline level at 14 
days p.i., the SI of the spleen remained constant over the 
imaging time period. Additionally, we performed a 
histopathological analysis on the liver and spleen by Perls’ 
Prussian blue staining at 28 days p.i. of FeraSpin XS. Only 
very few iron oxide nanoparticles were observed in both 
organs indicating that the nanoparticles are cleared from 
the liver and spleen in the healthy animal group within one 
month. 
 
NSG-CLL mice (tumor)
In the NSG-CLL mice, at 24 hours p.i. of FeraSpin XS, a 
significant decrease in SI (60%) was observed in the liver but, 
in comparison, only a slight decrease in the SI (20%) was 
observed in the spleen (figure 2A, B). 
Immunohistochemistry of the liver and spleen using the 
anti-human-CD20 antibody to reveal the focal aggregates 
of human CD20+ CLL showed that these aggregates were 
localized only in the white pulp of the spleen (figure 1C) and 
close to the vessels within the liver (data not shown). 
Interestingly, iron oxide nanoparticles were detectable only 
in the red pulp (healthy area) of the spleen and were found 
to be absent in the white pulp, where the CLL cells were 
localized. 
Our findings demonstrate that after FeraSpin XS 
administration, a significant initial decrease in SI is observed 
in the healthy liver and spleen (NSG mice), which is 
attributed to phagocytosis of iron oxide nanoparticles by 
the reticulo-endothelial cells. In the NSG-CLL mice, however, 
a reduced uptake of FeraSpin XS by the spleen is observed 
and is due to the presence of the CLL foci within the white 
pulp. This report demonstrates the suitability of the MRI 
method to detect the presence of a non-solid tumor, such 
as chronic lymphocytic leukemia, within the spleen. The 
clearance of iron oxide nanoparticles within the spleen after 
28 days p.i. in the healthy group of mice offers the potential 
to apply this technique for the MR imaging follow-up of CLL 
mouse models in order to evaluate the response to therapy.
Figure 1: NSG mice
A) Coronal MR images before, 24 hours, 6 days, and 14 days after 
FeraSpin XS administration. Signal intensity changes are observed in 
the liver (asterisk) and spleen (arrow).
B) Time-dependence of SI in the liver and spleen before and after 
FeraSpin XS administration. 
C) Histopathological analysis of the healthy spleen by Perl’ Prussian 
blue staining 28 days after FeraSpin XS administration reveals only few 
nanoparticles present.
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Figure 2: NSG-CLL mice
A) Coronal MR images before and 24 hours after FeraSpin XS 
administration. Signal intensity changes are observed in the liver 
(asterisk) and spleen (arrow). 
B) Time-dependence of SI in the liver and spleen before and after 
FeraSpin XS administration.
C) Immunohistochemistry with anti-human-CD20 antibody reveals that 
CLL cells are localized in focal aggregates in the white pulp of the 
spleen.
D) Histopathological analysis of the spleen by Perls’ Prussian blue 
staining 6 days after FeraSpin XS administration shows that iron oxide 
nanoparticles are present only in the red pulp of the spleen; no 
nanoparticles are present in the white pulp where the CLL cells are 
localized.
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ORIGINAL ARTICLE
Effects of miRNA-15 and miRNA-16 expression replacement
in chronic lymphocytic leukemia: implication for therapy
G Cutrona1, S Matis1, M Colombo1, C Massucco1, G Baio2,15, F Valdora1,3, L Emionite4, S Fabris5, AG Recchia6,7, M Gentile6,7,
CE Neumaier2, D Reverberi1, R Massara1, S Boccardo8, L Basso9, S Salvi8, F Rosa9, M Cilli4, S Zupo10, M Truini8,16, P Tassone11,
M Calabrese2, M Negrini12, A Neri5,13, F Morabito6,7, F Fais1,3 and M Ferrarini14
Chronic lymphocytic leukemia (CLL) clones are characterized by loss of a critical region in 13q14.3, (del(13)(q14)) involving the
microRNA (miRNA) cluster miR-15a and miR-16-1. We have investigated the effects of replacement of miR-15a and miR-16-1. CLL
cells transfected with these miRNA mimics exhibited a decrease in cell viability in vitro and impaired capacity for engraftment and
growth in NOD/Shi-scid,γcnull (NSG) mice. No synergistic effects were observed when the two miRNA mimics were combined. The
phenomena were not restricted to CLL with the del(13)(q14) lesion. Similar effects induced by miRNA mimics were seen in cells with
additional chromosomal abnormalities with the exception of certain CLL clones harboring TP53 alterations. Administration of
miRNA mimics to NSG mice previously engrafted with CLL clones resulted in substantial tumor regression. CLL cell transfection with
miR-15a and miR-16-1-specific inhibitors resulted in increased cell viability in vitro and in an enhanced capacity of the engrafted
cells to grow in NSG mice generating larger splenic nodules. These data demonstrate that the strong control by miR-15a and
miR-16-1 on CLL clonal expansion is exerted also at the level of full-blown leukemia and provide indications for a miRNA-based
therapeutic strategy.
Leukemia (2017) 31, 1894–1904; doi:10.1038/leu.2016.394
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is characterized by the
monoclonal expansion of B cells expressing CD19, CD5 and
CD23 and low levels of surface immunoglobulin.1 The mechanisms
underlying the disease have only been partially elucidated. In CLL,
well-defined chromosomal abnormalities, such as deletions at (17)
(p13.1), (11)(q22.3) or trisomy 12 (+12) are infrequent at early
stages and more common in patients with more advanced disease
or at relapse. Therefore, these lesions are unlikely to contribute to
the initial pathogenetic mechanisms, although they may be
involved in both disease progression and resistance to therapy.2–8
The 13q14.3 (del(13)(q14)) deletion represents a remarkable
exception, as it is observed in approximately 50% of cases either in
a mono- or biallelic form and is also present in the early disease
stages,4,9 including monoclonal B cell lymphocytosis or MBL,10,11
suggesting a pathogenetic role. The deletion identified involves
primarily the DLEU2 gene which carries the locus of two
microRNAs (miRNAs): miR-15a and miR-16-1 (miR-15 and miR-16,
respectively).12–17 MiRNAs are single stranded, non-coding RNA,
which are evolutionary conserved and capable of regulating the
expression of several genes concomitantly.18 The regulation of
gene expression occurs mainly through the specific binding of
miRNAs to the 3′-un-translated region (3′-UTR) of the messenger
RNA of the target gene via a RNA-induced silencing complex,19
although additional mechanisms have been described.20
Biallelic del(13)(q14) results in an incapacity of the cell to
express miR-15 and miR-1614,15,17,21,22 (Supplementary Figure S1) and
the deregulation of several target genes, including those involved
in cell cycle progression and apoptosis.23–25 This confers an
increased resistance to apoptosis and a propensity to leukemic
cell proliferation. Low levels of miR-15 or miR-16 are observed in
patients with monoallelic deletions and in many patients without
del(13)(q14).15,21,22,26–28 Additional support for the role of the
miR-15/miR-16 locus in CLL pathogenesis comes from the New
Zealand Black (NZB) mice strain harboring a germ-line point
mutation downstream of the miR-16 locus, which prevents normal
expression of both miR-15 and miR-16 and facilitates leukemia onset
and possibly autoimmune manifestations.29 An analogous lesion,
present in particular families, genetically predisposes humans to
CLL and possibly to other neoplasias.30 Finally, the selective
deletion of the miR-15/miR-16 locus in mice predisposes the
development of a CLL-like leukemia.16,31 Therefore, impairment of
miR-15 and miR-16 function may be involved in promoting the
initial phases of leukemogenesis; however, little is known
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regarding the role of these lesions in maintaining the transformed
status and the clonal expansion of full-blown leukemia.32
Here, we investigated the possibility of interfering with both
miR-15 and miR-16 expression by CLL cells, both in in vivo and
in vitro.
MATERIALS AND METHODS
Patients and CLL cell preparations
Newly diagnosed CLL patients from participating Institutions were enrolled
within 12 months from diagnosis in the O-CLL1 protocol (clinicaltrial.gov
identifier NCT00917540). All participants provided written informed
consent in accordance with the declaration of Helsinki and the study
was approved by the appropriate institutional review boards. Supple-
mentary Table S1 summarizes the phenotype and the major cytogenetic
features of CLL cases (n=59) selected for in vitro (n= 48) and in vivo
(n=17) experiments reported in this study.11,33,34
PBMCs from patients with CLL were isolated by Ficoll-Hypaque
(Seromed, Biochrom, Berlin, Germany) density gradient centrifugation. In
selected experiments, CD19-positive CLL cells were enriched by negative
selection with the EasySep-Human B-cell Enrichment Kit without CD43
depletion (STEMCELL Technologies, Voden Medical Instruments S.p.A,
Milan, Italy).
Cell transfection
MirVana miRNA mimics or inhibitors (Ambion, Inc., Thermo Fisher
Scientific, Grand Island, NY, USA) were delivered to CLL cells with a Neon
Transfection System (Invitrogen, Thermo Fisher Scientific) at the final
concentration of 50 nM/2× 106 CLL cells. Optimal transfection and survival
of CLL cells was obtained by applying 1 pulse at 2150 pulse voltage and 20
pulse width, as indicated by the manufacturer for the primary blood-
derived suspension cells protocol. After transfection, cell suspensions were
seeded in 24-well plates containing 500 μl of culture medium without
antibiotics (RPMI-1640 with L-glutamine and 10% FBS (Gibco, Thermo
Fisher Scientific, Paisley, UK), Sodium piruvate 0.1% (Euroclone, Pero, Milan,
Italy) at 37 °C and incubated at the final concentration of 2 × 106 CLL cells/
ml/well in a 5% CO2 atmosphere. The following miRNA mimics and
inhibitors were employed: hsa-miR-15a-5p, hsa-miR-16-5p, and miRNA
Negative Control (CTR)#1, miRNA Inhibitor Negative CTR #1.
Evaluation of miRNA expression
MiR-15 and miR-16 expression was evaluated with two methods:
SmartFlare RNA Detection Probes (Merck Millipore, Guyancourt, France)
in n=13 CLL cases and quantitative real time PCR (qRT–PCR; n= 38 CLL
cases; Supplementary materials and methods and Supplementary
Figure S2).
SmartFlare technology is useful to study miRNA expression at the single-
cell level. SmartFlare RNA Detection Probes, are constituted by tiny gold
nanoparticles conjugated to oligonucleotides duplexed with reporter
strands (oligo+fluorophore). When Smartflare probes bind to their
complementary RNA sequences the fluorophore is released and can be
detected by flow-cytometry (FC). The following Smartflare probes
conjugated with the Cyanine 5 (Cy5) fluorophore were used: SF-430/
miR-15a-5p (miR-15 CY5); SF-178/ miR-16-5p (miR-16 CY5); SF-102/
Scramble CTR Cy5. The latter reagent does not bind to any RNA sequences
within the cells and is used to measure the level of background
fluorescence within CLL cells. Cells were incubated with Smartflare probes
overnight, harvested and analyzed by FACSCanto (BD Biosciences, San
José, CA, USA) and DIVA 6 (BD Biosciences) or FLOWJO V.9.8.3 software
(Treestar, Inc., Ashland, OR, USA).
Counter staining with propidium iodide (PI; 50 mg/ml, Sigma-Aldrich,
Milan, Italy) in isotonic solution was employed to evaluate cell viability.
Changes in miR-15/miR-16 expression following transfection with miRNA
mimics or inhibitors were expressed as: % fold induction= (%smartflare
positive cells transfected with miR-15/miR-16 mimic)—(%smartflare
positive cells transfected with miR-CTR mimic)/(%smartflare positive cells
transfected with miR-15/miR-16 mimic) × 100% fold inhibition= (%smart-
flare positive cells transfected with miR-CTR inhibitor)—(%smartflare
positive cells transfected with miR-15/miR-16 inhibitor)/(%smartflare-
positive cells transfected with miR-CTR inhibitor) × 100.
Apoptosis assays
Cultured cells were double stained with Annexin-V-FITC conjugate (cat.
556419, BD Biosciences Pharmingen, San Josè, CA, USA), and PI in isotonic
solution, and then analyzed by FC. Viable cells were defined as double
negative cells.35
Xenogeneic mouse transplantation
Six- to 8-week-old female NOD/Shi-scid,γcnull (NSG) mice (The Jackson
Laboratory), a xenograft model for CLL growth in vivo36,37 were
housed in sterile enclosures under specific pathogen-free conditions.
All procedures involving animals were performed in the respect
of the current National and International regulations and were
reviewed and approved by the Licensing and Animal Welfare Body of
the IRCCS-AOU San Martino-IST National Cancer Research Institute,
Genoa, Italy.
Depending on the number of leukemic cells available for animal
injection, groups of 2–3 NSG mice were employed for each test and
treatment group. The number of animals used for each treatment is
detailed in brackets in Table 1 and Supplementary Tables S3–S5. Full
details are in Supplementary Material and Methods.
In miRNA pre-treatment experiments NSG mice (n=38) were inoculated
with CLL cells (n= 6) transfected with miRNA mimic/inhibitors and cultured
for 6 h prior to injection. A total of 50 × 106 CLL cells per mouse were
injected together with a proportion of autologous T cells (~5–10%).
After four weeks, mice were anesthetized by intraperitoneal injection of
combination of xylazine (10 mg/kg) and ketamine (100 mg/kg) and
analyzed by Magnetic Resonance Imaging (MRI) with USPIO contrast
reagent.38
On termination of the experiment (maximum 6 weeks from start),
animals were sacrificed in a saturated CO2 chamber and autopsies were
performed. Spleens were evaluated by FC and by immunohistochemical
(IHC) analysis. The Animal Welfare Body posed a time limit to the
experimental protocol to prevent unneeded suffering.
Fresh spleen samples were enzymatically digested using the Spleen
Dissociation Kit (Miltenyi Biotec) and mechanically resuspended with
gentleMACS™ Dissociator (Miltenyi Biotec). The single-cell suspensions
were stained with anti-human CD45-FITC (555482), CD19-PECy7(557835),
CD5-APC(555355), (BD Biosciences) and analyzed by FC. Apoptosis was
evaluated using Annexin-V-FITC, CD19-PE-Cy7, CD5-PE (555353) (BD
Biosciences), CD45-APC(130-091-230, Miltenyi Biotec,) cell staining.
Formalin-fixed and paraffin-embedded spleen specimens were analyzed
for the presence of human CLL infiltrates and for the presence of co-
injected bystander T-cells by IHC as detailed above.38 The primary
antibodies anti-CD20 Mouse monoclonal antibody (760-2531, clone L26-
Ventana Medical System, Roche) and CD3 Rabbit Monoclonal Antibody
(790-4341, clone 2GV6—Ventana Medical System, Roche) were incubated
for 30 min at 37 °C and signals revealed using the polymeric detection
system, Ultraview Universal Red Detection Kit (Ventana Medical System).
An appropriate positive tissue control was used for each staining run; the
negative control consisted of performing the entire IHC procedure on
adjacent sections in the absence of the primary antibody; the sections
were counter-stained (automatically) with Gill's modified hematoxylin and
then cover-slipped. The sections were evaluated by two observers with an
Olympus light microscope using 4, 10, 40 × and objectives under a Leica
DMD108 optical digital microscope (Leica Microsystems, Wetzlar,
Germany).
To evaluate therapeutic effects of miRNA, CLL (n = 11) engraftment in
the spleen was determined by MRI following USPIO contrast reagent
injection after 2–3 weeks from cell injection. At this stage, mice were
treated intraperitoneally (every second day with mirVana miRNA mimic,
(In Vivo Ready formulation, Ambion, Inc.) complexed with Invivofecta-
mine 2.0 (Thermo Fisher Scientific) at a final concentration of 0.7 mg/ml
(200 μl/mouse). Overall three doses were administered. The following
miRNA were used: hsa-miR-15a-5p, hsa-miR-16-5p, miRNA negative
control#1. Three days from the last injection, mice (n= 74) were analyzed
again by MRI and then sacrificed in a saturated CO2 chamber and
autopsies were performed. Spleens were analyzed by FC and IHC.
Apoptosis was evaluated by Annexin-V-FITC, CD19-PE-Cy7, CD5-PE,
CD45-APC, and FC or by Cleaved Caspase-3 (Asp175) (5A1E) Rabbit
mAb (9664, Cell Signaling Technology, Danvers, MA, USA) and IHC on
spleen tissue sections.
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Magnetic resonance imaging
All in vivo MRI experiments and MRI analyses, using USPIO nanoparticles,
were carried out and acquired as previously described.38 Details are
reported in the Supplementary Information.
Definition of IHC index
The IHC index is a measure of the spread of leukemia based on the average
diameters of the follicular lesions. We assigned a numerical value of 1 to
the follicles with diameters ± s.d. of 102(±90) × 42(±7) μm; a value of 3 to
follicles with a diameter 195(±80) x 138(±85) μm; a value of 6 to follicles
between 399(±245) × 300(±39), and a value of 12 to follicles between 734
(±461) × 540(±167). The IHC index is given by the sum of the number of
follicles multiplied by the value assigned according to size (Supplementary
Figure S3).
Statistical analysis
The statistical package SPSS for Windows, v13.0, 2004 software (SPSS,
London, UK) was used for all analyses of statistical significance from
adequately powered sample sizes for two-tailed tests. Statistical compar-
isons between related samples were carried out by nonparametric
Wilcoxon signed rank (paired data) or by Mann–Whitney U- (unpaired
data) tests. A value of Po0.05 was considered significant for all statistical
calculations. Values are given as mean± s.e.m. or mean± s.d. as stated in
figure legends, which was calculated invariably from n (the number of
patients or animals, biological replicates). All exact P-values are provided in
the figure panels, in figure legends or in Results section.
RESULTS
Transfection of miR-15 and miR-16 mimics or inhibitors into CLL
cells in vitro
Transfection of miRNAs mimics or inhibitors into purified CLL
cells was verified by FC using Smartflare technology and
qRT–PCR.
For the experiments with miRNA mimics, 7 CLL cases with
biallelic del(13)(q14) deletions were selected (Supplementary
Information and Supplementary Table S1 for case characteristics).
At 24 h after transfection, a significantly larger number of cells
were found to express miR-15 (%fold induction = 79± 5, mean±
s.e.m.) and miR-16 (%fold induction=75±5) compared with control
preparations (P= 0.015; Figure 1a and Supplementary Figure S4a).
Comparable data were obtained by qRT–PCR (Supplementary
Figure S2a).
For experiments with miRNA inhibitors, we selected 6 CLL cases
that did not display biallelic del(13)(q14) and expressed miR-15
and miR-16 to a variable extent. Transfection with specific miRNA
inhibitors efficiently reduced miRNA expression in all CLL clones
Figure 1. Transfection with miRNA mimics and inhibitors and variations in CLL cell viability in vitro. (a) Expression of miR-15 and miR-16
following transfection with miR-15 (% of positive CLL cells mean± s.e.m.= 55.7± 5.2) or miR-16 (49.1± 7.6) or miR-CTR mimics (10.9± 2.2 for
miR-15; 10.8± 1.9 for miR-16) determined by smartflare technology. Summary of tests on 7 CLL cases with biallelic del(13)(q14) (MG0248,
DT0300, MA0088, LD0062, GM0041, RD0296 and GD0051). (b) Summary of viability determinations obtained on cells from 12 different biallelic
del(13)(q14) CLL cases after a 48-h culture following transfection of the indicated miRNA mimics (data for individual cases are reported in
Supplementary Figure S6a). The asterisks indicate data from a CLL case (CG0620) harboring the TP53 mutation (Supplementary Table S1).
(c) Expression of miR-15 and miR-16 following transfection with miR-15 (23.17± 3) or miR-16 (16.5± 2.8) or miR-CTR inhibitors (50.17± 6.4 for
miR-15; 38.17± 4.2 for miR-16). Summary of tests on 6 CLL cases (CP0036, CR0203, PA0145, PM0608, CG0623, MA0342). (d) Summary of the
viability results obtained on cells from 24 CLL cases transfected with miRNA inhibitors. In (a) and (c) purified CLL cells were transfected with
the indicated miRNA mimics or inhibitors and cultured overnight in the presence of miR-15-CY5, miR-16-CY5 or scramble CY5 Smartflare
probes. Counter staining with propidium iodide (PI) was employed to evaluate cell viability (see also Supplementary Figure S4). In b and d
viable cells (%) are measured as Annexin-V/PI-double negative cells (Supplementary Figure S5). The P-values were obtained by Wilcoxon test
in all panels.
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compared with controls (%fold inhibition = 54 ± 4, mean± s.e.m.,
for miR-15; and %fold inhibition = 59± 4 for miR-16) (P= 0.03)
(Figure 1c and Supplementary Figure S4b). Again, comparable
data were obtained when miRNA expression was measured by
qRT–PCR (Supplementary Figure S2b).
As miR-15 and miR-16 expression may impact on CLL cell
survival in vitro, purified cells from 12 CLL cases with biallelic del
(13)(q14) were transfected with miR-15 or miR-16 miRNA mimics
and cultured for up to 72 h. Viable cells were measured at different
time intervals (Supplementary Figure S5a shows the data of a
representative experiment). A significant decrease in cell viability
(%fold reduction mean± s.e.m. = 53 ± 7 and 48 ± 6 for miR-15 and
miR-16 mimics, respectively in 11/12 CLL samples) after 48 h
(P= 0.001 for miR-15 and P= 0.0015 for miR-16) was observed.
Figure 1b shows the pooled data from the tests performed while
experiments on individual CLL cases are reported in
Supplementary Figure S6a. Viability of cells from the CLL case
CG0620, carrying a TP53 mutation, did not change, but the cells
from two other CLL cases (MG0248, PA0254), also displaying TP53
mutations, showed a substantial drop in cell viability following
Figure 2. CLL cell engraftment in NSG mice following in vitro transfection with miRNA mimics or inhibitors. Representative tests on mice
engrafted with CLL cells pre-treated in vitro with miRNA mimics (CLL CD0310), miRNA inhibitors (CLL PM0608), or miRNA-CTR. (a and b) The
figure shows the MRI images 24 h after USPIO administration. The position of the spleen is indicated by the dotted red outline. ΔSNR% values
also are indicated. The spleens with superior iron uptake and consequent lower ΔSNR% values, appear darker and less nodular. Conversely,
spleens with lower iron uptake and higher ΔSNR% values are not so dark and show a nodular structure possibly related to the presence of
follicles. Additional explanations are given in text. (c and d) α-CD20 Ab staining (red) of paraffin tissue embedded spleen samples following
injection of CLL cells pre-treated with the indicated miRNA (d). The CD20+ follicle-like structures are highlighted by red squares in c
(magnification × 40). The × 400 magnification of a representative follicle for each panel is shown. IHC index is indicated in each panel. (e and f)
Flow-cytometry analysis of cells from of the same spleens used for the IHC analyses shown in (c) and (d). CLL cells (CD5+/CD19+) and T cells
(CD5+/CD19-) were identified on gated huCD45-positive cells (Supplementary Figure S8). (e) Pooled flow-cytometry data obtained from 4 CLL
cases with biallelic del(13)(q14) pre-treated with miRNA mimics in vitro before injection into mice (n= 8 mice for each treatment group). The
cells, harvested from mice at the end of tests, were stained and counted. Statistical comparisons were carried out using Wilcoxon-matched
pair test. A P-value= 0.0078 is indicated by **. (f) Pooled flow-cytometry data on cells from 2 CLL cases with normal FISH pre-treated in vitro
with miRNA inhibitors prior to injection into mice (n= 5 mice for miR-CTR, n= 4 for miR-15 and n= 5 for miR-16 inhibitors). *P= 0.016 and
**P= 0.007, respectively (Mann–Whitney U-test). In e and f values are expressed as mean± s.d. and detailed in Supplementary Table S3.
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transfection with either miR-15 or miR-16 (Supplementary Table S1
and Supplementary Figure S6a).
Co-transfection of biallelic del(13)(q14) CLL cells with both
miR-15 and miR-16 miRNAs never resulted in an additive/
synergistic effect (data not shown). Consistent with previous
observations, transfection of miR-15 or miR-16 into del(13)(q14)
CLL cells caused down-regulation of BCL-2 or MCL1 (antiapoptotic)
and of Cyclin D1 or D2 (cell cycle induction) proteins encoded by
target genes of these miRNAs.23,24 In contrast, Survivin, which is
involved in an alternative apoptotic pathway, was not down-
regulated (Supplementary Figure S6b–c).
Inhibition of miR-15 or miR-16 expression with specific miRNA
inhibitors resulted in a substantial increase in CLL cell viability.
Supplementary Figure 5b reports the cell viability of a representa-
tive CLL case. A significant increase in cell viability was measured
until 48-hours culture, whereas at 72 h, a drop in cell viability
was observed both in the presence of miR-15/miR-16 inhi-
bitors and in the presence of miR-CTR inhibitor, although there
were still differences in the two conditions. Pooled viability data,
measured after a 48-h culture from a group of 24 CLL cases
displaying different cytogenetic features (Supplementary Table S2
and Supplementary Figure S7), are summarized in Figure 1d
(%fold increase = 40± 3 and 42 ± 4 with miR-15 or miR-16
inhibitor, respectively; Po0.0001) and show that miRNA inhibition
expression resulted consistently in a better in vitro survival of
CLL cells.
Figure 3. Effects of in vivo treatment with miRNA mimics on CLL cells engrafted in NSG mice. (a and b) MRI analysis of the spleen before and
after the indicated treatment (representative experiment with cells from MP0456 CLL case). (MRI) images obtained 24 h after Spleens which
are characterized by high USPIO uptake appear darker and less granular, a finding which correlates with a low presence of leukemic follicles.
See text and legend to Figure 2 for additional details. (c) Summary of MRI results observed on cells from 6 CLL cases biallelic for del(13)(q14)
treated with the indicated miRNA mimics. After 2 weeks from CLL cells injection (NSG-CLL, gray dots), mice displayed ΔSNR% values
significantly higher compared with those not receiving CLL cells (NSG-CTR, green dots). NSG-CLL mice treated with miR-15 (red dots) or
miR-16 (blue dots) mimics had significantly different MRI patterns from the same mice before therapy or after treatment with miR-CTR (black
dots). (d) Summary of the flow-cytometry analysis of freshly isolated cells from the same spleens analyzed in (c). Percentages of CD19+CD5+
CLLs cells or CD19-CD5+ T cells detected by gating CD45+ cells are expressed as mean± s.d. (e) Summary of the IHC analysis of splenic tissue
stained by α-CD20 mAb. In c–e each dot represents an individual mouse. Values also are expressed as mean± s.d. Statistical comparisons were
carried out using Mann–Whitney U-test. All data are detailed in Supplementary Table S4.
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Effects of in vitro transfection with miRNA-15 or miRNA-16 mimics/
inhibitors on the growth of CLL cells in NSG mice
Purified cells from four CLL cases with biallelic del(13)(q14) were
transfected with miR-15, miR-16 or miR-CTR mimics, cultured for
6-h and then injected intravenously (i.v.) into NSG mice together
with autologous T cells (B/T cell ratio 5–10:1). Two/three mice were
used for each treatment group. Disease engraftment was
measured after 4 weeks by USPIO-MRI of the spleen.38 Iron
uptake is inversely correlated with the presence of CLL follicles-like
structures which prevent iron uptake. Signal-to-Noise ratio change
(ΔSNR%) values are higher when low iron levels enter the splenic
tissue. Thus, higher uptake of the USPIO contrast reagent was
observed in the spleens of NSG mice receiving CLL cells
transfected with miR-15 or miR-16 mimics which resulted into a
lower ΔSNR% value compared with the spleens of mice receiving
miR-CTR-transfected CLL cells (Figure 2a). The ΔSNR% of mice
injected with miR-15 (mean± s.d. =− 31.1 ± 25.1) or miR-16
(mean± s.d. =− 18.2 ± 28.19) mimics pre-treated cells resembled
that of NSG mice that had not received leukemic cells (mean ±
s.d. =− 54.3 ± 15), whereas this value was higher (+30.7 ± 23.4) in
the mice receiving miR-CTR pre-treated cells. ΔSNR% values of
mice groups pre-treated with miR-15 (n= 7) or with miR-16 (n= 6)
were significantly lower compared with those pre-treated with
miR-CTR (n= 8; P= 0.001 for miR-15; P= 0.01 for miR-16). This MRI
Figure 4. Effects of treatment with miR-15 or miR-16 mimics on the expansion of CLL clones in NSG mice. (a and b) IHC analysis of the spleen
of a mouse a representative CLL case (MP0456).The typical CD20+ aggregates (a) surrounded by CD3+ T cells (b), that are evident in the
spleens of the mice treated with miR-CTR, virtually disappear following treatment with miR-15 or miR-16 mimics. × 40 magnification view of
splenic sagittal sections. The inset indicates the same areas at a higher magnification (×400). (c) Numerous cells were stained by α-Cleaved
Caspase-3 mAb in the spleen of mice treated with miR-15. These were virtually absent in mice treated with miR-CTR (magnification × 200 and
×400 in the inset). (d) Summary of flow-cytometry results observed in mice injected with the cells from 6 CLL cases biallelic for del(13)(q14.3).
Annexin-V positive cells were determined at the end of the experiment. Each dot represents an individual mouse. Values are expressed
as mean± s.d. Statistical comparisons were carried out using Mann–Whitney U-test (****Po0.0001). All data are detailed in Supplementary
Table S5.
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pattern was likely related to the lower number of neoplastic foci
within the splenic white pulp, a finding consistent with the
observation of a lower number of follicle-like structures detected
by IHC with anti-CD20 mAb in the spleen of mice receiving
miR-15/16 treated cells compared with controls. Likewise, the IHC
index (as detailed in Supplementary Figure S3) of mice receiving
CLL cells treated with miR-15/16 mimics was decreased compared
with that of mice receiving cells transfected with miR-CTR. The
average ± s.d. of the IHC index reduction was 68 ± 11 and 67 ± 11
following transfection of miR-15 and miR-16 mimics, respectively
(Figure 2c) (P= 0.0078 for both miRNAs compared with miR-CTR).
FC showed a significantly lower proportion of CD19+CD5+ cells in
the spleens of mice inoculated with miR-15/16-mimic-transfected
CLL cells than in controls (P= 0.012; Figure 2e and Supplementary
Figure S8a). B cells recovered from NSG mice consistently shared
the same BCR gene rearrangements as the leukemic clone used
for injection, whereas T cells displayed oligoclonal TCR rearrang-
ments (data not shown).
Cells from two CLL cases (PM0608, PA0145) lacking del(13)(q14)
were pre-treated with miR-15 or miR-16 inhibitors in vitro and
subsequently injected into NSG mice together with T cells according
to the same schedule described above. This treatment resulted in a
better splenic engraftment of the CLL cells as documented by the
differences in the ΔSNR% (Figure 2b). In the spleen of mice injected
with the cells from PM608 CLL case, these values were of +49±8.4
and +33±19.3 after pre-treatment of the cells with miR-15 and
miR-16 inhibitors, respectively and of +8±11.1 after cell pre-
treatment with miR-CTR inhibitors. This was paralleled by an average
IHC index increase (mean± s.d.) of 69±6% and 71±17% respec-
tively, in mice inoculated with miR-15 or miR-16 inhibitor pre-treated
cells (P=0.039 for miR-15 and P=0.05 for miR-16 inhibitors
compared with miR-CTR inhibitor, Figure 2d). Consistent with these
data was the significant increase in the percentage of CD45+CD19
+CD5+ cells observed by FC in the mice inoculated with miRNA
inhibitor-treated cells (71±3% and 69±1%, mean± s.d., respec-
tively) (Figure 2f, and Supplementary Figure S8b). All data are
detailed in Supplementary Table S3. Again, the BCR and TCR gene
rearrangement analyses confirmed that the engrafted B cells were
mostly from the leukemic clones, whereas T cells were oligoclonal
(not shown).
Inhibition of CLL cell expansion in NSG mice by treatment with
miR-15 and miR-16 mimics
Next, we investigated whether administration of miRNA mimics
could inhibit the expansion of a previously inoculated CLL clone
in NSG mice. In preliminary tests, six NSG mice were injected
with MG0248 CLL cells. After four weeks, a single potentially
therapeutic dose of miR-15 miR-16 or miR-CTR complexed
with Invivofectamine was administered intraperitoneally. Mice
were sacrificed 24-h after miRNA administration and CLL cells
Figure 5. Effects of treatment with miRNA mimics on the growth of cells from CLL with non-biallelic del(13)(q14. (a) Determination of viable
cells (measured as Annexin-V/PI- negative cells) in 26 CLL cases at 48-h culture following transfection of the indicated miRNA mimics. CLL
cases were grouped according to their karyotype. The asterisks indicate CLL cases carrying TP53 alterations (Supplementary Table S1).
(b) Summary of the results of the 26 CLLs cases (left panel) and subdivided in cases with monoallelic del(13)(q14) (n= 12) (central panel) and
with normal FISH (n= 9; right panel). P-values shown were calculated by Wilcoxon test.
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(CD45+, CD19+ and CD5+) were purified by FACS sorting from
splenic cell suspensions (the resulting preparations contained
498% CLL cells). qRT–PCR analysis showed an increase of
miR-15 (fold increase = 407.80) and of miR-16 (fold increase
34.15) levels above control mice injected with miR-CTR
(Supplementary Figure S9).
Next, CLL cells from six cases with biallelic del(13)(q14) were
inoculated into NSG mice together with T cells (NSG-CLL) and CLL
engraftment was verified in the spleen after approximately two
weeks by MRI.38 Mice found to have an above-average splenic
ΔSNR%, compared with NSG mice that had not received leukemic
cells (NSG-CTR, n= 12, ΔSNR% − 54.3 ± 15, mean ± s.d.), were
placed on treatment with miR-15 or miR-16 mimics or miR-CTR
(one injection on alternate days for a total of three injections).
Three days after the final treatment, splenic infiltration by
leukemic cells was evaluated (Figures 3 and 4). On MRI
(exemplified in Figure 3a and b), miR-CTR treated mice displayed
a splenic infiltration by leukemic cells with an 63 ± 14 average
increase of ΔSNR% over that of mice not receiving leukemic cells
(Po0.0001). In contrast, mice treated with miR-15 or miR-16
mimics showed a significant ΔSNR% decrease (Po0.0001 and
P= 0.0002, respectively) compared with mice before therapy
administration (Figure 3c). The values of the treated mice were
similar to those of NSG-CTR mice not receiving CLL cell inocula.
The ΔSNR% values of mice treated with miR-CTR following CLL cell
inoculation were similar to or greater than those at therapy start
time point (P= 0.002; Figure 3c). These results predicted a
response to therapy, which was subsequently confirmed by FC
analysis (average percentage CLL cells reduction of 61 ± 8
(P= 0.0006) and of 75 ± 12 (P= 0.0001) after miR-15 and miR-16
mimics treatment, respectively, vs. mice treated with miR-CTR;
Figure 3d) and IHC. A significantly lower IHC index was observed
in mice treated with miR-15 or miR-16 compared with mice
treated with miR-CTR (average IHC index reduction 62 ± 15
(P= 0.0007) and 78 ± 22 (P= 0.02), respectively) (Figure 3e and
Supplementary Table S4).
IHC analysis showed an almost complete disappearance of the
typical aggregates of leukemic (CD20+) cells after treatment with
miR-15 or miR-16 mimics (Figure 4a and Supplementary
Figure S3b). However, autologous T cells (CD3+ cells), surrounding
what was presumably the area of the previously existing CLL cell
aggregates/nodules, were still present in a substantial number,
possibly indicating that T cells were not affected by treatment
(Figure 4b). Cleaved CASP3 could be observed in the ‘empty
nodules’ possibly indicating apoptotic leukemic cells (Figure 4c
and Supplementary Figure S10) as also suggested by the
observation of an increased percentage of Annexin-V-positive
CLL cells (Po0.0001) in the splenic cell suspension by FC
(Figure 4d and Supplementary Table S5).
Decrease in vitro viability and growth ability of CLL cells with
different cytogenetic features following transfection with miR-15
or miR-16 mimics
We extended our observations to a set of 26 CLL cases lacking
biallelic del(13)(q14) (Figure 5 and Supplementary Table S1). The
cells from these cases, which expressed different levels of miR-15
and miR-16 as evaluated by qRT–PCR (Supplementary Figure S1c
and d), were purified and transfected with miR-15, miR-16 mimics
or miR-CTR (Supplementary Figure S2c). Cell viability was
significantly decreased following transfection in most cases
(Po0.001, Figures 5a and b). Decreased cell viability also was
observed when the two major CLL groups were analyzed
separately: ie, those with monoallelic del(13)(q14) (statistically
significant differences in the miR-15-mimic (P= 0.01), miR-16-
mimic (P= 0.005) -treated cells compared with controls) and the
group with normal FISH (P= 0.004).
In addition, viability of the cells from other cases, including one
with del(11)(q22.3), involving the ATM gene, and others with p53
mutations or del(17)(p13.1) was reduced following miR-15 and
miR-16 mimic transfection.
Finally, NSG mice were engrafted with cells from two cases
harboring monoallelic del(13)(q14) (FP0499, GN0095), one case
with trisomy 12 (RD0468), one with a normal FISH pattern
(VS0624) and one with del(17)(p13.1) and a TP53 mutation on the
remaining allele (RM0626), and were subsequently treated with
miR-15 or miR-16 as above. A significant reduction of splenic
disease was observed by FC (P= 0.0001 and P= 0.006 following
miR-15 or miR-16 mimic treatment, respectively compared with
miR-CTR; Table 1). A decrease in the IHC index of 72 ± 18% and
74± 10% following treatment with miR-15 and miR-16 mimics,
respectively (P= 0.001) was observed in four of the CLL cases
tested. Case RM0626 represented a remarkable exception, as
treatment with the miRNA mimics consistently failed to signifi-
cantly block the growth of CLL cells in vivo. Of note is the finding
that this case had low miR-15 and medium to high miR-16
expression. Thus, the findings were unlikely related to the
Table 1. Inhibition of non-biallelic del(13q14) CLL cell growth in NSG mice by miR-15 or miR-16 mimic treatment
ID miRNAs treatment
(n of mice)
CD45+CD19+CD5+ CLL cells (FC) %
(mean± s.d.)
CD45+CD19-CD5+ T cells (FC) %
(mean± s.d.)
IHC index
(mean± s.d.)
FP0499 miR-CTR mimic (3) 9± 1.7 90± 0.9 137± 36.8
miR-15 mimic (3) 4± 0.7 87± 2.1 72± 10.8
miR-16 mimic (2) 2± 0.3 86± 8 26± 7.4
GN0095 miR-CTR mimic (2) 13± 0.5 82± 2.8 107± 12.7
miR-15 mimic (3) 8± 1.8 86± 2.9 12± 10
miR-16 mimic (3) 7± 0.7 82± 8.5 23± 13.7
RD0468 miR-CTR mimic (4) 13± 5.4 51± 10.7 56± 5.5
miR-15 mimic (3) 4± 1.4 60± 2.8 12± 5.8
miR-16 mimic (3) 5± 1.5 51± 8.4 14± 9.8
VS0624 miR-CTR mimic (3) 18± 1.9 81± 2.7 248± 45.1
miR-15 mimic (3) 8± 3.6 87± 7.6 68± 7.5
miR-16 mimic (3) 14± 1.9 79± 6.9 101± 35.1
RM0626 miR-CTR mimic (3) 46± 12.7 51± 15.4 65± 12.9
miR-15 mimic (2) 58± 2.5 36± 1.4 53± 3.5
miR-16 mimic (2) 63± 1.8 28± 5.4 53± 8.5
Abbreviations: CLL, chronic lymphocytic leukemia; FC, flow-cytometry; IHC index, immunohistochemical index; miR-15, micro RNA-15.
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possibility that the miRNA values were already so high that could
not be changed by the transfection. Rather, a completely
dysfunctional TP53 was the possible cause for the findings.
DISCUSSION
This study demonstrates that in vitro transfection of miR-15 and
miR-16 mimics into CLL cells with del(13)(q14) results in a
significant inhibition of their subsequent growth in NSG mice.
Furthermore, administration of miR-15 or miR-16 mimics to NSG
mice, in which these CLL cells were already engrafted and
proliferating, caused significant tumor regression. Both observa-
tions are in line with the notion that miR-15 and miR-16 control
the cell apoptotic apparatus and proliferative capacities.17,23,24 No
additive/synergistic effects were noted when miR-15 and miR-16
mimics were co-transfected, suggesting that the regulatory
controls of the two miRNAs on the expression of other genes
largely overlap, a consideration consistent with the notion that
miR-15 and miR-16 interact with the same 3′-UTR region of
BCL-2 mRNA.24
Selective inhibition of miR-15 and miR-16 expression in CLL cells
resulted in improved in vitro survival and a more robust expansion
in NSG mice.16 In contrast, enforced expression of miR-15 or
miR-16 in cells retaining the capacity to express these miRNAs
resulted in impaired in vitro survival or diminished expansion in
NSG mice. Both findings provide further support for the regulatory
role of intracellular miR-15/miR-16 concentrations in full-blown
CLL14,23,24,32 (Figure 5). The experimental design utilized here was
intended to obtain a specific and selective inhibition or
replacement of miR-15 and miR-16 without further influence of
other gene segments such as Dleu2 or Dleu7,39 the absence of
which have been shown to synergize with that of miR-15 and
miR-16 in CLL pathogenesis. Thus, the data demonstrate that low/
absent expression of miR-15 and miR-16 plays a crucial
pathogenetic role per sè, in line with the observation that
replacement of these miRNAs in NZB mice using suitable viral
carriers blocks the expansion of CLL-like cells both in vivo and
in vitro.40
MiR-15 or miR-16 mimics did not apparently interfere with the
function of T cells that are normally needed to support in vivo CLL
cell growth. In the experiments where CLL cell growth in NSG mice
was inhibited by pre-exposure to miR-15/miR-16 mimics in vitro
(Figure 2), the T cells were added to the purified CLL cells
following their in vitro exposure to these miRNAs. However, in
experiments, where transfection was carried out in vitro on
unfractionated cell suspensions, containing both T and CLL cells,
before injection into mice, we observed an unaltered distribution
pattern of T cells in the spleen of mice even in the presence a
largely diminished proportion of B cells. Moreover, when mice
were treated with miR-15 or miR-16 mimics in vivo, seemingly
unaltered T cell proportions were observed surrounding the
‘empty’ areas, previously occupied by CLL cells (Figure 4). Thus,
inhibition of CLL cell growth in NSG mice presumably occurred
through interference of the transfected mimics with the CLL cell
survival/proliferating apparatus, rather than through an indirect
action on the T cells promoting CLL cell growth. Whether or not
progressive CLL cell death, induced by the transfected miRNA
mimics in vivo, may lead to T cell immune-priming capable of
causing further CLL cell elimination is presently unknown.
A final issue concerns the potential use of miR-15 and miR-16
for therapy. MiRNA mimics are effective on CLL cells growing
in vivo and on CLL cells with additional chromosomal alterations;
however, some results from both in vivo and in vitro experiments
showed that the presence of TP53 gene mutations/deletions may
render administration of the miR-15 and miR-16 mimics ineffec-
tive. This is expected, given the close interactions between miR-15
and miR-16, TP53 and the cluster of miR-34 genes in the regulation
of cell survival/apoptosis.41,42 Nevertheless, not all cases with TP53
defects failed to respond to miRNA mimics treatment suggesting
heterogeneity of functional TP53 alterations. These observations
are being extended to additional cohorts of patients including
more advanced stage/relapsed patients that more frequently
harbor additional TP53 alterations.43–46
We provide proof of principle data supporting the potential use
of miRNA mimics to block CLL clonal expansion. Additional
miRNAs, other than miR-15 or miR-16, may become suitable
therapeutic targets, as a number of studies have demonstrated
anomalous expression of various miRNAs in CLL cells compared
with normal cells.11,22,30 Moreover, when certain miRNA are
overexpressed, they can be targeted by miRNA inhibitors.47
Several anomalies in miRNA expression have prognostic/predic-
tive value for disease course and outcome, indicating a potential
mechanistic role in the disease pathogenesis/progression.22–24,30,48–52
Thus, the miRNA approach, especially if multiple miRNA mimics
and inhibitors can be targeted, either alone or in combination with
other drugs, may represent an additional therapeutical strategy. In
connection with this, it should be noted that therapy with miR
inhibition/replacement is being employed in a variety of experi-
mental tumors. Moreover, there are many available studies on
human tumors, some of which have reached the clinical stage I,
with potentially promising results.53 Thus, miR therapy may
represent a ‘real’ tool in the future armamentarium of drugs
usable in CLL, a disease that so far has escaped attempts toward a
radical cure.
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Discussion and Conclusion 
 
Where are we now? Where are we going? 
 
Despite many recent advances in non-invasive imaging technologies, 
such as MRI, we are still limited in our ability to detect, monitor, and assess 
tumour response to treatment at molecular levels. The advent of “molecular 
imaging” with specific molecular probes was set to radically change this 
situation, and to revolutionise our approach to the detection and treatment of 
cancer [15,16,147,148].  
 
To better understand the impact of the “molecular revolution” in medicine, 
we must look at the astonishing developments in other specialties that we 
have witnessed over the past ten years. The most striking examples have 
been the introduction of more specific drugs and inhibitors, the ability to 
genetically engineer and repair cells and tissues, and the commercialisation 
of a multitude of diagnostic tools and kits (such as DNA and protein assays). 
These tools have led to dramatic advancements in the understanding of the 
molecular pathways of cancer. The knowledge of these new targets and 
pathways can now be translated into new drugs and many of them are now 
commercially available. We expect that these developments will ultimately 
allow the earlier detection of disease, resulting in improved patient care.  
 
The question regarding the role of imaging in this “molecular revolution” is 
how we, as radiologists, can be actively engaged in molecular medical 
research, and how this can help the translation of molecular discoveries 
clinically facilitated by early imaging diagnosis. 
 
One of the key topics of radiology’s engagement in molecular imaging is 
more efficient involvement of biologists and chemists in our specialty. Basic 
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scientists and imaging specialties have long been in separate worlds. 
Bridging these two worlds is still difficult, but it is necessary to build bridges 
in order to advance the field. This can be achieved by attracting and training 
new Radiology trainees eager to learn more about molecular developments 
and stimulating their interest by engaging them more in basic science 
research, in order to successfully translate the new discoveries into clinical 
imaging applications. 
 
As I initially stated in this thesis, the first research that we developed in 2005 
was part of a pioneering Italian work. We were one of only two research 
groups in Italy working in the field of new molecular imaging probes for 
MRI, and we were the only radiologists, since the other group, led by Silvio 
Aime in Turin, were chemists.  
 
For myself, first as a radiology trainee and later as a consultant radiologist, 
it has been a great experience working and collaborating with people with 
such a variety of expertise: immunologists, biologists, bioengineers, 
chemists, and physicists. I had the opportunity not only to gain more 
knowledge in basic science, but also to “open my mind” as a clinician to 
something more adventurous, representing an important part of the future of 
radiology. 
 
Over these ten years of research, I had the opportunity to attend most of the 
European and International Molecular Imaging conferences, providing my 
active contribution either as attendee or as a scientific reviewer. The well-
known “translation from the bench to the bedside” has been, over these 
years, the main “leitmotif” of our MI scientific community and, especially 
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for MR molecular imaging probes, we are still far for applying these in our 
daily clinical routine. 
 
Magnetic resonance imaging has had a great development in 
biomedical engineering and computing science. MR scanners are now 
markedly improved in terms of resolution and speed as compared with those 
of only a few years ago, allowing concomitant acquisition of functional and 
physiological information. However, when we think about translating a 
preclinical MR imaging study into clinical practice, we need to consider that 
there are both technical and biological challenges that can impede immediate 
translation. Preclinical scanners often have technical advantages over 
clinical scanners, with increased field strength (from 4.7 to 9.4T, but can be 
as high as 22T) and high‐performance gradients that allow for higher 
temporal and spatial resolution compared with the clinical setting [149]. 
However, preclinical systems often lack the wide selection of clinically 
available coils optimised for target geometry or image acceleration (e.g. 
multichannel), requiring the development of lab‐specific coils. Finally, while 
the higher field strengths of preclinical systems are attractive from a signal‐
to‐noise perspective, the tissue contrast can be significantly reduced, 
especially for T1‐weighted imaging, confounding translation to typical 
clinical field strengths of 1.5T and 3.0T. For this reason, one of the novelties 
of our MI research was the application of a clinical MR scanner to a 
preclinical imaging study to facilitate the translation of the results obtained 
preclinically into the clinical setting. This study led to the development of a 
new prototype birdcage coil for a clinical MR scanner in collaboration with 
a well-known imaging healthcare company. 
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In addition to the technical considerations mentioned above, the 
translation of a novel imaging study depends also on the selection of an 
appropriate animal model. Cancer animal models are developed to 
recapitulate the imaging and pathophysiological features of human cancers; 
however, we learned by the recent introduction of the models based on 
patient‐derived xenografts, that the knowledge gained from certain type of 
cancer animal models may be of limited value for optimising an imaging 
approach (for example, the rodent models of C6 and 9L glioblastoma 
tumour, which grow in different patterns compared with a human brain 
tumour) [149]. 
 
The development of an MR contrast agent is a very complex field 
which requires a long experimental phase, from the proof of concept until 
the clinical application of the new agent. Sometimes this leads to a very 
unsuccessful clinical application: an example has been the clinical 
application of USPIO (Sinerem, Guerbet, Paris) to visualise metastatic 
prostate or urinary bladder lymph nodes. After a long phase 3, this contrast 
never reached the imaging market and it is not routinely used in the clinic. 
One of the main reasons that MR contrast agents are very difficult to get into 
clinical environment is the potential toxicity of the compounds, which 
necessitates strict safety regulations. 
 
 
On the other side, with the advent of PET/CT in Nuclear Medicine, 
we have seen the development of a large number of new PET tracers over 
the years. These new tracers are applied not only preclinically but also 
clinically, as diagnostic as well as therapeutic tools, in keeping with the 
concept of “theragnostic imaging”.  
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One of the most striking examples has been shown in detection of 
metastatic prostate cancer in initial and recurrent staging prostate cancer: 
novel functional and targeted imaging agents,exhibiting both high sensitivity 
and specificity for detecting metastatic prostate cancer, have been developed, 
including radiolabelled choline, prostate specific membrane antigen 
(PSMA), and anti-18F-fluorocyclobutane-1-carboxylic acid (18F-FACBC) 
that are among some of the most promising novel PET agents [150]. The 
combination of specific PET tracer, such as 68Ga-PSMA-PET/CT and MRI, 
in guiding intra-prostatic biopsy, has been successfully shown in several 
studies [151, 152]. Furthermore, PET tracer avidity correlates well with 
gross tumour volume as detected by multiparametric MRI, and voxel based 
determinants directly match to histopathological specimens. This correlation 
supports another important concept of “multimodality imaging”, where the 
utilisation of the data provided by the combination of the two techniques is 
partially reducing sampling error and improving diagnostic accuracy of 
targeted biopsy. Attempts at improving surgical detection by probe 
techniques, similar to those described with sentinel node biopsy, have also 
been attempted, to improve lymphadenectomy both in the primary and 
salvage settings of prostate cancer. Although data are limited, the use of a 
gamma probe to detect the 111In-PSMA injected pre-operatively appears 
promising in detecting PSMA-avid occult small volume/micro-metastatic 
nodal disease [153-155]. 
All these studies are demonstrating the potential theragnostic 
implications of PET tracers and their applications that are increasingly at the 
forefront of oncology [156-159]. The power of this theragnostic paradigm, 
prior to that of prostate cancer, has been well demonstrated in gastroentero-
pancreatic neuroendocrine tumors (GEP-NETs) over many years [160-167] 
and recently confirmed in the randomized controlled NETTER-1 trial 
   
 
P a g e  113 | 136 
 
showing a five-fold improvement in response with 177Lu-DOTATATE 
(LutatheraTM) compared with conventional treatment [168]. 
The theragnostic principle is simply allowing us “to see what we treat 
and treat what we see” [167]. In this optic, the use of molecular imaging 
agents to target specific therapy is directly analogous to the use of Herceptin 
in patients with breast cancer that we have discussed in Chapter 1 [14] where 
treatment is only given following the demonstration of specific HER-2 
receptor expression on tumor cells [169] or for example, as we demonstrated 
in our early experiments, by applying a specific UPSIO conjugates antibody 
anti-CD20 (rituximab) directed to high CD20 lymphoma tumours [17]. 
PET/CT imaging by using 68Ga-PSMA performs the same gate keeping 
function by in vivo demonstration of the upregulation of the PSMA receptor 
in prostate cancer. 
In the course of using these novel agents we need to consider that a 
manifold of pitfalls has also been discovered and in this regard, a great deal 
of progress has been made by the introduction of several framework systems 
for theragnostic PET radiotracers (such as for example, the PROstate cancer 
Molecular Imaging Standardization Evaluation (PROMISE), the European 
Association of Nuclear Medicine and Molecular Imaging and Society of 
Nuclear Medicine and Molecular Imaging joint procedure guideline for 
PSMA-targeted PET (EANM), and the NeuroEndocrine Tumor Positron 
Emission Tomography (NETPET) grading system for NETs) [170-172]. 
 
 
Both, PET/CT with novel PET tracer and MR with specific MRI 
probes, are clearly demonstrating that MI is not the exclusive domain of a 
single imaging technology or field. In fact, the success of this field is in the 
integrated application of a broad range of technologies for producing image 
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signals [173]. The information gained through multimodality imaging 
permits more complete delineation and characterisation of the biological 
process than by using only one modality. Thus, while we cannot state that 
Molecular Magnetic Resonance probes are easily translatable into the 
clinical setting, we can certainly state that a multimodality imaging approach 
has now been brought to the bedside, as is evident from the increasing use 
of hybrid imaging such as PET/CT, SPECT/CT, and recently the application 
of clinical PET/MR imaging. The concept of integrated multimodality 
imaging in clinical practice will certainly improve accuracy for detecting and 
quantifying diseases, permit monitoring responses to treatment, and provide 
a means for improved targeting and outcome prediction. 
 
The progress, made in medical imaging techniques, and the 
development of high-throughput algorithms to extract quantitative features 
from medical images has led to the development of  another approach to 
perform molecular imaging, called “radiomics” [174]. In clinical research, 
radiomics is becoming a meaningful tool and might be considered as an 
additional and complementary source of the so called “omic information” 
(such as genomics, transcriptomics, or epigenomics), not achievable in a 
multi-omics biological environment. In this scenario, the growing impact of 
non-invasive imaging techniques for disease definition, in parallel with the 
evolution of next-generation sequencing tools, provides powerful methods 
for investigating tissue phenotype through the combination of imaging 
characteristics (radiomic features) into a multi-omics biological framework. 
Indeed, the correlation of radiomic features with genomic features, has given 
rise to a field of study defined as “radiogenomics” [175].  The increasing 
scale and availability of a high volume of health data certainly requires new 
and efficient strategies for data management, data linkage and data 
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integration. These types of datasets are defined as “multimodal” [176]. In 
this context, there are many challenges to overcome such as: i) identifying 
relationships between the data produced by different imaging modalities, ii) 
joining multimodal information for prediction, iii) learning information to 
help understand limited data of another modality and iiii) representing, 
integrating and summarizing multimodal data [174]. Thus, in order to 
optimise data management and analysis, it is necessary to reshape the 
existing information systems into innovative multi-layer data systems by 
combining statistical and computational methods. So far, no tools integrating 
genomic and radiomic data have been designed; therefore, consolidating 
single-omic datasets from different domains in a meaningful manner is the 
next ambitious undertaking of this “new approach of radiology analysis”. 
 
To conclude, this thesis, and the publications collected herein, is not 
meant to demonstrate the impact of each single topic within the scientific 
community but, in a broader, more general view, it is intended to 
demonstrate how the improvement of knowledge gained either by preclinical 
or clinical studies is of great support for cancer detection and diagnosis. 
Furthermore, I propose that radiology has its own important place in basic 
science supporting the identification of cancer targets for therapeutic 
strategies and therapy response monitoring. 
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ISMRM Molecular and Cellular Imaging Study Group Workshop: Cruising Into 
Molecular and Cellular Imaging. Western Caribbean Cruise from Galveston, Texas, 
USA to Cozumel, Mexico, February 2007. 
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